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Abstract 
Background 
Lung cancer has a dreadful prognosis and is the leading cause of cancer deaths 
in the world and in the UK. The UK survival rates are particularly poor when 
compared with survival in other countries in Europe. More than two-thirds of 
people with lung cancer in the UK are diagnosed at a late stage when curative 
treatment is no longer possible. Since lung cancer survival rates are higher with 
earlier diagnosis, there is need to diagnose cases earlier. This suggests a 
potential to examine and if possible, modify the care pathway for people with 
lung cancer to achieve earlier diagnosis. 
 
Aim 
The overall aim of this thesis was to explore the patient characteristics and 
interactions in primary care before the diagnosis of lung cancer, as a means of 
identifying the features that are predictive of lung cancer and the potential for 
earlier diagnosis. To achieve this aim, it was necessary to investigate and 
validate the use of lung cancer data from The Health Improvement Network. 
 
Methods 
The Health Improvement Network (THIN) database of United Kingdom general 
practice records, was used to identify and study the characteristics of cases of 
lung cancer in the UK. To ensure that THIN was a valid source of lung cancer 
information for research, a study was done to assess the completeness and 
representativeness of the lung cancer data in THIN by comparing the lung cancer 
patient characteristics, incidence and survival in THIN with the UK National 
Cancer Registry and the National Lung Cancer Audit Database. Experian's Mosaic 
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Public Sector tm  variable linked into THIN database was then used to identify 
detailed profiles of the UK sectors of society where lung cancer incidence was 
highest as a means of exploring the potential of using this geo-demographic tool 
to facilitate disease ascertainment.   
Two case-control datasets were developed from the database using the identified 
cases of lung cancer. The first dataset was matched on age, sex and general 
practice and it was used to carry out three studies in this thesis. The first study 
was a pilot study of methods to identify the socio-demographic and clinical 
features independently associated with lung cancer as well as to identify the 
timing of these clinical features before lung cancer was diagnosed. This was 
followed by two studies to examine separate hypotheses on the variation in lung 
cancer risk firstly between smokers of different socioeconomic status, then 
between smokers with and without a recorded history of depression, as 
socioeconomic deprivation and depression are both associated with increased 
prevalence of cigarette smoking.  
The second case-control dataset was matched only on practice and this dataset 
expanded on the methods from the pilot study to identify the socio-demographic 
factors including age and sex, as well as the early clinical features that are 
predictive of lung cancer. This was followed by a study which used the identified 
predictors to develop and validate a risk-prediction model for lung cancer. The 
model validation was carried out using another dataset of patients in a more 
recent version of THIN with records spanning a time period after the last date of 
records for patients used for the earlier studies in the thesis. 
 
Results 
A study population of 12,135 patients with incident lung cancer were identified 
from the 1st of January 2000 to the 28th of July 2009. The overall incidence of 
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lung cancer, median survival and general lung cancer patient characteristics in 
THIN were similar to other national lung cancer databases - The National Lung 
Cancer Audit Data and the UK National Lung Cancer Registry data from the 
Office of National Statistics. Mosaic™ classifications identified wider variations in 
lung cancer incidence than existing markers of socioeconomic deprivation and 
therefore allowed more detailed classifications of the UK sectors of society where 
lung cancer incidence was highest. For example the incidence rate in Mosaic 
Public Sector™ type I50 (Cared-for pensioners) was 31.2 times higher (IRR 
31.2; 95% CI 21.9-44.5) than the incidence rate in Mosaic Public Sector™ type 
B10 (Upscale new owners).   
With regards to the risk of lung cancer among smokers from different 
socioeconomic groups, stratified analyses of the association between smoking 
and lung cancer by Townsend deprivation quintiles showed that the risks of lung 
cancer were similar in smokers of different socioeconomic status. Depression 
was associated with a 30% increased risk of lung cancer (odds ratio 1.30; 95% 
CI 1.24-1.38) which was completely explained by smoking. Cigarette smoking 
was more common and levels of consumption were higher among depressed 
compared to non-depressed individuals. Stratified analyses of the association 
between smoking and lung cancer by depression showed that there was no 
difference in lung cancer risk among depressed and non-depressed smokers. 
Socio-demographic features - age, sex, socioeconomic status and smoking, 
increase in the frequency of general practice consultations as well as early 
records of presentation for symptoms of cough, haemoptysis, dyspnoea, weight 
loss, lower respiratory tract infections, non-specific chest infections, chest pain, 
hoarseness, upper respiratory tract infections and Chronic Obstructive 
Pulmonary Disease (COPD) were found to be independently associated with lung 
cancer 4 to 12 months before diagnosis. A risk prediction model was developed 
with these variables, and on validation using an independent THIN dataset of 
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1,826,293 patients, the model performed well with an area under the curve 
statistic of 0.88. 
 
Conclusions 
Routine electronic data in THIN are a valid source of lung cancer information for 
research. Mosaic™ identifies greater incidence differentials than standard area-
level measures and as such could be used as a tool for public health programmes 
to ascertain future cases more effectively. 
Neither socioeconomic deprivation nor a history of depression increases an 
individuals' vulnerability to the carcinogenic effects of cigarette smoke. The 
increase in lung cancer risk among more deprived individuals and those with 
depression is largely explained by the greater cigarette consumption by these 
groups of people. Smoking cessation interventions targeted to these groups of 
people are needed to reduce the lung cancer-related health inequalities 
associated with deprivation and depression.  
A combination of patients' age, sex, socioeconomic characteristics, smoking 
status and early stage symptoms in general practice aid earlier identification of 
patients at increased risk of lung cancer. The model developed using these 
variables performed substantially better than the current NICE referral guidelines 
and all comparable models, being able to predict lung cancer early enough to 
make detection at a potentially curable stage feasible by allowing general 
practitioners to better risk-stratify their patients. 
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1. Chapter 1.   Introduction 
Although the improvement of treatment and survival of people with lung cancer 
is of utmost priority among those in the field of lung cancer research in the UK, 
very few studies have explored the interaction between general practitioners 
(GPs) and patients who develop lung cancer before they are diagnosed. Using a 
computerised database of UK general practice records, this thesis aims to 
extensively investigate the GP-patient interaction in the period before lung 
cancer diagnosis, with a view to determining the possibility of developing a 
predictive score for lung cancer that could be used to aid earlier diagnosis of 
future cases.  
This introductory chapter gives an overview of what is already known about the 
burden of lung cancer globally and in the UK in particular, the risk factors and 
other characteristics associated with lung cancer, the clinical presentation as well 
as current guidelines for diagnosing lung cancer in the UK. It also highlights the 
need to recognise lung cancer earlier in general practice, an overview of 
predictive scores with particular emphasis on existing scores for lung cancer and 
the gaps in the evidence. This will be followed by a rationale of the work in this 
thesis as well as detailed aims and objectives of the thesis. 
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1.1   Background 
1.1.1 Definition of Lung cancer  
Lung cancer is an epithelial tumour arising in the mucosa of the bronchi or more 
rarely, in the lung parenchyma1 . These cancers may: 
 expand into the airways and cause symptoms such as cough, 
haemoptysis, airway obstruction. 
 invade locally within the thorax, leading to compression and invasion of 
the chest wall. 
 spread through the hilar, mediastinal and supraclavicular nodes.  
 metastasize through the blood, to other parts of the body, particularly to 
the brain, liver, adrenals and the axial skeleton. 
 induce changes in the peripheral or central nervous system 
(paraneoplastic effects), causing symptoms such as anorexia and 
inappropriate hormone production.  
 
1.1.2 International and national burden of lung cancer  
Lung cancer is the most common cancer globally2, with over 1.6 million cases 
diagnosed worldwide in 2008. In the western world, lung cancer is associated 
with a significant health burden3 and is the leading cause of cancer deaths in 
Europe4. In 2008 in Europe, the number of diagnosed cases and deaths from 
lung cancer alone were an estimated 391,000 cases and 342,000 deaths 
respectively4. In the UK, lung cancer is the second most common cancer 
diagnosed5 after breast cancer with 41,397 cases diagnosed in 2009 alone6-9 
(Figure 1.1). It is also the leading cause of cancer deaths in the UK, accounting 
for 22% of all cancer deaths and 6% of all deaths. In 2010, there were 34,874 
deaths from lung cancer in the UK10-12, which was over 7000 more deaths than 
20 
 
the 2nd and 3rd most common causes of cancer deaths, bowel cancer and breast 
cancer, combined (Figure 1.2).     
  
 
Figure 1.1 The 20 most commonly diagnosed cancers (excluding non-
melanoma skin cancer) in the UK in 2009. 
Based on data from Cancer Research UK13 
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Figure 1.2  The 20 most common causes of cancer death in the UK in 
2010. 
Based on data from Cancer Research UK14 
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The survival rates for people with lung cancer are very low, thereby resulting in 
mortality rates that closely follow incidence15. Due to the poor prognosis for lung 
cancer, the survival outcome is one of the worst of any cancer. The latest data 
from the Office of National Statistics (ONS) show that for adults diagnosed in 
England during 2005 to 2009 and followed up to 2010, the one-year survival for 
lung cancer was 29% for men and 33% for women, falling to 8% and 9% 
respectively after five years16.  
Lung cancer survival rates have been shown to have great variation across 
Europe17-20. Evidence from data of lung cancer cases recorded in 44 population-
based cancer registries in 17 countries showed that the highest relative age-
standardized 1-year survival rates for lung cancer were approximately 40% in 
Finland, France, The Netherlands and Switzerland while they were relatively low 
for patients in the UK at 24%17. A recent study which compared lung cancer 
survival in England, Norway and Sweden, countries with a similar expenditure on 
healthcare, showed that across all categories of age and sex, 5-year survival 
after lung cancer diagnosis was lower in England compared to Norway and 
Sweden18. The difference in survival between England and the other 2 countries 
was much larger than the difference in survival between Norway and Sweden. 
Survival differences were most marked during the early period of follow-up after 
diagnosis and these diminished considerably with increasing years of follow-up 
(Figure 1.3). 
The poor survival of patients with lung cancer in the UK has been suggested to 
be partly explained by a later stage at diagnosis among patients with lung cancer 
in the UK18 and poor access to specialized care and treatment17. 
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Figure 1.3  Excess deaths from lung cancer/ 100 person-years in 
England, Norway and Sweden, by age group and period of follow-up. 
Adapted from Holmberg et al.18 
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1.1.3 Risk factors for lung cancer 
1.1.3.1  Smoking 
The first large-scale studies which examined the relationship between cigarette 
smoking and lung cancer21-25 form the basis of some of the epidemiological 
studies in current use. This association was established over 60 years ago23 and 
cigarette smoking has remained the most important risk factor for lung cancer26. 
Smoking has also been linked to other cancers including cancers of the oral 
cavity and pharynx, oesophageal cancer, stomach cancer and pancreatic 
cancer26.  
Cigarette smoking became popular in the United Kingdom in the early 20th 
century with the uptake occurring about 20 years earlier in men than women. 
Smoking prevalence peaked in the 1940s in men and in the late 1960s in women 
and has declined steadily since then27. Surveys by the Tobacco Advisory Council 
(TAC) in 1948 estimated that the prevalence of cigarette smoking among men 
and women in Britain were 65% and 41% respectively28. In 2010, the smoking 
prevalence among men and women in Britain as estimated by the General 
Lifestyle Survey (GLS) was 21% and 20% respectively29. Trends in the incidence 
of lung cancer largely reflects peoples' past smoking pattern with a latency 
period of more than 20 years30.  
In 2010 in the UK, 85% of the lung cancer in males and 80% of lung cancer in 
females were attributable to tobacco smoking26. Current smokers have a 15-fold 
higher risk of death from lung cancer compared with lifelong non smokers31, 
however the risk reduces significantly in people who stop smoking before middle 
age32.  There is a dose-response relationship between cigarette consumption and 
lung cancer risk33, people who smoke fewer cigarettes daily for a longer duration 
have an increased risk of lung cancer compared with those who smoke more 
cigarettes for a shorter duration34 35. There is also an increase in the risk of lung 
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cancer following exposure to Environmental Tobacco Smoke (ETS)36 37 and an 
estimated 14% to 15% of lung cancers among individuals who have never 
smoked are thought to be due to exposure to ETS26. 
 
1.1.3.2  Occupational carcinogens 
Past exposure to occupational carcinogens have been shown to increase the risk 
of lung cancer38-41. The most commonly implicated occupational agent in lung 
cancer aetiology is asbestos and it increases the risk of lung cancer among 
smokers and non-smokers alike42. The incidence of lung cancer occurs as early 
as 5 to 9 years after first exposure to asbestos but the excess lung cancer risk 
continues to increase for up to 20 years or longer42. Other occupational agents 
that increase the risk of lung cancer  include silica, diesel engine exhausts, 
mineral oils, paint dust (combined with solvents exposure) and arsenic. In the 
UK, an estimated 21% of male lung cancer cases and 4% of female lung cancer 
are associated with occupational exposures43 44.  
 
1.1.3.3  Radon 
Radon is a noble gas produced from the decay of naturally occurring uranium 
that can accumulate indoors in buildings as well as in underground mines. It is 
carcinogenic to humans and has found to be strongly associated with lung 
cancer45. Exposure to Radon is much more likely to cause lung cancer in people 
who smoke but it is also the leading cause of lung cancer in non-smokers46. In 
the UK, 3.4% of the lung cancers are attributable to residential exposure to 
radon47 and it has been estimated that 9% of lung cancer deaths in Europe are 
as a result of indoor radon exposure48. 
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1.1.3.4  Family history of lung cancer 
A history of lung cancer in a first-degree relative is associated with a two-fold 
increased risk of lung cancer regardless of smoking status49 and suggests the 
possibility of a hereditary predisposition to lung cancer or shared environmental 
risk factor exposure by members of the same family.  In individuals less than 60 
years of age, there is a five-fold increase in lung cancer risk if they have a first 
degree relative who was diagnosed with lung cancer at less than 60 years50. 
 
1.1.3.5  Previous cancer treatment  
The risk of lung cancer is significantly increased up to 25 years after treatment 
for Hodgkin's lymphoma51. Prior treatment with chemotherapy and radiotherapy 
contribute to the risk and this is further increased in smokers compared to non-
smokers52. The risk of lung cancer has also been shown to increase after 
treatment for non-Hodgkin's lymphoma53, breast cancer54 and testicular 
cancer55. Following surgical resection of early-stage lung cancer, there is a 1% to 
2% risk per patient per year of developing a second lung cancer56. Individuals 
who survive for 2 years or longer after treatment for small-cell lung cancer also 
have a 2% to 13% risk per patient per year of developing a second lung cancer. 
 
1.1.3.6  Acquired lung diseases 
Several acquired lung diseases may increase susceptibility to lung cancer38 and 
these associations have been noted for obstructive lung diseases such as chronic 
obstructive pulmonary disease (COPD) and fibrotic lung diseases. Although lung 
cancer and COPD are both principally caused by cigarette smoking57, surplus 
evidence suggest an increase in lung cancer incidence in individuals already 
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diagnosed with COPD58 even after adjusting for the confounding effect of 
smoking59 60. A few studies had shown an inverse relationship between asthma 
and lung cancer61 62. However, evidence from several other studies suggest that 
after adjusting for the effect of cigarette smoking, a positive association exists 
between asthma and the risk of lung cancer63-65. An increased risk of lung cancer 
has also been found with interstitial lung diseases such as Idiopathic pulmonary 
fibrosis66 67, certain pneumoconiosis and systemic sclerosis68.  
 
1.1.3.7  Other risk factors for lung cancer 
Air pollution such as traffic-related air pollution, power plants and waste 
incinerator emissions69, domestic air pollution from heating and cooking with 
solid fuels70 71 are all associated with an increased risk of lung cancer.  
Studies have shown that increased levels of physical activity reduce the risk of 
lung cancer72 and this risk has been shown to reduce even in people who are 
current or ex-smokers73 74. 
Dietary factors are related to the risk of lung cancer and studies have suggested 
that a high intake of fruits and vegetables may reduce lung cancer risk in 
individuals75-77. A reduced lung cancer risk has been found with high dietary zinc 
and copper intakes78.  A recent study showed that 9% of lung cancer cases in 
the UK in 2010 may be related to low intake of fruits79.  
There have been conflicting evidence on the association between alcohol 
consumption and lung cancer risk. A pooled analysis of data from seven 
prospective studies suggested a slightly greater risk of lung cancer in male never 
smokers who consume high quantities of alcohol80 while other studies have failed 
to show an independent association between alcohol consumption and lung 
cancer risk81 82. A recently conducted meta-analysis which assessed this 
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association in never smokers however showed that alcohol consumption does not 
have an independent positive association with lung cancer83. 
 
1.1.4 Other factors associated with lung cancer  
1.1.4.1  Lung cancer and age 
Lung cancer is predominantly a disease of older adults, being rare in individuals 
less than 40 years5. Most cases are diagnosed over the age of 60 years and 
incidence rate peaks between 80-84 years5. In England, the median age of lung 
cancer diagnosis is 71 years84.  
 
1.1.4.2  Lung cancer and sex 
Lung cancer is more common in males than females. In the 1950s, the ratio of 
lung cancer in males compared to females was 6:1, this difference has however 
narrowed considerably and the lung cancer ratio in males compared to females is 
now 1.3:185. While the incidence rate is declining in men, it appears to be 
increasing in women and most likely reflects the much steeper decline in 
smoking prevalence over the years in males compared to females85. A few 
studies have examined the association between smoking and lung cancer risk in 
males and females, and although findings from some of the studies suggest that 
females may have a higher risk of lung cancer per cigarette smoked86 87, others 
have failed to show any difference in the smoking-associated risk of lung cancer 
among the sexes88 89. Between 1993 and 2008, the UK male lung cancer 
incidence rates declined by about 30% whereas the rate increased by 11% in 
females85. In 2009, there were 18,492 men and 14,622 women diagnosed with 
lung cancer in England6.  
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1.1.4.3  Lung cancer and socio-economic status 
There is a socio-economic gradient in the incidence of lung cancer, being higher 
among individuals of lower socio-economic status based on various measures of 
socio-economic status38 90-92. Differential exposure to factors such as smoking93 
94, diet93, occupational exposures95 and educational attainment90 95  have all been 
implicated to explain the differences in incidence between socioeconomic groups. 
However, these have not fully explained these differences. Evidence from a 
meta-analysis found an overall increase in lung cancer risk among individuals of 
lower socioeconomic status which persisted after pooling risk estimates from 
smoking-adjusted and smoking-unadjusted studies90. Using data of patients 
diagnosed with cancer from all eight English cancer registries in the UK, Shack et 
al96 assigned patients to an index of multiple deprivation (IMD) based on their 
area of residence and then investigated the differences in the incidence of lung 
cancer and other cancers among different socioeconomic groups. Results of the 
study showed the highest incidence of disease among the most deprived patients 
such that lung cancer was 2.5 times higher among the most deprived men than 
the most affluent men. Outside the UK, a similar association between deprivation 
and lung cancer exists in other countries including Canada97 and The 
Netherlands98. Whether the socioeconomic difference in lung cancer incidence is 
explained by factors other than smoking or if it is due to residual confounding, is 
currently unknown.  
A study by Fidler et al.99 assessed the distribution of saliva cotinine levels (a 
metabolite of nicotine and an indicator of daily nicotine consumption) among 
cigarette smokers in the Health Survey for England (HSE) and showed that 
cotinine levels were higher among individuals with lower social class and higher 
levels of deprivation than individuals with higher social class and lower 
deprivation levels, and this remained even after accounting for reported daily 
cigarette consumption99. Although cigarette smoking is known to be higher 
30 
 
among more deprived individuals100, the findings from the study by Fidler et al.99 
suggest that there may be higher nicotine intake per cigarette and therefore 
higher levels of nicotine addiction among more deprived individuals. While this 
study may have been subjected to reporting bias in the reported number of daily 
cigarettes smoked as well as unmeasured confounding from factors such as 
exposure to environmental tobacco smoke, the likelihood that there are 
differences in the amount of cigarette smoke inhaled between deprived and non-
deprived individuals implies that deprived individuals may have a higher 
susceptibility and therefore higher cigarette smoke-associated risk of lung cancer 
per cigarette smoked than less deprived individuals. 
A commercial geodemographic classification system, Experian's Mosaic Public 
Sector TM classification tool classifies postcodes in the UK into 11 groups and 61 
types based on demographics, lifestyle, education and values101. Mosaic profiling 
is done at finer levels than available deprivation markers and it has been used to 
identify socioeconomic differentials in several health-related behaviours including 
smoking102. There have however been no studies yet on the socioeconomic 
differentials in lung cancer incidence using Mosaic tool. 
 
1.1.4.4  Lung cancer and depression 
Individuals with depression and other mental disorders such as phobias and 
obsessive compulsive disorders are twice as likely to smoke and are more likely 
to smoke more heavily than those without mental disorders103. It has also been 
suggested that depression alters the body's immune system possibly leading to 
an increase in the risk of immune-related disorders such as cancer104. There 
have been a few studies on the association between depression and lung cancer 
but evidence from these studies have been conflicting. Whereas one study has 
described an independent association between depression and an increased lung 
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cancer risk105, others have either failed to show any increase in risk among 
depressed individuals106 or have found an increased lung cancer risk only among 
depressed individuals who are smokers107 108. A meta-analysis which synthesized 
the evidence from several prospective, general population-based studies of 
depression and cancer risk found no statistically significant association between 
depression and subsequent lung cancer risk109.  
 
 
1.1.5 Clinical presentation/symptoms 
More than 90% of people with lung cancer are symptomatic at presentation 110 
111 and they present either with symptoms relating to the primary tumour, non-
specific symptoms or specific symptoms from metastatic disease. Most patients 
present with cough, dyspnoea, fatigue, chest pain, loss of appetite, weight loss 
and haemoptysis before a diagnosis of lung cancer is made112-114. Cough is the 
most frequently reported symptom, being reported by more than half of 
patients113 115 whereas haemoptysis is relatively uncommon prior to diagnosis113 
115. Although other respiratory symptoms are more common than haemoptysis 
before diagnosis, they are yet more common in other benign conditions116 and 
have positive predictive values for lung cancer of less than 2%. The positive 
predictive value for lung cancer with haemoptysis is 2.4% to 7.5% and is higher 
when accompanied by other symptoms113 117. Table 1.1 summarises prevalence 
of symptoms prior to lung cancer diagnosis as reported in different studies. 
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Table 1.1. Summary of studies on symptoms reported before lung cancer diagnosis 
Study 
 
Population studied Age of patients Symptoms reported before lung cancer diagnosis Source of data  
Lovgren, M et 
al.* 
2008118 
314 patients diagnosed with primary 
lung cancer in Sweden in 2003 
 
38 - 92 years 
Cough - 41.8% 
Dyspnoea - 32.3% 
Thoracic related pain - 17.7% 
Weight loss - 32.1% 
Fatigue - 25.7% 
Appetite loss - 12.9% 
Haemoptysis - 5.1% 
Hoarseness - 2.2% 
Neurological symptoms - 10.9% 
First reported symptoms based on 
hospital physician's documentation 
in medical records  
Bjerager, M et 
al.* 
2006114 
84 patients newly diagnosed with lung 
cancer in Denmark between 1 April 
and 31 May 2003, and 1 September 
and 31 September 2003 
 
34 - 83 years 
Cough - 31.5% 
Dyspnoea - 16.9% 
Fatigue - 10.8% 
Weight loss - 7.7% 
Thoracic pain - 5.4% 
Haemoptysis - 4.6% 
Shoulder pain - 3.1% 
Hoarseness - 0.8% 
Telephone interview with patients' 
general practitioners 
Hamilton, J et 
al. 
2005113 
247 primary lung cancers diagnosed 
between 1998 and 2002 in all 21 
general practices in Exeter, UK 
 
Over 40 years 
Cough - 65% 
Haemoptysis - 20% 
Weight loss - 27% 
Loss of appetite - 19% 
Dyspnoea - 56% 
Chest or rib pain  - 42% 
Fatigue - 35% 
Anonymised photocopies of general 
practice records for 2 years before 
lung cancer diagnosis 
Corner, J et al. 
2005112 
22 patients diagnosed with lung cancer 
at two cancer centres in the south and 
north of England 
 
Not stated 
Cough - 68% 
Fatigue - 68% 
Appetite change - 64% 
Chest pain - 64% 
Shortness of breath - 59% 
Sleep changes - 59% 
Weight loss - 50% 
Haemoptysis - 41% 
Interview study of patients' 
accounts and hospital and primary 
care records 
Buccheri, G et 
al. 
2004119 
 
1,277 consecutive lung cancer patients 
seen in a single institution, over 14 
years, from January 1989 to October 
2002, in Italy 
 
32 - 90 years 
Cough - 50.0% 
Dyspnoea - 33.9% 
Chest pain - 31.5% 
Haemoptysis - 29.8% 
Chest infection - 19.7% 
Systemic symptoms - 49.3% 
Hospital database of prospectively 
built records of lung cancer patients 
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Koyi, H et al.* 
2002111 
 
365 patients newly diagnosed with 
lung cancer in Sweden between 1997 
and 1999  
 
23 - 96 years 
Cough - 24.9% 
Dyspnoea - 15.1% 
Fatigue - 14.2% 
Pain in thorax - 4.9% 
Back pain - 3.8% 
Haemoptysis - 3.2% 
Hoarseness - 2.0% 
Neurological symptoms - 2.3% 
Data collected from patients 
through questionnaires after 
referral to the hospital respiratory 
department 
Cromartie, RS 
et al. 
1980115 
 
702 patients treated with lung cancer 
in Charleston, South Carolina between 
1960 and 1970 
10-year age 
category under 
40 to 80 and 
over 
Cough - 64.2% 
Weight loss - 55.3% 
Pain - 52.7% 
Sputum - 44.4% 
Haemoptysis - 28.3% 
Malaise - 26.5% 
Dizziness - 4.0% 
Hospital records of patients at two 
hospitals in Charleston, South 
Carolina 
Weiss, W et 
al. 
1978120 
33 newly diagnosed cases of lung 
cancer in the cohort of 6,027 men 
enrolled in the Philadelphia Pulmonary 
Neoplasm Research project 
 
45 years and 
older 
Expectoration - 52% 
Chronic cough - 42% 
Dyspnoea - 52% 
Heaviness in chest - 3% 
Haemoptysis - 3% 
Chest pain - 3% 
Hoarseness - 6% 
Symptoms recorded six months 
before lung cancer detection. 
Records were taken during the six-
monthly screening done for all 
volunteers to this study. 
      * study shows percentage of patients who had the symptom at first presentation (percentage either increased or decreased before specialist referral) 
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1.1.6 Histological classification of lung cancer 
Histologically, lung cancer can be broadly classified into 2 types - small cell lung 
cancers (SCLC) which accounts for approximately 20% of all cases of lung 
cancer, and non-small cell lung cancers (NSCLC) accounting for the remaining 
80% of lung cancers121. NSCLC are further subdivided into 3 subtypes: 
squamous cell cancer, adenocarcinomas and large cell lung cancer and these 
make up  35%, 27% and 10% of all lung cancers in the UK respectively122. The 
histological subtype of lung cancer determines its treatment and prognosis. 
NSCLC overall has better prognosis than SCLC. While the main treatment for 
SCLC is chemotherapy, the treatment options for NSCLC are surgery, radical 
radiotherapy and/or chemotherapy depending on the stage of the disease, the 
lung function adequacy and suitability of the patient for treatment122. Surgical 
resection however remains the treatment of choice for NSCLC123 and the 
prognosis is good for patients with localised disease.  
 
1.2  The importance of early lung cancer diagnosis 
The outcome of lung cancer depends on the tumour stage at diagnosis1 and is 
favourable with patients diagnosed at the early stages with tumours that can be 
treated with surgery124 or radical radiotherapy. Reports of five-year survival after 
treatment of clinical stage I disease range from 38% to 76%124 125 while five-
year survival for patients with clinical stage IIIB and IV disease is between 1% 
and 7%124. A study which demonstrated a difference in survival between patients 
with localised early-stage lung cancer who were surgically treated and those who 
were untreated (due to patients' refusal) showed that the longer survival after 
surgical resection of early-stage tumours may not be attributable to lead-time 
and length-time bias126. There are currently no widely available screening tests 
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for lung cancer although several randomised controlled trials on the use of CT 
screening to detect the disease in the early asymptomatic stages are under 
way127-130.  
Delays in diagnosis and in receiving definitive treatment have been recognized 
as important factors in the overall outcome of lung cancer treatment131 and 
survival rates have been found to be higher in patients whose disease was 
diagnosed earlier132 and who were referred to a specialist earlier119. Evidence 
from a single-centre study of 29 lung cancer patients in the UK showed that 
following a delay of 18 to 131 days (median of 54 days) between diagnosis of 
lung cancer at the oncology clinic and radiotherapy planning, an increase in 
cross-sectional tumour size was noted on CT scans and 21% of potentially 
curable cancers became incurable133 .  
 
1.3  The problem of late diagnosis in the UK  
In the UK almost all of the population are registered with general practitioners 
(GPs) who act as the gate-keepers to all specialised health care. Most patients 
diagnosed with lung cancer present initially with symptoms to their GP134. If the 
GP suspects a diagnosis of lung cancer, further investigations can be carried out 
with subsequent referral to a specialist if the investigations are abnormal or if 
there is diagnostic delay134. In order to diagnose lung cancer early, it is 
important that the GP recognizes patients who have symptoms of lung cancer 
and are at the same time, at potential risk of having the disease. This should 
then be followed up with a chest x-ray investigation and/or prompt referral to a 
chest physician. 
In the UK, two-thirds of lung cancer patients get to specialist care when they 
have metastatic disease with evidence of spread to other organs135 and curative 
36 
 
treatment is no longer possible. As a result, less than 20% of patients seen by 
specialists have potentially surgically resectable tumours136, 17% undergo 
surgery137 and about half of these will be alive for up to 5 years. 
In an effort to reduce the time taken to diagnose cancer in the UK, the UK 
department of health produced a white paper in December 1997 titled "The new 
NHS - modern, dependable" in which all patients with suspected lung cancer 
were guaranteed prompt access to specialist services in a hospital within two 
weeks of an urgent GP referral138. This policy took effect for lung cancer in April 
2000 and was clearly aimed at earlier detection of cancers by reducing referral 
and treatment delays139. These are delays from referral for further care or 
diagnostic investigation to being seen in secondary care and delays from being 
seen in secondary care to treatment respectively139. The National Awareness and 
Early Diagnosis Initiative (NAEDI) established more recently in 2008 as part of 
the UK government's strategy to improve cancer outcomes, have also set up 
programmes to increase public awareness of symptoms of lung cancer140. There 
has however been less focus on delays in other stages of the diagnostic process 
including primary care delay (from first presentation in primary care to referral 
or initiation of diagnostic investigations). Data from the 2002 National survey of 
NHS patients showed that patient and primary care delays contributed more 
significantly to the total diagnostic delay than referral and secondary care 
delays139. The median primary care delay in the UK is 51 days141 whereas in 
Sweden, it is 28 days118.  
A study of all cancer diagnoses within a 2-year period at the Bradford hospitals 
NHS trust 142 showed that only 23% of patients diagnosed with lung cancer were 
referred urgently by their GPs. Others presented through other pathways such as 
non-urgent referrals, emergencies or referral from other clinics. In a more recent 
study in Exeter, 45% of patients with lung cancer were referred by their GP to 
hospital respiratory departments for specialist investigation while 23% were 
37 
 
admitted to hospital as emergencies, many of which will have been for 
respiratory infections141. 
The problem with early recognition of lung cancer by GPs however, is that most 
symptoms of lung cancer can be found in benign conditions and the benign 
causes of these symptoms are more common in general practice113 116.  Although 
lung cancer is a relatively common disease, GPs only encounter one to two new 
cases every year making it even more difficult to identify patients early134 135. As 
a result, lung cancer diagnosis is only suspected in 50% of the actual cases seen 
by GPs1 143. The remaining are seen in hospital either as emergencies or 
following referral for other non-respiratory conditions. Data published by the 
National Cancer Intelligence Network (NCIN) in 2010 shows that in England, 
more than a third of lung cancers (38%) are diagnosed on acute admission 
following an emergency presentation144.   
 
1.4  Current guideline for lung cancer diagnosis in 
UK primary care  
To reduce variation in the availability and quality of NHS treatments and care, a 
special health authority - the National Institute for Health and Clinical Excellence 
(NICE), was set up by the department of health in 1999145. One of the functions 
of NICE is to produce evidence-based guidelines on the most effective ways to 
diagnose, treat and prevent disease and ill health.  
The UK Department of Health in 2000, published cancer referral guidelines to 
facilitate appropriate referral between primary and secondary care for patients 
whom a GP suspects may have cancer146. These guidelines have since been 
reviewed and updated by NICE in February 2005147 and subsequently in April 
2011122.  
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The following excerpt from the NICE guidelines for lung cancer published in 
2011122, lists the criteria on which general practitioners should select patients for 
specialist referral as well as indications for chest radiography in primary care:  
 
1) Urgent referral for a chest x-ray should be offered when a patient 
presents with: 
 Haemoptysis or 
 Any of the following unexplained or persistent (lasting more than 3 
weeks) symptoms or signs: 
 Cough 
 Chest/shoulder pain 
 Dyspnoea 
 Weight loss 
 Chest signs 
 Hoarseness  
 Finger clubbing 
 Features suggestive of metastasis from a lung cancer (for example 
in brain, bone, liver or skin) 
 Cervical/supraclavicular lymphadenopathy  
 
2) If a chest X-ray or chest computed tomography (CT) scan suggests lung 
cancer (including pleural effusion and slowly resolving consolidation), 
patients should be offered an urgent referral to a member of the lung 
cancer multidisciplinary team (MDT), usually a chest physician. 
 
3) If the chest X-ray is normal but there is a high suspicion of lung cancer, 
patients should be offered urgent referral to a member of the lung cancer 
team MDT, usually the chest physician. 
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4) Patients should be offered an urgent referral to a member of the lung 
cancer MDT, usually the chest physician, while awaiting the result of a 
chest X-ray, if any of the following are present:  
 Persistent haemoptysis in smokers/ex-smokers older than 40 
years 
 Signs of superior vena cava obstruction (face or neck swelling with 
fixed elevation of the jugular venous pressure) 
 Stridor 
 
The UK department of health warrants that following an urgent GP referral, 
patients with suspected lung cancer should be provided prompt access to 
specialist services within two weeks146. 
 
1.5  Mesothelioma 
Mesothelioma is a highly fatal cancer148 that principally affects the pleura (lining 
of the lungs) and the peritoneum (lining of the abdominal cavity). Pleural 
mesothelioma makes up over 90% of cases of mesothelioma with a known first 
site135. Unlike lung cancer where the most important risk factor is smoking, 
mesothelioma has been linked with exposure to asbestos fibres148-151. It is a rare 
disease although its incidence has been increasing 148 149. It has a long latency 
period, the median interval between asbestos exposure and development of the 
disease being 30 years135. It also has a poor prognosis with a median survival of 
7 to 9 months135.  
In the early stages of mesothelioma, there are no symptoms.  When symptoms 
present, they are similar to those of lung cancer. They are non-specific and 
include persistent cough, dyspnoea, voice hoarseness, chest pain, fatigue and 
weight loss 152. As a result, the same guidelines for urgent referral of lung cancer 
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patients also cover patients with suspected mesothelioma. However, there is 
currently no real potential for the cure of mesothelioma.  
As mentioned in the introductory section of this chapter, the principal aim of the 
research covered in this thesis is to extensively investigate the interaction 
between GPs and patients prior to the diagnosis of lung cancer. Since 
mesothelioma is not covered in the scope of this research, the work in this thesis 
has therefore been done using data of patients with lung cancer with the 
exclusion of patients with a known diagnosis of mesothelioma. 
 
1.6  Risk prediction scores  
Risk prediction scores also known as predictive tools or predictive models, are 
tools designed to estimate or predict the risk of a patient developing some future 
clinical event by combining two or more items of patient and disease 
characteristics153. The main aim of these tools is to aid clinical decision-making 
by doctors, by providing objective estimates of risk probability as a supplement 
to other relevant clinical information154.  They therefore have a potential to 
improve clinician performance with active guidelines for preventative and active 
care155. These tools can also be used to select patients with an increased risk of 
disease, for therapeutic research. Because clinical risk prediction tools are 
designed to guide clinical practice, it is important that they are reliable and 
accurate156.  
A few published papers have compiled characteristics which clinical risk 
prediction tools should conform to if they are to be clinically useful. Among the 
features listed in an editorial by Grady et al.156, it was noted that these tools 
should be developed using data from patients who are representative of the 
population for whom the score will eventually be used, they should be relatively 
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easy to incorporate into routine clinical practice and most importantly, risk 
prediction tools will only achieve improved clinical outcomes if the predicted 
outcome could be prevented or delayed with effective treatment156. 
In a publication in the BMJ by Wyatt, J et al.157, while highlighting the need for 
risk prediction tools to show evidence of clinical credibility and ability to support 
with decisions to guide patient care, the authors stated that some prediction 
models predict outcomes that are not clinically relevant or they do not predict 
outcomes in enough time to inform clinical decisions. They also reiterated the 
fact that in applying risk prediction tools in practice, it should be easy for 
clinicians to obtain all the patient data required without expending undue 
resources157. 
On the issue of evaluating and validating risk prediction models, the important 
characteristics of model performance described by Freedman, A et al. are 
calibration, discrimination and accuracy158. The calibration of a model is assessed 
by comparing the observed number of events with the expected number of 
events. It is commonly evaluated using the goodness-of-fit or chi-square test158. 
Good calibration of a model is especially important in planning population-level 
interventions. Model discrimination on the other hand, is a measure of how well 
the model can separate those who do and do not have the outcome of 
interest159. Discrimination is often measured using the receiver operating 
characteristic curve (ROC) curve or concordance statistic (c statistic)159, which 
for binary outcomes is identical to the area under the ROC curve160. Model 
discrimination is particularly useful in assessing tools used in classifying into 
groups with and without disease such as in diagnostic testing. Calibration and 
discrimination are the two major components used to measure the performance 
of prediction models159. Model accuracy scores which include the positive and 
negative predictive values, can be used to evaluate how well a model categorises 
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specific individuals158. These measures however even with good sensitivity and 
specificity, may be low particularly with rare outcomes. 
Several risk prediction scores such as the Framingham score161, QRISK162 and 
ASSIGN163  are used to predict patients' cardiovascular risk based on socio-
demographic, clinical and lifestyle characteristics. Other assessment scores 
which have been developed to inform decision-making in clinical practice include 
the Finnish diabetes risk score164 to identify individuals at high risk of type 2 
diabetes as well as scores to assess the status of the central nervous system of 
patients such as the Glasgow-coma scale165, APACHE III166 and the simplified 
acute physiology score (SAPS II)167.  
 
1.6.1 Cancer risk prediction scores 
Some cancer risk prediction models have also been developed to aid the 
identification of individuals at high risk of cancer who may benefit from targeted 
screening or other intervention, to aid clinical decision-making, to develop 
benefit-risk indices, to estimate the population burden, cost and impact of 
specific interventions158.  
Models to predict the risk of breast cancer in women were developed using 
known risk factors such as age, age at menarche, age at first live birth, 
oestrogen use, number of previous benign breast biopsies and family history of 
breast cancer or other reproductive cancers in a first degree relative168-172. 
Following the discovery in the mid 1990s of the BRCA1 and BRCA2 genes which 
were found to increase susceptibility to breast cancer, models to predict the 
likelihood that an individual carried any of these genes predisposing to breast 
cancer were developed173-175. 
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Risk prediction tools have also been developed for colorectal cancer. A model 
was developed using a weighted numerical score which was derived from 
weighting of primary symptoms and symptom complexes, and comprehensive 
patient consultation questionnaires176. This model was shown to have a high 
sensitivity and specificity and therefore high accuracy in prioritising patients with 
colorectal symptoms following referral by their general practitioners using the 
current NHS guidelines176. Another qualitative index of colorectal cancer risk was 
developed using information on age and modifiable factors such as alcohol use, 
smoking status and body mass index (BMI) to define 10 risk groups177. More 
recently, an absolute risk prediction model for colorectal cancer was developed 
using data from two population-based case-control studies178. By combining the 
risk estimates from age and several risk and protective factors, the risk factors 
which were found to be related to colorectal cancer risk and therefore included in 
the model were age, cancer-negative sigmoidoscopy/colonoscopy in the last 10 
years, history of polyp in the last 10 years, family history of colorectal cancer in 
first-degree relatives, use of aspirin and non steroidal anti-inflammatory drugs, 
cigarette smoking, BMI, vegetable consumption and leisure-time vigorous 
activity. Exposure to hormone-replacement therapy (HRT) and oestrogen 
exposure were additional risk factors in the model for women. This model was 
found to be well calibrated when validated in a large prospective cohort study 
and has been judged to be clinically useful179. 
Several clinically applicable tools have been designed to predict the risk of 
prostate cancer in individuals. The cancer of the Prostate Risk Index (CAPRI) 
model was developed to predict a patient's overall risk of prostate cancer at 
biopsy by including four variables: prostate-specific antigen (PSA), digital rectal 
examination (DRE), race and age180. Despite the high predictive capability of the 
CAPRI test for prostate cancer, another prostate cancer risk assessment tool was 
developed using prostate biopsy data from men who participated in the Prostate 
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Cancer Prevention Trial (PCPT)181. Following logistic regression modelling of 
several risk factors for prostate cancer, the variables which were found to be 
predictive of prostate cancer in this model were higher PSA level, race/ethnicity, 
family history of prostate cancer, age, abnormal DRE, and a previous prostate 
biopsy. The risk equation that was developed from this model has been used to 
develop a clinical prostate cancer risk calculator that can be used by physicians 
or patients181. Also to assess the risk of prostate cancer in individuals, a clinical 
nomogram was constructed by assessing all known risk factors for prostate 
cancer in a cross-sectional study of men who had a prostate biopsy as well as 
some volunteers with normal PSA levels182. Results showed that in addition to 
age, family history of prostate cancer, ethnicity, PSA and DRE, other variables 
which were important to consider were urinary voiding symptoms and the ratio 
of free:total PSA. 
An epidemiologic-genetic risk assessment model to project the individualized 
probability of developing bladder cancer was developed using data from a large 
case-control study of White individuals in the United States183. Cases were 
patients with newly diagnosed and histologically confirmed bladder cancer while 
controls were healthy individuals who had no previous history of cancer and who 
had come to clinic for their annual health check-ups. Cases and controls in the 
study were matched by age, sex and race. By incorporating the epidemiologic 
risk factors: duration of smoking (pack-years smoked), past exposures to diesel 
fuels, aromatic amines, dry cleaning fluids, radioactive materials and arsenic and 
the genetic factor: mutagen sensitivity (a phenotypic marker), this prediction 
model aids the identification of populations at high risk of bladder cancer. 
A risk model to identify individuals at high risk of melanoma was developed 
using information such as age, host characteristics and geographical area184. 
Another risk model exists which estimates an individual's risk of melanoma using 
self assessed risk factors such as sex, age, hair colour, density of freckles, 
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history of severe sunburns in childhood and adolescence, raised moles on the 
arms and history of non-melanoma skin cancer185.   
To improve diagnostic test performance for ovarian cancer in the early stages, a 
model which predicts based on a combination of any two of the three tests: the 
Symptom Index (SI), serum Human Epididymis protein 4 (HE4) test and Cancer 
Antigen 125 (CA-125) test, was found to be more highly discriminatory of 
ovarian cancer than previously developed ovarian cancer detection tools186. 
Another cancer for which risk prediction models have been developed, is 
pancreatic cancer. The first risk prediction model for familial pancreatic cancer 
was the PancPRO which uses a Mendelian risk prediction approach to provide the 
probability that an individual carries a mutation in a pancreatic cancer 
susceptibility gene187. This model was developed using the Bayesian modelling 
framework and apart from providing information on mutation carrier probability, 
it also provides the absolute risk of pancreatic cancer for specified age 
intervals187. Another prediction model was developed to stratify risk of pancreatic 
cancer in chronic pancreatitis patients with focal pancreatic mass lesions with 
prior negative endoscopic ultrasound guided fine needle aspiration (EUS-FNA)188. 
In developing this model, logistic regression modelling was used to test the 
association of  different cancer predictors with pancreatic cancer in a cross-
sectional study of 138 consecutive chronic pancreatitis patients with focal 
pancreatic mass lesions who attended one of three hospitals for an initial EUS-
FNA. Based on findings from this model, the predictors of pancreatic cancer were 
age, mass location, mass number, direct bilirubin and cancer antigen 19-9 (CA 
19-9)188. 
A few risk prediction models have also been developed for lung cancer189-193, 
however these are described in more detail in the following section.  
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Although the cancer risk prediction scores described above have all been shown 
in their respective studies to be clinically useful, it is difficult to ascertain those 
that are routinely used in clinical practice and their actual usefulness in practice. 
 
1.6.2 Lung cancer risk prediction scores 
Several models have been developed to estimate the risk of lung cancer using 
individual baseline risk factors.  
The Bach model was developed in 2003 to determine predictable variations in 
the risk of lung cancer among smokers189. The model was created using data 
from 18,172 individuals aged between 45 and 69 years who had a documented 
history of current or former smoking and who were enrolled in the Carotene and 
Retinol Efficacy Trial (CARET), a randomised trial of lung cancer prevention. Lung 
cancer predictors that were analysed in the development of this model were age, 
sex, prior history of asbestos exposure, smoking duration, average daily number 
of cigarettes smoked and duration of smoking abstinence for former smokers. 
The authors of this model did not consider other possible predictors of lung 
cancer such as history of chronic obstructive pulmonary disease (COPD), chest 
x-ray findings, exposure to second hand smoke, radon exposure and type of 
asbestos exposure because these were not recorded in the CARET study. Using 
Cox proportional hazards regression modelling, the associations between the 
predictors of lung cancer and a diagnosis of lung cancer or death in the absence 
of a diagnosis, were estimated and used to derive 1-year risk models for the 
prediction of lung cancer. The calibration of the models were assessed by 
comparing the observed and predicted rates of lung cancer across different risk 
cut-offs and this was validated by assessing the extent to which the model could 
predict cancer in an independent CARET study site. To determine variation in 
lung cancer risk among smokers, the predicted 10-year lung cancer risk among 
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55 to 74 year old current or former smokers who were enrolled in an ongoing 
low dose CT trial were examined. In the one year risk model to predict lung 
cancer diagnosis, significant predictors of lung cancer among current or former 
smokers were duration of smoking, average number of cigarettes smoked daily, 
duration of abstinence, age and history of asbestos exposure. With a 
concordance index of 0.72 on comparing observed and predicted rates of lung 
cancer, this model was found to be internally valid and well calibrated. Validation 
of the model in an independent CARET study site showed that the observed rates 
of lung cancer were closely matched with that predicted by the model. A major 
limitation of this model however results from the fact that it was derived using 
data of participants enrolled in a clinical trial of lung cancer prediction. Also, 
since all the participants were current or former smokers, this model is only 
applicable to smokers, a subset of individuals at risk of lung cancer. 
An absolute risk prediction model for lung cancer, The Spitz model190 published 
in 2007, extended the work of Bach et al. and incorporated additional risk factors 
apart from smoking and asbestos exposure, in the development of the risk 
prediction model. The model was derived using epidemiologic data from a large 
case-control study of 1,851 newly diagnosed, histologically confirmed cases of 
lung cancer and 2,001 healthy controls, matched by age, sex, ethnicity and 
smoking status to the cases. Information was collected on smoking history 
(including exposure to environmental tobacco smoke (ETS)), age at smoking 
cessation for former smokers, family history of any cancer and of smoking-
related cancers in first-degree relatives, exposure to wood dust, asbestos 
exposure, previous history of respiratory disease and hay fever, and then logistic 
regression models were constructed separately for never, former and current 
smokers. Multivariable logistic regression analyses were used to construct the 
final risk models to determine variables that were predictive of lung cancer. 
Variables which were found to be associated with lung cancer in never smokers 
48 
 
were exposure to ETS and family history of any cancer. In current and former 
smokers, lung cancer was associated with dust exposure, no previous history of 
hay fever, previous history of emphysema, family history of any cancer or 
tobacco-related cancers, smoking intensity and age at smoking cessation (in 
former smokers). Lung cancer was also found to be associated with exposure to 
asbestos in current but not former smokers. On validating the risk models, the 
concordance statistics in validation sets for the never, former and current 
smokers were 0.57, 0.63 and 0.58 respectively. Overall, the discriminatory 
accuracy of this model was found to be modest but was consistent with those 
from other risk-prediction models. A drawback of the model however, is that 
cases and controls were frequently matched on smoking status therefore 
affecting the importance of smoking as a risk factor. Also, the model was derived 
using data from non-Hispanic whites which limits its generalisability to other 
ethnic groups.  
To compensate for the modest precision of the Spitz model, an expanded Spitz 
model194 which incorporated select markers of DNA repair capacity was 
developed and published in 2008. This model was developed using assay data 
from 725 lung cancer cases and 615 controls - a subset of cases and controls 
from the original analysis. All the cases and controls included in this analysis 
were current or former smokers. Multivariable modelling were carried out using 
the variables in the original Spitz model with the addition of the biomarker 
assays. Comparison with the original Spitz model showed an improvement in the 
discrimination of the expanded Spitz model, with concordance statistics of 0.70 
and 0.73 for former and current smokers respectively. The authors of this model 
however cautioned that the biomarker assays were time consuming and require 
some level of technical expertise. The model may therefore be applied in a 
controlled academic setting but it is not feasible to implement in the general 
population.  
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Another lung cancer risk prediction model - The Liverpool Lung Project (LLP) risk 
model191, was developed to project the individual 5-year absolute risk of 
developing lung cancer using data from a case-control study of lung cancer in 
Liverpool, UK. Information on socioeconomic and demographic characteristics, 
medical history, family history of cancer, history of tobacco consumption and 
lifetime occupational history were collected from all 579 lung cancer cases aged 
between 20 and 80 years of age, and 1157 controls who were matched by age 
and sex with the cases. Conditional logistic regression models were constructed 
to identify the variables that were associated with lung cancer in multivariate 
analysis. Variables which were found to be associated and therefore included in 
the risk-prediction model were individuals' age, sex, duration of smoking, family 
history of lung cancer, occupational exposure to asbestos, prior history of 
pneumonia and prior diagnosis of any cancer other than lung cancer. Although 
the authors had yet to validate the model using independent data, assessment in 
the case-control dataset showed good discrimination between cases and 
controls. 
Compared to the Bach and Spitz models, the LLP model has been found to 
correctly identify a higher proportion of lung cancer patients but it also has a 
much higher rate of false positives and therefore falsely identifies more 
individuals who have low risk of lung cancer than the previous two models195. At 
a cut-off value to capture 62% of cases of lung cancer, the LLP model falsely 
identifies 30% of non-lung cancer controls. Despite the shortcomings of this 
model, it is currently being employed to identify individuals at risk of lung cancer 
for the UK lung screen (UKLS) trial of low dose CT screening for lung cancer128. 
Lung cancer risk prediction models were also developed in 2011 using 
prospective data from 55 to 74 year old men and women enrolled in the 
Prostate, Lung, Colorectal and Ovarian Cancer screening Trial (PLCO) - a 
randomised clinical trial designed to study the effect of screening modalities on 
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cancer mortality rates193. Four annual chest radiographs were done for subjects 
in the screening arm of the study while other subjects in the control arm were 
given regular care as recommended by their physicians. Risk prediction models 
were developed using data from control subjects who were cancer-free at the 
time of entry into the study. One model was developed using data from 70,962 
control subjects and another was developed using a sub-cohort of 38,254 control 
subjects who were ever smokers. The models were validated with 44,223 
subjects who were in the intervention arm of the PLCO trial. Potential predictors 
of lung cancer which were analysed in the development of these models were 
age, socioeconomic status (education), race, sex, family history of lung cancer, 
body mass index, history of COPD, history of chest x-ray in the past 3 years and 
smoking history (including smoking intensity, quit time for former smokers, and 
pack-years smoked). In the first model that was developed using all eligible 
control subjects, the variables that were associated with lung cancer were age, 
educational attainment, BMI, family history of lung cancer, history of COPD, 
history of chest x-ray in the past 3 years, current smoking status, pack-years 
smoked and smoking duration. In the second model based on only the ever-
smokers in the control arm of the study, the variables that were associated with 
lung cancer were age, pack-years and quit-time. On validation of the models 
using subjects in the intervention arm of the study, both models demonstrated 
high discrimination and calibration. The authors however acknowledged that 
several potentially useful predictors which had been included in previous models 
(for example, exposure to occupational carcinogens and history of adult 
pneumonia) were not included in the model. Also, the external validation sample 
came from the same PLCO referent screening trial population from which the 
prediction models were developed. The models may therefore not be 
generalisable and the discrimination may not be as good, when applied to other 
populations. 
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All the lung cancer risk models discussed thus far have estimated the risk of lung 
cancer using individual baseline risk factors. In a case-control study of 3,197 
patients with lung cancer and 1,703 cancer-free controls, the discriminatory 
power of the Bach, Spitz and LLP models were assessed and in this study, the 
positive predictive values of the models were found to be high overall (>75%), 
indicating that they had a high probability of accurately categorising affected 
participants195. However, all three models had relatively low negative predictive 
values (between 45% and 56%) and therefore had a moderately low probability 
of accurately categorising unaffected participants in the study. The need to 
identify other important risk factors (than smoking) that have a different 
distribution in lung cancer patients compared to those who will not develop lung 
cancer were suggested as a means of improving the discriminatory power of 
these models195. 
A population-based case-control study using data from all 21 general practices in 
Exeter, UK, showed that several symptoms were independently associated with 
lung cancer up to 180 days before diagnosis113. However, if lung cancer risk 
were to be predicted using only alarm symptoms without the inclusion of other 
baseline risk factors, more than 75% of cases would be excluded117. 
A recently developed risk algorithm took account of baseline risk factors and 
symptoms in primary care as a means of identifying patients at high risk of lung 
cancer192. This algorithm was developed using data of primary care patients in 
QResearch, a computerised database of primary care records in England and 
Wales. Derivation of the algorithm was done using data from two-thirds of the 
practices while it was validated using the remaining one-third of practices. 
Predictor variables that were analysed to develop this risk algorithm were: 
current GP consulting for clinical symptoms of haemoptysis, loss of appetite and 
weight loss, recent GP consulting within the past 12 months for symptoms of 
cough, dyspnoea, tiredness, and hoarseness, body mass index, smoking status, 
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history of COPD, Townsend deprivation score, family history of lung cancer, 
previous cancer diagnosis, previous history of asthma, previous history of 
pneumonia, asbestos exposure and history of anaemia. The study outcome was 
the incident diagnosis of lung cancer during the subsequent 2 years. Variables 
which were found to be predictive of lung cancer were age, body mass index, 
Townsend score, smoking status, COPD, current GP consulting for haemoptysis, 
current loss of appetite, current weight loss and recent consultation for cough. A 
prior diagnosis of cancer was predictive of lung cancer only in females. Validation 
of the algorithm using the remaining one-third of QResearch practices, showed 
that it was well calibrated. In developing this algorithm, symptoms that were 
recorded in the period preceding lung cancer diagnosis when patients would 
likely be undergoing investigations for suspected cancer were not excluded. 
Therefore in these clinical situations where GPs may already be investigating 
patients' symptoms for possible lung cancer diagnosis, the association made by 
this algorithm between patients' current consulting for clinical symptoms and the 
incident diagnosis of lung cancer in the subsequent 2 years may only be stating 
the obvious. Based on the fact that a fundamental characteristic of good clinical 
prediction tools is not simply to predict clinical outcomes but to also provide 
opportunity for the outcomes to be prevented or delayed156, it follows therefore 
that the clinical usefulness of this risk-prediction algorithm may be limited. 
 
1.7 Summary of the evidence on lung cancer risk 
assessment scores 
Most of the models that have been developed to predict the risk of lung cancer, 
use baseline risk factors to estimate an individual's risk of lung cancer. A case-
control study which assessed the discriminatory performances of the Bach, Spitz 
and LLP models found these to be modest195. The need to identify other 
important risk factors (other than smoking) that have a different distribution in 
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lung cancer patients compared to those who will not develop lung cancer was 
suggested as a means of improving the lung cancer risk discriminatory power of 
these models195.  
Clinical symptoms in primary care have been shown to be independently 
associated with lung cancer up to 180 days before diagnosis113. However, to 
attempt to predict lung cancer risk using only alarm symptoms without the 
inclusion of other baseline risk factors would exclude more than 75% of cases117. 
The only lung cancer predictive model which has been developed using a 
combination of patients' baseline risk factors and symptoms in primary care did 
not exclude symptoms that were reported to the GP in the period leading up to 
lung cancer diagnosis in the model development. This model has the tendency to 
predict lung cancer in patients who are already being investigated for possible 
lung cancer by their GPs and its clinical usefulness is therefore limited. 
 
1.8 Rationale of the thesis 
Lung cancer survival is poor in the UK and delay in diagnosis has been 
recognised as an important factor contributing to this. There are currently no 
screening tests for lung cancer so earlier diagnosis is vital in order to improve 
treatment outcomes and overall survival. Several studies have suggested that 
the delay in lung cancer diagnosis may be partly due to late presentation of lung 
cancer symptoms by patients to general practice112 139 196 while others suggest 
that delay in symptom recognition in general practice113 139 197 may be to blame. 
While there is a well recognised need to address the issue of late presentation of 
symptoms of lung cancer to general practice, there is also a pressing need for 
research to understand the interactions between GPs and patients in primary 
care before the diagnosis of lung cancer is made198.  
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To diagnose lung cancer earlier and improve survival, it is important that signs 
and symptoms are recognized promptly in primary care, especially among 
individuals who are at high risk of lung cancer134. The NICE referral guidelines 
developed to facilitate urgent referral of suspected lung cancer cases were based 
on a weak evidence base142 and in some instances, may be misleading134. The 
low predictive power of the referral guidelines as a marker for lung cancer was 
demonstrated in a study conducted in a hospital trust in England which showed 
that only 42% of the patients urgently referred by their GPs for suspected lung 
cancer based on the criteria for urgent referral were diagnosed with lung cancer 
142.  
To further aid the identification and subsequent early investigation by GPs, of 
patients who are at high risk of lung cancer from those who present with non-
specific symptoms associated with other illnesses, there is the need for a 
predictive tool that combines patients' baseline risk factors and early symptoms 
of lung cancer. The only risk prediction model which was developed using a 
combination of symptoms and other lung cancer baseline risk factors has been 
shown to be methodologically flawed192 and necessitates further work to 
accurately determine the predictors of lung cancer in primary care.  
Drawing on all the points above, this thesis aims to validate the use of lung 
cancer data from a large computerised database of UK general practice for 
research and then extensively explore the GP-patient interaction before lung 
cancer diagnosis over a 10 year period, with the aim of identifying factors which 
are associated with lung cancer. The database used for analysis in this thesis had 
been linked with Experian's Mosaic Public Sector TM classification, a geo-
demographic social marketing tool that classifies all households and postcodes 
within the UK into 61 types and 11 groups based on their typical demographics, 
consumer behaviour, lifestyle and attitudes101. This has enabled the identification 
of particular sectors of the UK where lung cancer incidence is highest with a view 
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to enabling focused and targeted public health interventions to improve lung 
cancer awareness and care. Following the identification of the predictors of lung 
cancer in general practice, the possibility of developing a predictive score will be 
explored. It is hoped that the results from this thesis will inform guidelines that 
will aid diagnosis and care of patients with lung cancer in primary care. 
 
1.9 Thesis objectives 
The aim of this thesis is to investigate the GP-patient interaction in the period 
before lung cancer diagnosis, with a view to determining the possibility of 
developing a predictive score for lung cancer that could be used to aid earlier 
diagnosis of future cases. The objectives that have been set in order to achieve 
this aim are to: 
 Determine the validity of THIN database for studies on lung cancer in the 
UK and at the same time, identify the sectors of UK society where the 
incidence of lung cancer is highest. 
 Explore the differences in the risk of lung cancer among different sub-
groups of patients with similar recorded levels of cigarette smoke 
consumption, using a dataset of lung cancer cases and controls matched 
by age (year of birth), sex and general practice. 
 Determine the independent predictors of lung cancer in a case-control 
dataset, matched only by practice and then develop a predictive score for 
lung cancer 
 Investigate the validity of the lung cancer predictive score in an 
independent dataset of THIN patients  
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1.10 Outline of thesis sections 
The following chapters of this thesis discuss the database that was analysed in 
this thesis, a description of how the analysed datasets were prepared and three 
chapters on studies that address the objectives of the thesis. The content of 
each chapter is detailed below: 
Chapter 2: Description of The Health Improvement Network (THIN) database, 
key dates in THIN, the process of data preparation and an account of how the 
lung cancer population was derived, ethical approval for the studies in this thesis 
and statistical software.   
Chapter 3: In the first study, the characteristics of patients with lung cancer in 
THIN is summarised and the validity of THIN for lung cancer research is 
assessed. The potential use of Experian's Mosaic Public Sector ™ classification to 
facilitate disease ascertainment by identifying particular sectors of the UK society 
where lung cancer incidence is highest, is also explored. 
Chapter 4: A matched case-control dataset is developed for the primary purpose 
of piloting the methods for the development of a lung cancer score. This is 
followed by a description of studies using this dataset to explore differences in 
the risk of lung cancer, firstly among deprived compared to non-deprived 
smokers, then among depressed compared to non-depressed smokers. Lastly, a 
study which used the thesis dataset to assess the difference in smoking-
associated risk of lung cancer among men and women is summarised. 
Chapter 5: An unmatched dataset of lung cancer cases and controls is developed 
and this is used to identify the socio-demographic and early clinical factors 
predictive of lung cancer in general practice.  
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Chapter 6: A lung cancer risk-predictive model is derived using the lung cancer 
predictors identified in chapter 5, and this is followed by the validation of the 
model in an independent cohort of patients in THIN. 
Chapter 7: A summary of the main findings in the thesis, what it adds to the 
existing knowledge of lung cancer and suggested future research.  
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2. Chapter 2.  Description of the dataset and 
derivation of the lung cancer population 
This chapter describes The Health Improvement Network (THIN) database - the 
computerised database of general practice records that was used for the 
analyses in this thesis. It describes the component files that make up the 
database including Experian's MOSAIC Public Sector™ variable which had been 
linked with the database and this is followed by a step-by step account of the 
process that was used to prepare the dataset for all the analytic work that was 
undertaken. The steps taken to derive the final population of lung cancer cases 
are also described and lastly, a brief summary of the ethical approval for this 
study, funding and the statistical software used for all the analyses in this thesis.   
 
2.1  The Health Improvement Network database 
The Health Improvement Network (THIN)199 is a computerised longitudinal 
database of anonymised primary care records from the UK. In October 2009 
when the data for this study were compiled, THIN contained data from 446 
general practices across the UK with a total of 8.2 million patients. More than 3.2 
million of these patients were actively registered and could be prospectively 
followed while the remaining patients who had historic data, had either left the 
practice or died. 
In May 2002, THIN was set up through the collaboration between Epidemiology 
and Pharmacology Information Core (EPIC) - a research organisation that for 
many years facilitated access to the General Practice Research Database (GPRD) 
for medical research, and In Practice Systems (InPS)200 who provide Vision 
software - the general practice interface software to about 2000 general 
practices in the UK199 201. On joining the THIN scheme, general practices 
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contribute data prospectively using the practice's Vision computer software 
without interruption to normal practice operation. All retrospective data are also 
uploaded into the patients' records, most of which were recorded using the Value 
Added Medical Products (VAMP) practice management system202 that was used 
in the GPRD. Incremental data are downloaded monthly by EPIC, processed and 
added to existing data to create the THIN data that is made available to 
researchers199. 
 
2.1.1  Structure of THIN database 
The database contains all records relating to patients such as information on 
signs and symptoms, diagnosis, prescriptions, routine health checks, 
preventative health information and referrals to secondary care203. These data 
are contained in four standard files - patient, medical, therapy and additional 
health data (AHD) files; as well as two linked files - postcode variable indicators 
(PVI) and dosage records (Table 2.1). All entries are organised by practice and 
each patient has a unique identifier to enable linking of patients' records across 
all files. Data are entered into THIN using Read codes which are a standard 
hierarchical classification system used by general practitioners in the UK to 
record patient medical information203. Table 2.2 shows the formats for the 
different files in THIN database.  
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Table 2.1. Structure of THIN database 
   
THIN data file 
 
Information recorded 
 
Standard 
files 
 
Patient  
Patient demographics, registration details 
such as date of registration with practice, 
date of transfer out of practice, date of 
death. 
 
Medical  
Symptoms, diagnosis, interventions 
recorded in primary care as well as 
discharge summaries from hospital and 
letter from specialists 
 
Therapy 
Prescriptions issued to patients (including 
formulation and strength of medications, 
dose and quantity) 
 
Additional health 
data  
Lifestyle data, test results, details of 
death, immunizations and physical 
measurements 
 
Linked 
files 
Dosage Dosage instructions 
Postcode variable 
indicators 
Postcode-linked area based 
socioeconomic, ethnicity and 
environmental indices  
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Table 2.2  Example of file formats in THIN 
The tables below show the formats of the different data files in THIN. This is followed by a description of what the different fields 
represent. 
 
a. Patient data file  
combid prac patid patflag yob hh regdate regstat xferdate regrea deathdate amrdate visdate pracstart lastdate 
a6732  00?? a6732 00?? A  1961 48661 19881102 2 0   20010101 20070711 20010101 20090729 
a6732  00?0 a6732 00?0 A  1970 37682 19960830 5 20050604 3  20010101 20070711 20010101 20090729 
a6732  00?1 a6732 00?1 A  1938 22561 19410815 2 0   20010101 20070711 20010101 20090729 
a6732  00?2 a6732 00?2 A 1952 21402 20020903 99 20061018 1 20061018 20010101 20070711 20010101 20090729 
a6732  00?3 a6732 00?3 A 1912 10641 19581010 2 0   20010101 20070711 20010101 20090729 
 
b. Medical file 
combid prac patid evdate medcode medflag diagnosr source episode NHSspec locate textid 
a6831  01OF a6831 01OF 19920518 8B41.00 R 00000D 0 0 000 I 1yYe 
a6831  01OF a6831 01OF 19921020 173..00 R 00000D 0 1 000 I 22Ie 
a6831  01OF a6831 01OF 19930527 ZZZZZ00 R 00000D L 4 000 I 0rdr 
a9928  02Y8 a9928 02Y8 20031007 8B28.00 R 00000c 0 1 000 I 0000001 
a9928  02Y8 a9928 02Y8 20031007 8B63.12 R 00000c R 0 000 I 0000001 
 
c. Therapy file 
combid prac patid rxdate drugcode therflag doscode rxqty rxdays private prscber rxtype opno bnf seqnoiss maxnoiss packinfo dosgval 
a6732  009Z a6732 009Z 20020228 95617998 Y 0001826 60 0 N 000000B 1 0 2080200 1 0 0 -1 
a6732  00?e a6732 00?e 20061012 90841998 Y 0003563 30 0 N 0000004 1 0 1060400 0 0 0 1 
a6732  00BF a6732 00BF 20060106 86990998 Y 0000200 56 0 N 0000004 1 0 2060200 14 0 0 1 
a6732  00Sr a6732 00Sr 20041020 97085997 Y 0000424 2 0 N 000000A 1 0 3010101 11 0 0 -1 
a6732  00dO a6732 00dO 20060113 97217998 Y 0000200 56 0 N 0000003 1 0 2020100 29 0 0 1 
  
d. Additional health data (AHD) file 
combid prac patid evdate ahdcode ahdflag ahdval1 ahdval2 medcode source NHSspec locate 
a6732  009Z a6732 009Z 20050413 1003040001 R 00000000 00000000 137S.00 0 000 I 
a6732  00?e a6732 00?e 19931001 1003050000 R 0 Y 1362.00 0 000 I 
a6732  00BF a6732 00BF 20031013 1003050000 R 0 Y 1363.00 0 000 I 
a6732  00Sr a6732 00Sr 20071003 1003050000 R 28 Y 136..00 0 000 I 
a6732  00dO a6732 00dO 20031007  1003050000 R 0 N 1361.00 0 000 I 
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Description of the fields in THIN dataset 
combid Patient identifier which is unique within the entire THIN dataset 
(combination of practice id and patient id) 
prac Practice identifier 
patid Patient identifier which is unique within practice 
patflag Flag which indicates the integrity of the data for that patient 
yob Year of birth 
hh Household identifier 
regdate Date of patients' registration with the practice 
regstat Registration status (for example, 2 = permanent, 5 = transferred out, 15 
= walk-in centre, 99 = death) 
xferdate Date when patient was transferred out from the general practice 
regrea Additional registration information (for example, 1 = death, 3 = internal 
transfer, 23 = registration cancelled) 
deathdate Date of death 
amrdate Acceptable mortality recording date. This denotes the year when the 
practices' is deemed to be reporting all-cause mortality based on predicted 
numbers from national statistics. It is a measure of when data records 
from the practice became broadly reliable 
visdate Date when the practice started to use the vision software 
pracstart Earlier of amrdate and visdate 
lastdate Date of last data collection from the practice 
evdate Date of the event recorded 
medcode Read codes which are coded clinical language 
medflag Flag indicating integrity of the clinical record (for example, R = acceptable 
record, E = source invalid) 
diagnosr Identifier of person entering record 
source Variable indicating origin of record 
episode Episode type (for example, 1 = First ever episode, 2 = new event) 
NHSspec Secondary care specialty 
locate Location of consultation 
textid Link to free text comment 
rxdate Prescription date 
drugcode Multilex drug code 
therflag Flag indicating integrity of the record 
rxqty Quantity prescribed 
rxdays Duration of the prescription in days 
prscber System assigned identifier or prescriber 
rxtype Variable denoting if acute or repeat prescription 
opno Number of original packs ordered 
bnf BNF (British National Formulary) 1 code 
seqnoiss Issue sequence number for repeat prescriptions 
maxnoiss Maximum number of issues for repeat prescriptions 
packinfo pack size information 
dosgval The calculated daily dosage 
ahdcode AHD (Additional Health Data) code 
ahdflag Flag indicating integrity of record 
ahdval1 AHD value 1 
ahdval2 AHD value 2 
 
 
63 
 
2.1.2  Quality of data in THIN  
To ensure high quality data, each general practice that contributes data to THIN 
receives expert advice and training on quality data recording, and audits are 
performed to ensure that practices are recording data to a sufficiently high 
standard199. The Health Improvement Network has been demonstrated to have 
high quality data201 and several published validation studies have shown the 
database to be valid for pharmacoepidemiology research204 205 with a high degree 
of completeness and accuracy for records of several disease diagnoses206-208. A 
recent study showed that the records of incidence of all cancers in THIN were 
consistent with that reported in cancer registries209. More specifically, the 
observed recording rates of pancreatic, colorectal and lung cancers in THIN 
which were lower than cancer registry rates between 2000-2002, had increased 
to approximately 80% of registry years in later years, after 2004209. 
In addition to the validation studies, there have been several publications to date 
from medical research conducted using THIN data and these include: a nested 
case-control study published in 2006, which assessed the risk of diabetes 
associated with prescribed glucocorticoids210. A study published in 2010 
estimated the incidence of dementia and survival after a primary care diagnosis 
of dementia211 using data from 353 UK general practices contributing to THIN. 
Another study published in 2011 assessed the trends in long-term oral 
glucocorticoid prescription in the UK212. More recent research conducted using 
THIN database includes a study which aimed to determine the prevalence of 
underlying disease in men with erectile dysfunction receiving phosphodiesterase 
type 5 inhibitors in the UK213 and another study which evaluated the risk of 
myocardial infarction and death from coronary heart disease after 
discontinuation of low dose aspirin in individuals with a previous history of 
cardiovascular events214. 
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2.1.3  Strengths and weaknesses of THIN 
THIN dataset is well known to be a source of high quality data for 
epidemiological studies. As with any other data source, it inevitably has some 
limitations. This section highlights some of the key strengths of THIN and also 
considers some limitations of using data from general practice databases for 
research.  The design of the study in this thesis was made following 
consideration of the limitations of the dataset. 
 
2.1.3.1  Size 
THIN is a large dataset containing primary care records of approximately 5.8% 
of the UK population in 2009. Due to its large size, an adequate number of 
patients with relatively rare outcomes can be identified. It is therefore a good 
source of data for studies investigating rare diseases such as lung cancer.  
 
2.1.3.2  Scope of data recording 
Data in THIN are collected during routine general practice consultation without 
interruption to normal practice operation and therefore reflects "real-life"199. A 
drawback of THIN and other computerised routine general practice databases 
however, is that the data recorded in GPs' medical record system are collected 
primarily for the purpose of patient and practice management and not for 
research199. In routine medical care, the recording of information tends to be 
selective rather than comprehensive215 and there is a tendency therefore for GPs 
to record only the information that they require or which they consider relevant 
to the patients' condition at the time of consultation. Not only does this imply 
that certain information that is vital for research may be not be obtainable from 
the dataset, but there is a likelihood of ascertainment bias and misleading 
associations arising from differential surveillance of patients215.  
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2.1.3.3  Representativeness  
All individuals residing in the UK have a right to be registered with a GP and the 
care provided at general practices are free of charge. To a large extent, data 
from general practices represent all sections of the UK population. Evidence 
however suggest that there may be a slight over-representation of practices 
from more affluent areas in THIN216 217. Despite these assertions, validation 
studies have found data in THIN to be widely representative of the UK 
population. Also as mentioned above, records of cancer incidence in THIN have 
been found to closely resemble records of incidence in the cancer registries209. 
 
2.1.3.4  Temporality 
The method of data entry into the THIN database enables the prospective follow-
up of patients and an ability to identify the timing of data collection in relation to 
the outcome of interest. It is therefore possible to establish the cause-effect path 
and this overcomes any bias due to loss of temporality. Information in THIN is 
also continually updated and allows the investigation of any effects of new drugs 
or interventions on the outcome.  
 
2.1.3.5  Diagnostic criteria 
A limitation with routine general practice data is that the perception of morbidity 
may vary between different practices and even within GPs in the same 
practice218. Analyses done using these data are therefore based on the recorded 
diagnosis being the best diagnostic formulation. The accuracy and variation of 
lung cancer diagnoses in different general practices has not been assessed. 
However considering that lung cancer diagnosis is made following investigations 
in primary care or by the chest physician in secondary care, it is unlikely that 
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there will be significant variation in the GP diagnostic criteria for lung cancer in 
this study. 
 
2.1.4  Measures of socioeconomic status in THIN 
In addition to routine health information, patients' records in THIN have area-
level information such as strategic health authority (SHA) regions. There are two 
area-based measures of socioeconomic status available in the THIN dataset. 
These are the Townsend quintile of deprivation and the Mosaic public sector TM 
classification. 
Townsend quintile of deprivation is a widely used and well validated measure of 
deprivation219. It measures the level of material deprivation for each output area 
(corresponding to approximately 125 households with similar characteristics220) 
using the following four indicators derived from census data221:  
 Unemployment: the percentage of economically active residents aged 16-
64 who are unemployed 
 Car ownership: The percentage of private households who do not possess 
a car 
 Home ownership: The percentage of private households not in owner 
occupied accommodation 
 Overcrowding: The percentage of private households in overcrowded 
accommodation 
Postcodes in the UK are matched to their output-area Townsend deprivation 
quintiles and during THIN data collection, the Vision software maps the 
anonymous id of patients in THIN to these quintiles using the patients' postcode. 
Records of patients in THIN were also linked with another measure of 
socioeconomic status - The Mosaic public sector TM variable. This is a lifestyle 
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segmentation tool originally designed by Experian to profile customers for the 
purpose of market research222. Mosaic Public Sector™ refines areas at a higher 
level than available deprivation markers by using data from 400 variables to 
classify all postcodes within the UK into 61 types, each type being a member of 
one of 11 groups. Of the 400 variables used to develop a Mosaic Public Sector™ 
profile, 54% are sourced from the 2001 Census while the other 46% are derived 
from sources such as the Experian Lifestyle Survey, consumer credit databases, 
the electoral roll, shareholder registers, Land registry data, Council Tax 
information, the Hospital Episode Statistics, the British Crime Survey, 
Expenditure and Food Survey and other sources222. Mosaic Public Sector™ 
classification is based on typical demographics, behaviour, consumer values, 
consumption patterns, lifestyle, education and social and health-related 
attitudes101.  Table 2.3  shows the Mosaic public sector TM classification into 11 
groups and 61 types, as well as a concise description of the characteristics of 
individuals in these Mosaic types. 
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Table 2.3. Mosaic Public Sector™ groups and types 
 
Code 
 
Mosaic Public Sector™ group 
 
Cod
e 
 
Mosaic Public Sector™ type 
 
A 
(Symbols of 
success) 
 
Career professionals living in sought 
after locations  
A01 Financially secure people living in smart flats in cosmopolitan inner city locations 
A02 Highly educated senior professionals, many working in the media, politics and law 
A03 Successful managers living in very large houses in outer suburban locations 
A04 Financially secure couples, many close to retirement, living in sought after suburbs 
A05 Senior professionals and managers living in the suburbs of major regional centres 
A06 Successful, high earning couples with new jobs in areas of growing high tech employment 
A07 Well paid executives living in individually designed homes in rural environments 
 
B 
(Happy 
families) 
 
Younger families living in newer 
homes 
B08 Families and singles living in developments built since 2001 
B09 Well qualified couples typically starting a family on a recently built private estate 
B10 Financially better off families living in relatively spacious modern private estates 
B11 Dual income families on intermediate incomes living on modern estates 
B12 Middle income families with children living in estates of modern private homes 
B13 First generation owner occupiers, many with large amounts of consumer debt 
B14 Military personnel living in purpose built accommodation 
 
C 
(Suburban 
comfort) 
 
Older families living in suburbia 
C15 Senior white collar workers many on the verge of a financially secure retirement 
C16 Low density private estates, now with self reliant couples approaching retirement 
C17 Small business proprietors living in low density estates in smaller communities 
C18 Inter war suburbs many with less strong cohesion than they originally had 
C19 Attractive older suburbs, typically occupied by families but with increasing singles and childless couples 
C20 Suburbs sought after by the more successful members of the Asian community 
 
D 
(Ties of 
community) 
 
Close-knit, inner city and 
manufacturing town communities 
D21 Mixed communities of urban residents living in well built early 20th century housing 
D22 Comfortably off manual workers living in spacious but inexpensive private houses 
D23 Owners of affordable terraces built to house 19th century heavy industrial workers 
D24 Low income families living in cramped Victorian terraced housing in inner city locations 
D25 Centres of small market towns and resorts containing many hostels and refuges 
D26 Communities of lowly paid factory workers, many of them of South Asian descent 
D27 Multi-cultural inner city terraces attracting second generation settlers from diverse communities 
 
E 
(Urban 
intelligence) 
 
Educated, young, single people living 
in areas of transient populations 
E28 Neighbourhoods with transient singles living in multiply occupied large old houses 
E29 Economically successful singles, many living in privately rented inner city flats 
E30 Young professionals and their families who have gentrified terraces in pre 1914 suburbs 
E31 Well educated singles and childless couples colonising inner areas of provincial cities 
E32 Singles and childless couples in small units in newly built private estates 
E33 Older neighbourhoods increasingly taken over by short term student renters 
E34 Halls of residence and other buildings occupied mostly by students 
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F 
(Welfare 
borderline) 
 
People living in social housing with 
uncertain employment in deprived 
areas 
F35 Young people renting hard to let social housing often in disadvantaged inner city locations 
F36 High density social housing, mostly in inner London, with high levels of diversity 
F37 Young families living in upper floors of social housing 
F38 Singles, childless couples and older people living in high rise social housing 
F39 Older people living in crowded apartments in high density social housing 
F40 Older tenements of small private flats often occupied by highly disadvantaged individuals 
G 
(Municipal 
dependency) 
Low income families living in estate 
based social housing 
G41 Families, many single parent, in deprived social housing on the edge of regional centres 
G42 Families with school age children, living in very large social housing estates on the outskirts of provincial cities 
G43 Older people, many in poor health from work in heavy industry, in low rise social housing 
H 
(Blue collar 
enterprise) 
 
Upwardly mobile families living in 
homes bought from social landlords 
H44 Manual workers, many close to retirement, in low rise houses in ex-manufacturing towns 
H45 Older couples, mostly in small towns, who now own houses once rented from the council 
H46 Residents in 1930s and 1950s council estates, typically in London, now mostly owner occupiers 
H47 Social housing, typically in 'new towns', with good job opportunities for the poorly qualified 
I (Twilight 
subsistence) 
Older people living in social housing 
with high care needs 
I48 Older people living in small council and housing association flats 
I49 Low income older couples renting low rise social housing in industrial regions 
I50 Older people receiving care in homes or sheltered accommodation 
 
J 
(Grey 
perspectives) 
 
Independent older people with 
relatively active lifestyles 
J51 Very elderly people, many financially secure, living in privately owned retirement flats 
J52 Better off older people, singles and childless couples in developments of private flats 
J53 Financially secure and physically active older people, many retired to semi rural locations 
J54 Older couples, independent but on limited incomes, living in bungalows by the sea 
J55 Older people preferring to live in familiar surroundings in small market towns 
J56 Neighbourhoods with retired people and transient singles working in the holiday industry 
 
K 
(Rural 
isolation) 
 
People living in rural areas far from 
urbanisation 
K57 Communities of retired people and second homers in areas of high environmental quality 
K58 Well off commuters and retired people living in attractive country villages 
K59 Country people living in still agriculturally active villages, mostly in lowland locations 
K60 Smallholders and self employed farmers, living beyond the reach of urban commuters 
K61 Low income farmers struggling on thin soils in isolated upland locations 
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2.2 Preparation of the dataset for this thesis 
For the work in this thesis, data management and the initial cleaning of THIN 
database were performed by Chris JP Smith, the data manager in the Division of 
Epidemiology and Public Health, University of Nottingham. Following a rigorous 
systematic search of the Read code list, Barbara Iyen-Omofoman compiled the 
Read code lists for extraction of the THIN lung cancer population. This was used 
by Chris Smith to extract the entire THIN population of patients with a recorded 
code of lung cancer. Barbara Iyen-Omofoman performed subsequent data 
management of the lung cancer patient population and devised the eligibility 
criteria for the extraction of other populations that were used to develop the 
case-control populations analysed in this thesis. Chris Smith and Barbara Iyen-
Omofoman worked together to extract the first case-control dataset (matched on 
age, sex and general practice) and then Barbara Iyen-Omofoman independently 
extracted the second case-control dataset (matched on practice alone).  
Apart from the Read code lists for smoking status, Chronic Obstructive 
Pulmonary Disease (COPD) and depression which had previously been used and 
validated in other studies within the Division of Epidemiology and Public Health, 
Barbara Iyen-Omofoman compiled the Read code lists that were used to extract 
information on quantity of cigarettes smoked, lung cancer histology and the 
clinical symptoms and investigations in general practice. All stages of the data 
preparation for this thesis were supervised by Professor Richard Hubbard and Dr 
Laila Tata and they reviewed all Read code lists prior to data extraction. 
A preliminary set of data analyses were conducted in the first nine months of this 
PhD using data from the version of THIN that was released in October 2008. 
Following a review of the methodology, the release of an updated version of 
THIN database in July 2009 and in-depth discussion with my PhD supervisors, it 
was decided that amendments should be made to the methodology initially used 
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and that I should repeat all the analyses using slightly different methods and the 
more recent version of the database. All the analyses described in this thesis on 
the lung cancer population as well as analyses using the two case-control 
datasets are the results of analyses done with the July 2009 version of THIN. 
The last set of analyses which were done to validate the lung cancer predictive 
score were done using data from the most recent version of THIN which was 
released in September 2010.  
The following sections describes the steps that were taken to prepare the 
datasets for all the analytical work that was undertaken in this thesis.  
 
2.2.1  Definition of incident lung cancer cases  
To study the interaction between GPs and patients in the period before lung 
cancer is diagnosed, it was decided that the lung cancer cases included in the 
study should have their first date of lung cancer diagnosis within the study 
period. This would also enable a measure of the true survival of lung cancer and 
avoid any survival bias that may arise with prevalent cases. To ensure that only 
incident cases of lung cancer were included in the study, the patients had to 
have been actively registered in the general practice for at least one year prior 
to the first diagnosis of lung cancer.  
An arbitrary study start date of January 1st 2000 was assigned for the study. 
The last date of data collection in the version of THIN that was used for this 
study was July 28th 2009. The study was therefore carried out on patients with a 
first diagnosis of lung cancer between the 1st of January 2000 and the last date 
of data collection - 28th of July 2009. Certain inclusion and exclusion criteria 
were applied in deriving the population that were included in the analyses but 
these will be described in a subsequent section after defining some key dates in 
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the dataset as well as amendments that were made to records that had incorrect 
dates. 
 
2.2.2  Key dates in THIN and the derivation of study specific 
dates 
Most of the work in this thesis entails the follow-up of patients from a start date 
to a defined end date. In THIN database, dates are provided by EPIC to indicate 
the date of registration of patients in their respective GP practices, the date that 
the various GP practices started contributing data to THIN, the dates when the 
general practices were deemed to have mortality records that were comparable 
with national records, the date of patients' death, the date of transfer of 
patients' from their practice if applicable as well as the date of last data 
collection from the practices by EPIC. Some of the dates provided by EPIC had to 
be combined in order to create new dates that map out the beginning and end of 
the periods when good quality follow-up data could be confidently ascertained 
from the patients. The dates provided by EPIC and the new dates created by 
combining the EPIC dates are detailed below. 
 
2.2.2.1  EPIC dates 
In THIN database, some of the key dates provided by EPIC are :  
 Patient registration date (regdate)199 - Date of patient registration with 
the general practice 
 Vision date199 - Date that the general practice joined the THIN scheme 
and started using the vision software to record consultations 
 AMR date199 - Date when the practice is deemed to be recording all-cause 
mortality based on predicted numbers from the national statistics given 
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the practice age/sex register. Data collected after this date are 
considered to be of high quality for research. 
Other dates provided by EPIC in the THIN dataset are: 
 The date of death of the patient 
 The date of transfer of patients' from the practice (if applicable) 
 Date of last data collection from the practice by EPIC 
 
2.2.2.2  Dates derived from the combination of EPIC dates 
To define clear inclusion and exclusion criteria for cases in the study, dates 
indicating the "start" and "finish" dates for each patient in the dataset had to be 
assigned. These were derived from a combination of some of the dates provided 
by EPIC. The following dates were created by combining original dates from 
EPIC: 
 Practice start date199 - This is used as a measure of when the practice 
started recording good quality data. It is the earlier of AMR (acceptable 
mortality reporting) date or vision date.  
 Start date (S) - defined as the later of a patient's registration date at the 
practice or the practice start date  
 Finish date (F) - This is the date of last data collection for a patient. It is 
the earlier of the "transfer-out" date, death date or date of last data 
collection for the practice 
 
 
 
 
74 
 
2.2.3  Amendments made to records with incorrect dates  
Despite defining start and finish dates during which a patients' follow-up could 
be assessed, there remained some inconsistencies within the dataset and these 
had to be resolved before analyses for this study could be carried out. These 
inconsistencies include instances where the date of lung cancer diagnoses was 
later than the date of death or the patients' finish date or where the recorded 
date of death was later than the finish date.   
In making amendments to these records with incorrect dates, consideration was 
taken of the fact that lung cancer has very poor survival and it is thus likely that 
some cases in the dataset may have been diagnosed post-mortem. Also, 
logistical issues with record keeping may result in some time lag before the entry 
of data into patients' electronic notes and this was also an issue that was 
considered. To avoid dropping data unnecessarily therefore, gaps that were 
deemed reasonable had to be determined based on an examination of the 
distribution of the incorrect time intervals. The determination of the reasonable 
gaps and the subsequent amendments to the data were done consecutively in 
the order shown in the following sections 2.2.3.1, 2.2.3.2 and 2.2.3.3. 
 
2.2.3.1  Lung cancer cases with diagnoses date later than date of death 
There were cases in the dataset whose first record of lung cancer diagnosis was 
after the recorded date of death. A distribution of the death-to-diagnosis interval 
was plotted for these cases and is shown in Figure 2.1. 
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Figure 2.1:Histogram showing distribution of the interval between diagnosis 
and death in cases diagnosed after death (n=378) 
Median interval =7 days after death (IQR 3 to 31 days) 
 
The median interval between death and the subsequent record of lung cancer 
diagnosis in patients where diagnosis was recorded after death, was 7 days. The 
inter-quartile range was 3 to 31 days showing that 75% of them had their 
diagnosis made within the 31 days after death. Based on this, 31 days after 
death was considered a reasonable cut-off within which to accept records of lung 
cancer diagnosis. Patients whose lung cancer diagnoses were made within 31 
days of death were considered to be most likely post-mortem diagnoses and 
they were retained in the study with their dates of death taken as the date of 
diagnoses (Figure 2.2). Records of lung cancer incidence made more than 31 
days after death were considered to be a data entry error and these patients 
were excluded from further study analyses.  
                                
                                 date of death 
                                          (0) (31 days) 
                    -----------------|------------------------|-----------------------------> 
                                           |<-------------------diagnosis-----------------------> 
                        | 
 
Figure 2.2: Re-coding of diagnosis date in cases diagnosed after death.   
                   These cases had their diagnosis date re-coded as the date of death. 
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2.2.3.2  Lung cancer cases with diagnosis date later than the finish date 
By excluding or adjusting all cases with diagnosis date later than the recorded 
date of death in section 2.2.3.1 above, all dead cases now had diagnoses dates 
that were either on or before the date of death. There however remained a few 
patients in the dataset who had lung cancer diagnoses dates that were later than 
the recorded finish date. A distribution of the interval between the finish date 
and the diagnosis date were plotted in these cases and is shown below in Figure 
2.3. 
 
Figure 2.3: Histogram showing distribution of the interval between finish date 
and diagnosis in cases diagnosed after finish date (f) (n= 39) 
 
Since all dead cases already had dates of diagnosis before or at death, this 
meant that the dead cases who had dates of diagnosis after their finish date, had 
finish dates that were earlier than their date of death. In this instance, the finish 
dates were re-coded to the date of death (Figure 2.4). 
For the live cases whose had records of diagnoses after their recorded finish 
dates, a decision was made to use the same 31 day cut-off that was used in the 
exclusion of cases diagnosed after death. Cases who were diagnosed more than 
31 days after their finish date were dropped from the dataset whereas those who 
0
1
0
2
0
3
0
n
u
m
b
e
r 
o
f 
c
a
s
e
s
0 200 400 600 800 1000
number of days from finish date to diagnosis
77 
 
were diagnosed within 31 days of the study finish date had their finish dates re-
coded to the diagnosis date (Figure 2.4). 
 
       ----------------diagnosis---------------------| 
                           
        ------------------------|-------------------(death)---------------> (dead cases) 
                             (finish date)   
 
      
        ------------------------|---------------------|--------------------> (live cases) 
        (0)         (31 days) 
   finish date 
      |<--------------diagnosis---------------> 
                                  |<---dropped----> 
 
Figure 2.4: Re-coding of finish date in cases with diagnosis date after finish date 
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2.2.2.3 Lung cancer cases with deaths after the study finish date 
Some cases had their recorded date of death later than the study finish date. 
Figure 2.5 shows the distribution of the interval between the study finish date 
and the date of death in these cases. 
 
 
Figure 2.5: Histogram showing the distribution of the interval between f and 
death in cases where death was recorded after f (n=175) 
 
Using the same 31-day cut-off previously used in excluding cases diagnosed 
after death and finish dates respectively, all remaining cases who had their 
deaths recorded more than 31 days after their finish dates were dropped from 
the dataset. Cases whose deaths were recorded within the 31 day period 
following the study finish date, had their finish dates re-coded as the date of 
death (Figure 2.6). 
 
     X                                              f 
diagnosis)        (finish)            f+31 days 
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                                         |------deaths------|-------------> 
                                                                                    |<-dropped-> 
Figure 2.6: Re-coding of finish date in cases with date of death after finish date 
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2.3 Eligibility criteria for lung cancer cases in this 
study 
After defining key dates in the dataset, the following inclusion and exclusion 
criteria were applied to derive the population of lung cancer cases that were 
studied in this thesis. The lung cancer Read code list that was used in extracting 
the population of lung cancer patients is in Appendix I. 
2.3.1 Criteria for inclusion of patients in study 
 First coded diagnosis of lung cancer between the 1st of January 
2000 and the 28th of July 2009 
 Actively registered in the GP practice for at least 1 year before 
diagnosis 
2.3.2 Exclusion criteria 
 Patients with missing month of diagnosis (If month was recorded 
but day was missing, day was re-coded as the first day of the 
given month)  
 Cases with less than 1 year (365.25 days) between their start date 
and diagnosis date of lung cancer  
 Cases with date of lung cancer diagnoses more than 31 days after 
death (cases diagnosed within 31 days after death had the date of 
diagnosis re-coded as the date of death: section 2.2.3.1). 
 Cases with date of diagnoses more than 31 days after their finish 
date (cases diagnosed within 31 days after the finish date, had 
their finish date moved forward and re-coded as the date of 
diagnosis: section 2.2.3.2). 
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 Cases with date of death more than 31 days after the finish date 
(If death was within 31 days after finish date, the finish date was 
re-coded as the date of death: section 2.2.3.3).  
Derivation of lung cancer cases for this study was based on the inclusion and 
exclusion criteria listed above. Figure 2.7 below shows the number of cases that 
were excluded from the study based on the criteria and shows how the final 
numbers in the study were obtained.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Flow chart showing how the population of lung cancer cases were 
derived from THIN dataset.   
1470 cases with first 
incidence before 2000 
13,754 cases 
81 cases with missing 
month and day of diagnosis 
468 patients with less than 
1 year between start date 
and diagnosis date  
22 cases diagnosed 
more than 31 days after 
finish date 
 
93 cases diagnosed  
more than 31 days after  
death. 
 
13,062 cases 
Lung cancer- 12,135 
Mesothelioma- 927 
 
 
28 cases with deaths 
recorded >31 days 
after finish date 
 
15,224  cases of lung cancer 
and mesothelioma  in THIN   
      13,673 cases   
13,205 cases 
13,112 cases 
13,090 cases 
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2.4  What proportion of lung cancer information in   
THIN is recorded as free text? 
This section gives a general overview of free text data in THIN as well as a 
description of the free-text records in the medical dataset of the lung cancer 
cases that were included in this study. Free-text data were explored in these 
patients in order to determine how much of the information from variables such 
as histology, performance status and lung cancer staging were recorded by GPs 
as text and how much of these could be extracted for the analyses in this study. 
 
2.4.1  Description of THIN free text 
In THIN database, general practitioners are allowed to enter records as data 
comments or scanned information223 and every entry in the medical dataset can 
have a data comment associated with it. These data comments are known as 
free text. Since this field may contain confidential information such as people's 
names, places, etc, not all of this information is made available for researchers.  
Fifty seven percent (168,037 comments) of free text in the medical records of all 
patients has been anonymised including the 10,000 most frequently used free 
text223, and these anonymised comments have been linked to a 7 character 
unique identifier which can be looked up in an ancillary file called 
THINComments. 
There are different types of free text data that can be obtained from patients' 
medical records in THIN and these are described below:  
 The 7 character numeric identifier (anonymised text) which has been 
linked to a unique comment and can be looked up in the ancillary file 
called THINComments.  
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 4-character alphanumeric textids which represent free text that are not 
one of the 168,037 anonymized comments (non-anonymised text). To 
ensure confidentiality of these texts, access can only be provided by EPIC 
on request and involves extrapolation of records by scrutiny of individual 
comment fields. Provision of access to these free text comments can 
therefore be a time-consuming and arduous task for the staff at EPIC and 
this access is quite expensive for researchers. 
 A 7-character numeric identifier coded as "0000001" which is an empty 
text and does not code for anything (no text). 
 
2.4.2 Free text in lung cancer patients' records 
In the medical dataset of the 12,135 lung cancer cases in this study, a total of 
1,896,389 free text records were identified. Of these, only 152,075 (8%) were 
anonymised texts which could be looked-up in the ancillary file and could 
potentially be retrieved if required. There were 1,184,309 (62.5%) non-
anonymised texts with restricted and expensive access and the remaining 
560,005 (29.5%) free texts were empty texts that did not code for anything. 
Figure 2.8 shows the proportion of the different types of free text comments in 
the medical dataset of patients with lung cancer in the thesis database. 
 
Figure 2.8: Types of free text in the medical dataset of patients with lung cancer  
62.50% 
8.00% 
29.50% 
free texts with restricted access  
coded and accessible free texts 
empty free text codes 
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2.4.2.1 Free text data entries recorded with lung cancer Read codes 
A total of 17,449 lung cancer Read code entries were identified in the medical 
dataset of cases in the thesis database. The free text records that were 
associated with these lung cancer entries were explored and the results showed 
that only 677 (3.9%) of these lung cancer-associated free text comments were 
coded texts that could be looked up in the ancillary file. There were 11,817 
(67.7%) uncoded text comments that had not been anonymised and 4,955 
(28.4%) were free text comments that were empty and did not code anything. 
Figure 2.9 shows the proportions of the different types of free text records that 
were associated with lung cancer entries. 
 
Figure 2.9: Free texts associated with lung cancer Read code entries 
 
Among the 677 anonymised free text comments (3.9% of lung cancer Read 
code-associated free texts) that could be looked up in the ancillary file, the 20 
most common free text entries were examined (Table 2.4)  and apart from 37 
entries of the histological sub-type "Adenocarcinoma", there was no other 
information from the free text entries that was considered relevant to this study. 
 
 
67.70% 
3.90% 
28.40% 
free texts with restricted access 
coded and accessible free texts 
empty free text codes 
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Table 2.4. Most common free text comments associated with lung cancer Read 
code entries 
 
Free text entry associated with lung 
cancer Read code entry 
 
Total count 
Right 56   
Left 45 
Inoperable 44 
Cause of death 41 
Metastatic 39 
Adenocarcinoma 37 
Lung 24 
1A 23 
Rt 17 
1B 15 
Primary 14 
Probable 13 
Left lower lobe 11 
Right lower lobe 9 
R 8 
Confirmed 6 
Radiotherapy 5 
Right side 4 
Lt 3 
Recurrent 2 
 
 
2.4.2.2 Non-anonymised free text in the lung cancer patients' dataset  
As mentioned above in the introductory part of section 2.4.2, a total of 
1,184,309 non-anonymised free text comments were identified in the medical 
dataset of the cases (62.5% of all free text records). These text comments were 
associated with medical entries entered using 18,432 Read codes from the July 
2009 ('0907) EPIC Read code list. Although the free text comments were not 
accessed, an analysis was done to obtain the frequency of different Read codes 
associated with these comments. The median Read code frequency with non-
anonymised free texts was 3 (IQR 1 to 14). Therefore, 75% of the Read code 
entries had 14 or less records associated with the free texts. There were 206 
Read codes that were recorded in more than 1000 entries associated with non-
anonymised free texts. The 38 most frequently recorded Read codes which had 
more than 4000 entries associated with non-anonymised texts are shown in  
Table 2.5. 
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Table 2.5. Most common Read codes associated with non-anonymised free texts 
in the case dataset  
 
Read code associated with non-anonymised free text 
 
Total count 
Telephone encounter 59131 
Letter from specialist 33723 
Patient reviewed 29727 
Had a chat to patient 20868 
Home visit 16265 
Cancer care review 11801 
Medication requested 11041 
Incoming mail NOS 10878 
Administration NOS 9902 
Seen in GP's surgery 9837 
Dressing of wound 9237 
Cough 8821 
_Converted code 8087 
Chest pain 7630 
Seen in oncology clinic 7618 
Administration 7504 
Discharge summary 7451 
Blood sample -> Lab NOS 7043 
Communication from: 6912 
Chest infection 6564 
MED3 - doctor's statement 6542 
C/O - cough 6524 
Letter encounter from patient 6397 
Incoming mail 5981 
Seen in oncology clinic 5576 
Discharged from hospital 5420 
Third party encounter 5267 
Medication review 5154 
Chest infection NOS 5020 
Discussion 4565 
Patient's condition improved 4546 
Comment note 4427 
Letter encounter 4422 
Patient given advice 4371 
Lung cancer 4364 
Seen in hospital casualty 4321 
Hypertension monitoring 4243 
Nursing care blood sample taken 4149 
 
Investigation of the most common Read codes associated with the non-
anonymised free text showed that the majority of these codes were Read codes 
for encounters with patients via telephone, chat or home visit. Further analysis 
to identify the most common Read code categories associated with non-
anonymised free text was done (Table 2.6) and the results further confirmed 
that most of the non-anonymised free text entries were associated with Read 
codes of patient encounter by telephone, letter, chat or mail. 
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Table 2.6. Most common Read code categories associated with non-anonymised 
free texts in the medical dataset of cases 
 
Read code category associated with non-anonymised free text  
9N        Patient encounter admin. Data 
8H        Referral for further care 
66        Chronic disease monitoring 
R0        Symptoms 
ZL        Administrative statuses 
13        Social/personal history 
F4        Disorders of eye and adnexa 
7N        Subsidiary classification of laterality and operation sites 
8B        Other therapy 
9O        Prevention/screening admin. 
 
 
 
2.4.3 Summary of findings from analyses of free text 
Results from the preceding sections have shown that less than 10% (8%) of free 
text comments in the dataset of patients with lung cancer were easily accessible. 
Although 3.9% of the free text comments associated with entries of lung cancer 
Read codes were accessible, these did not provide much information of relevance 
to this study. Furthermore, examination of the Read code categories that were 
associated with the non-anonymised free text comments showed that the 
majority of these texts were associated with Read codes of encounters with 
patients by telephone, letter, chat, mail and may not provide very useful 
information in terms of signs and symptoms presented by the patients.  
Following these findings, it was not considered a worthwhile exercise to request 
the manual extrapolation of non-anonymised free texts from EPIC for the work in 
this thesis. 
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2.5 Statistical software for data analyses 
All the analyses undertaken in this study were performed using Stata release SE 
version 11 (StataCorp LP, Texas, USA). The statistical methods of analyses are 
described in more detail within each section. 
 
2.6 Study ethics 
Ethical approval for this study was granted by the Cegedim Strategic Data 
Medical Research scientific review committee in 2009. All records of patients in 
THIN are anonymised and do not contain any identifying information such as 
name, address, exact date of birth and NHS number199. 
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This PhD research was funded by a grant from the Economic and Social Research 
Council (ESRC). I also wish to acknowledge funding by the British Lung 
Foundation (BLF) and the Nottingham Respiratory Biomedical Research Unit. The 
principal supervisor for this PhD research - Professor Richard Hubbard, is the BLF 
chair in Epidemiological Respiratory research.  
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3. Chapter 3.  Validation of THIN and the distribution 
of lung cancer across sectors of society in the 
United Kingdom 
 
This chapter describes a study which firstly, assessed the completeness and 
representativeness of THIN database to ensure that it was a valid source of data 
for lung cancer research.  Then using Experian's Mosaic public sector TM variable 
which had been linked into THIN, the study identified detailed profiles of the UK 
sectors of society where lung cancer incidence is highest, as a means of 
exploring the potential of using this geo-demographic social marketing tool to 
facilitate lung cancer ascertainment. A brief justification for the study in this 
chapter is stated in the introduction and this is followed by the study methods, 
results, a discussion of the study findings with regards to what is already known 
and then a conclusion with a statement of what the study adds to current 
evidence. 
 
3.1 Introduction 
There exist socioeconomic variations in the incidence of lung cancer90 96 and 
evidence from studies of other cancer screening services and treatments show 
unequal participation among different population sub-groups in screening 
services224 as well as inequity in cancer treatment225. To increase earlier 
ascertainment of lung cancer and reduce lung cancer-related health inequalities, 
there is a public health need to enhance lung cancer awareness especially in 
sectors of society where lung cancer incidence is typically high, with a view to 
shortening the interval between symptoms and presentation to primary care. 
Computerised general practice records from THIN present a potentially useful 
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source of data to understand the current pathway of lung cancer diagnosis in 
general practice as well as identify the societal distribution of lung cancer.  
There are two area-based measures of socioeconomic status in THIN - The 
Townsend quintile of deprivation and the Mosaic public sectorTM classification, 
and these have been described in Chapter 2, "Description of the dataset and 
derivation of the lung cancer population". Compared with the well-known and 
commonly used Townsend Index221 which measures the area-based level of 
material deprivation using four indicators: unemployment, car ownership, house 
ownership and overcrowding, Mosaic Public Sector™ classifications take account 
of more granular characteristics of the population living at different UK postcodes 
and therefore allows a clearer identification of the characteristics and differing 
needs of people226. To date, Mosaic classification has been used to a limited 
extent for the targeting of population public health services to those most in 
need227 and studies have usefully applied it to demonstrate social disparities in 
health-related behaviours such as heavy episodic drinking228 and smoking 
prevalence102. However no study yet has used Mosaic classifications to identify 
particular sectors of the UK society that may benefit from targeted public health 
efforts to improve lung cancer awareness and care. 
Although THIN has been demonstrated to have a high degree of completeness 
and accuracy for records of several disease diagnoses206-208 and cancers209, it has 
not been fully exploited for lung cancer studies and its usefulness for this study 
and other lung cancer research will depend on its level of ascertainment and 
representativeness of lung cancer in the UK.  
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3.2  Methods 
3.2.1 Derivation of variables analysed 
3.2.1.1. Study population 
All patients with a first recorded diagnosis of lung cancer between the 1st of 
January 2000 and the 28th of July 2009 were identified. The process used to 
derive the 12,135 incident cases of lung cancer used in this study, has been 
previously described in Chapter 2 (section 2.3). 
 
3.2.1.2 Records of Lung cancer histology, Chronic Obstructive 
Pulmonary Disease (COPD) and smoking. 
Records of lung cancer histology, Chronic Obstructive Pulmonary Disease (COPD) 
and smoking were obtained from patients in the study using Read code lists that 
were compiled after a thorough systematic search of the Read code dictionary 
(Read codes listed in Appendix I).  
The Read codes for histology were developed based on the recommendations 
from the 2001 World Health Organisation classification of lung tumours229.  The 
list of Read codes for smoking had been developed and used for other research 
in the Division of Epidemiology and Public Health. All records of smoking status 
before lung cancer diagnosis were extracted for each patient and based on their 
most recent smoking status before diagnosis, patients were classified as current 
smokers, ex smokers or non-smokers. Non-smokers who had previous records of 
being current or ex smokers, were re-classified as ex-smokers.  
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3.2.2  Characteristics of the lung cancer patients in THIN  
To first address the need for validation, the completeness and 
representativeness of lung cancer data in THIN of the national UK population of 
patients with lung cancer were assessed. In doing this, the characteristics of 
patients with lung cancer in THIN as well as the incidence and survival rates of 
lung cancer in THIN between 2000 and 2009 were determined and these were 
compared with two reliable UK national lung cancer databases - The UK National 
Cancer Registry230 and the National Lung Cancer Audit Database (LUCADA)231. 
Using basic descriptive statistics in STATA, the characteristics of the lung cancer 
patients were determined. Lung cancer patient characteristics such as 
histological types, Chronic Obstructive Pulmonary Disease (COPD) prevalence 
prior to lung cancer diagnosis and smoking status were also determined.  
For the calculation of lung cancer incidence rate, the base population for analysis 
comprised of the entire population of patients registered in THIN general 
practices, who had contributed data after the 1st of January 2000 and who had 
records for at least one year in the dataset. Incidence rates with 95% confidence 
intervals (CI) were calculated as the total number of new lung cancer cases per 
100,000 person-years at risk. Overall incidence rates in the population were 
calculated for the study period (2000-2009) and the results were stratified by 
calendar years (3-year periods), age (10-year age bands up to ≥90 years), sex, 
socioeconomic status and Strategic Health Authority (SHA) regions. 
Socioeconomic status was measured using the Townsend Index of multiple 
deprivation in quintiles219 and the Mosaic Public Sector™ groups and types222. To 
assess the completeness of lung cancer ascertainment in THIN general practices 
and whether this varied by different UK SHA regions, the lung cancer incidence 
rates in THIN for each SHA were compared with the rates recorded by the 
National Cancer Registry230. Incidence rate ratios (IRR) between different 
population strata were obtained using multivariate Poisson regression. The 
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incidence rate ratios were further analysed using separate random effects 
Poisson regression models to adjust for any effects due to the variable reporting 
in different UK general practices232. 
Lung cancer survival rates were calculated from the period of first recorded lung 
cancer diagnosis to death or the date of last data collection from the general 
practice. Survival rates of lung cancer in THIN were compared with rates in the 
National Lung Cancer Audit database (LUCADA)231, which is a good source of 
highly representative information on diagnosis and survival of lung cancer 
patients in NHS trusts throughout England, Wales and Scotland. Cox proportional 
hazards models were used to model survival data with age, sex and 
socioeconomic status to determine the relationship between these factors and 
lung cancer survival. The Cox proportional hazards assumption was assessed for 
each of the models by plotting the log minus log transformation of the Kaplan-
Meier estimator of the survival function against time. 
 
3.2.3  UK societal distribution of lung cancer 
To identify the variation in lung cancer incidence across different UK sectors of 
society, the incidence rates of lung cancer in the different Mosaic Public Sector™ 
groups and types were determined. Because age and sex are used in part to 
derive the Mosaic Public Sector™ classification, models for the Mosaic analysis 
did not adjust for these covariates. Using the calculated lung cancer incidence 
rates in the different Mosaic types and the population make-up by Mosaic type in 
the different UK Primary care Trusts (PCT), the estimated number of lung cancer 
events in each PCT as well as the  estimated incidence rates per 100,000 person 
years were estimated (this was jointly carried out with Experian UK). 
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3.3  Results 
3.3.1 Characteristics of the lung cancer patients in THIN 
3.3.1.1 General patient characteristics 
Of the total  number of 12,135 incident cases of lung cancer recorded in THIN 
between the 1st of January 2000 and the 28th of July 2009, there were 7,184 
males (59.2%) and 4,951 females (40.8%). The median age at lung cancer 
diagnosis was 72.6 years (Inter-quartile range (IQR): 64.5-79.0). The median 
age at death was 73.8 years (IQR: 65.7-80.0).  
 
3.3.1.1 Description of lung cancer types in THIN 
The distribution of the different types of lung cancer description among patients 
in THIN is shown in Table 3.1. The most commonly recorded lung cancer 
description in patients' records were:  
 Lung cancer 
 Malignant neoplasm of the bronchus or lung 
 Malignant neoplasm of trachea, bronchus and lung 
 Malignant neoplasm of main bronchus 
 Malignant neoplasm of upper lobe of lung 
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Table 3.1  Description of lung cancer types among patients in THIN 
database  
 
Description 
 
Frequency 
 
Percent 
Lung cancer 4,204 34.64 
Malignant neoplasm of bronchus or lung 3,906 32.19 
Malignant neoplasm of carina of bronchus 35 0.29 
Malignant neoplasm of chest wall NOS 13 0.11 
Malignant neoplasm of hilus of lung 53 0.44 
Malignant neoplasm of lower lobe bronchus 60 0.49 
Malignant neoplasm of lower lobe of lung 204 1.68 
Malignant neoplasm of lower lobe, bronchus or lung 110 0.91 
Malignant neoplasm of lower lobe, bronchus or lung NOS 30 0.25 
Malignant neoplasm of main bronchus 452 3.72 
Malignant neoplasm of main bronchus NOS 91 0.75 
Malignant neoplasm of middle lobe bronchus 14 0.12 
Malignant neoplasm of middle lobe of lung 50 0.41 
Malignant neoplasm of middle lobe, bronchus or lung 35 0.29 
Malignant neoplasm of middle lobe, bronchus or lung NOS 6 0.05 
Malignant neoplasm of other sites of bronchus or lung 74 0.61 
Malignant neoplasm of overlapping lesion of bronchus and lung 15 0.12 
Malignant neoplasm of respiratory tract 28 0.23 
Malignant neoplasm of thorax NOS 1 0.01 
Malignant neoplasm of trachea 19 0.16 
Malignant neoplasm of trachea NOS 4 0.03 
Malignant neoplasm of trachea, bronchus and lung 1,763 14.53 
Malignant neoplasm of upper lobe bronchus 116 0.96 
Malignant neoplasm of upper lobe of lung 396 3.26 
Malignant neoplasm of upper lobe, bronchus or lung 287 2.37 
Malignant neoplasm of upper lobe, bronchus or lung NOS 43 0.35 
Malignant neoplasm, overlap lesion of resp and intrathor organs 1 0.01 
Pancoast's syndrome 31 0.26 
[X]Malignant neoplasm of bronchus or lung unspecified 30 0.25 
[X]Malignant neoplasm of respiratory and intrathoracic organs 62 0.51 
[X]Malignant neoplasm/ill-defined sites 2 0.02 
 
Total 
 
12,135 
 
100 
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3.3.1.3 Histological subtypes 
Lung cancer histology records were available in the records of only 1,704 out of 
the 12,135 patients with lung cancer (14% of cases). This consisted of 1,659 
records extrapolated from the patients' Medical and AHD datasets and 45 records 
retrieved from the medical free text comments. Small cell lung cancer was the 
histological type in 384 patients (22.5% of cases with histology), squamous cell 
carcinoma was the type in 689 patients (40.4%), adenocarcinoma was the 
histological type in 610 patients (35.8%) and 21 patients (1.2%) had large cell 
carcinoma. 
 
3.3.1.4 Prevalence of Chronic Obstructive Pulmonary Disease (COPD)  
Chronic Obstructive Pulmonary Disease (COPD) records were obtained from 
3,082 patients with lung cancer (25.4% of cases with lung cancer). Analyses of 
the interval between the first diagnosis of COPD and the date of lung cancer 
diagnosis showed that the median time of COPD diagnosis was 3.9 years prior to 
lung cancer diagnosis (IQR 11 months to 8.4 years prior to lung cancer 
diagnosis). 
 
3.3.1.5 Smoking status 
Information on smoking was available in the records of 11,718 patients with lung 
cancer (96.6% of the population of lung cancer cases). Prior to the diagnosis of 
lung cancer, 5,537 patients (45.6%) were current smokers, 4,848 patients 
(40.0%) were ex-smokers, 1,230 patients (10.1%) had never smoked and 520 
(4.3%) had no record of smoking status in their dataset. In total, 85.6% of 
patients with lung cancer had a history of ever-smoking before diagnosis (Figure 
3.1).  
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Figure 3.1: Last recorded smoking status of lung cancer patients prior to 
diagnosis 
** "missing" includes lung cancer patients with no recorded smoking data as well as 
patients who either had their smoking records taken after disease diagnosis. 
 
 
3.3.2  Lung cancer incidence in THIN 
3.3.2.1  Overall incidence 
The overall incidence of lung cancer in THIN for the whole study period from 
2000 to 2009 was 41.4 per 100,000 person-years (95% CI 40.6-42.1). Lung 
cancer incidence increased by approximately 4% for every 3-year period (IRR 
1.04, 95% CI 1.04-1.05) (Figure 3.2). The incidence rate in the 3-year period 
2000-2002 was 33.1 per 100,000 person years (95% CI 31.9-34.3). The 
incidence rate in 2003-2005 was 42.8 per 100,000 person years (95% CI 41.5-
44.2), incidence in 2006-2008 was 46.8 per 100,000 person years (95% CI 
45.4-48.2) and the incidence rate in 2009 was 45.1 per 100,000 person years 
(95% CI 42.0-48.4).  
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Figure 3.2: Trend in incidence of lung cancer, 2000-2009 
                   Bars represent 95% confidence intervals 
 
 
3.3.2.2  Lung cancer incidence by age-groups and sex 
Incidence rates were 50% higher in males (49.4 per 100,000 person-years, 95% 
CI 48.2-50.5) compared with females (33.5 per 100,000 person-years, 95% CI 
32.6-34.4) and increased with age, reaching a peak in the 80-90 year age-group 
in males and in the 70-80 year age-group in females (Table 3.2 & Figure 3.3).  
 
Table 3.2. Overall incidence rates of lung cancer by age group and sex (2000-
2009) 
 Lung cancer 
events 
100,000 
Person-yrs at 
risk 
 
Rate/ 100,000 person-years (95% CI) 
Age group (years) 
 Male Female Male Female All Male Female 
0-40 
40-50 
50-60 
60-70 
70-80 
80-90 
> 90 
All ages 
30 
168 
793 
1951 
2737 
1365 
139 
7184 
29 
147 
574 
1285 
1781 
1029 
105 
4951 
75.6 
22.1 
19.3 
14.5 
9.6 
3.9 
0.5 
145.5 
72.4 
21.3 
18.9 
14.9 
11.7 
7.0 
1.5 
147.8 
0.4 (0.3-0.5) 
7.3 (6.5-8.1) 
35.7 (33.9-37.7) 
110.0 (110-110) 
212.0 (210-220) 
219.4 (210-230) 
120.2 (110-140) 
41.4 (40.6-42.1) 
0.4 (0.3-0.6) 
7.6 (6.5-8.8) 
41.0 (38.3-44.0) 
134.4 (130-140) 
286.2 (280-300) 
348.1 (330-370) 
283.7 (240-340) 
49.4 (48.2-50.5) 
0.4 (0.3-0.6) 
6.9 (5.9-8.1) 
30.3 (28.0-33.0) 
86.3 (81.7-91.1) 
151.6 (140-160) 
147.2 (140-160) 
68.2 (56.3-82.5) 
33.5 (32.6-34.4) 
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 Figure 3.3: THIN lung cancer incidence rates by age and sex 
 
 
3.3.2.3 Lung cancer incidence rates by Strategic Health Authority (SHA) 
The SHAs with the highest lung cancer incidence rates in THIN were the North-
West of England with 58.6 per 100,000 person-years (95% CI 55.9 - 61.5) 
followed by the North-East of England with 57.1 per 100,000 person-years (95% 
CI 52.6 - 61.9) and Scotland with an incidence rate of 54.4 per 100,000 person-
years (95% CI 51.4 - 57.6) (Table 3.3). The lowest incidence rates for lung 
cancer were in London with 31.8 per 100,000 person-years (95% CI 29.8 - 33.8) 
followed by the South-East Coast of England with 32.3 per 100,000 person-years 
(95% CI 30.2 - 34.4) and the East Midlands with an incidence rate of 35.0 per 
100,000 person-years (95% CI 31.9 - 38.3). Comparing lung cancer incidence 
rates in THIN in the SHA regions over the 3 year period from 2006-2008 (when 
lung cancer incidence in THIN had increased from the initial stages of the study 
and reached a plateau) with the 2003-2007 lung cancer incidence rates 
recorded by the National Cancer Registry230, the rates in THIN and registry were 
comparable in 9 of the 13 SHAs (Table 3.3). THIN incidence rates were higher 
than registry rates in the South-West of England but the rates were lower than 
registry rates in London, Northern Ireland and the West Midlands. The overall 
lung cancer incidence rate in THIN for all the SHAs between 2006-2008 was 46.8 
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per 100,000 person-years and this accounts for 93.2% of the national cancer 
registry incidence rate of 50.2 per 100,000 person-years. 
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Table 3.3. Distribution and incidence rates of THIN lung cancer cases by UK Health authority  
 
Strategic health 
authority (SHA) 
 
Overall lung cancer 
incidence rate in THIN / 
100,000 person-years 
(95% CI) 
 
Number of new  
cases of lung 
cancer in THIN 
2006-2008 
 
100,000 person 
years at risk 
 
THIN 2006-2008 lung 
cancer incidence rates/ 
100,000 person years 
(95% CI) 
 
 
UK national cancer registry 
age-standardised incidence 
rates of lung cancer (2003-
2007)/ 100,000 person 
yrs230 
 
 
Crude lung 
cancer incidence 
rate ratio (THIN 
compared to 
Registry rates) 
East Midlands 35.0 (31.9 - 38.3) 172 4.1 41.7 (35.9-48.4) 47.1 (46.3-47.9) 0.89 
East of England 36.7 (34.3 - 39.1) 331 7.6 43.5 (39.1-48.5) 40.6 (39.9-41.2) 1.07 
London* 31.8 (29.8 - 33.8) 358 9.9 36.1 (32.5-40.0) 48.7 (48.0-49.4) 0.74 
North East 57.1 (52.6 - 61.9) 211 3.3 63.6 (55.5-72.7) 68.2 (66.9-69.5) 0.93 
North West 58.6 (55.9 - 61.5) 605 9.3 65.1 (60.1-70.5) 59.3 (58.6-60.1) 1.10 
Northern Ireland* 35.3 (32.1 - 38.9) 146 3.8 38.8 (33.0-45.6) 49.2 (47.8-50.6) 0.79 
Scotland 54.4 (51.4 - 57.6) 479 7.4 64.9 (59.4-71.0) 69.2 (68.3-70.1) 0.94 
South Central 36.5 (34.5 - 38.6) 459 11.3 40.5 (36.9-44.4) 39.4 (38.6-40.2) 1.03 
South East Coast 32.3 (30.2 - 34.4) 337 9.3 36.1 (32.5-40.2) 39.7 (39.0-40.5) 0.91 
South West** 42.4 (40.2 - 44.8) 476 10.2 46.5 (42.5-50.8) 38.9 (38.3-39.6) 1.20 
Wales 44.8 (41.7 - 48.0) 319 6.1 52.6 (47.2-58.7) 52.8 (51.8-53.9) 1.00 
West Midlands* 36.5 (34.3 - 38.7) 372 9.3 39.8 (36.0-44.1) 46.5 (45.8-47.2) 0.86 
Yorkshire & 
Humber 
47.4 (43.9 - 51.2) 233 4.4 52.6 (46.2-59.8) 56.9 (56.0-57.7) 0.92 
Overall 41.4 (40.6 - 42.1) 4498 96.2 46.8 (45.4-48.2) 50.2 (49.9-50.5) 0.93 
*    SHAs with lower incidence of lung cancer recorded in THIN compared to national cancer registry 
** SHAs with higher incidence of lung cancer recorded in THIN compared to national cancer registry 
     (There is an overlap of the 95% confidence intervals  in the incidence rates in the other 9 SHAs) 
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3.3.2.4 Lung cancer incidence rates by deprivation  
3.3.2.4.1  Lung cancer incidence rates by Townsend deprivation quintiles 
There was a strong relationship between socioeconomic deprivation and lung 
cancer incidence (Table 3.4). Using the Townsend Index as a measure of area 
level deprivation, the highest lung cancer incidence rate of 61.5 per 100,000 
person-years (95% CI 59.1-64.1) in the most deprived Townsend quintile was 
over twice the incidence rate of 28.7 per 100,000 person-years (95% CI 27.5-
30.0) in the least deprived quintile. After adjusting for the effects of age, sex 
and general practice (Table 3.4), there was an 11% increase in lung cancer 
incidence for every category increase in Townsend quintile (IRR 1.11, 95% CI 
1.10-1.12) and the rate of lung cancer for people in the most deprived Townsend 
quintile was 2.2 times higher than the rate for people in the least deprived 
quintile (IRR 2.2, 95% CI 2.0-2.3).  
Table 3.4. Overall incidence of lung cancer by Townsend Index quintiles and Mosaic Public 
Sector™ groups 
 Lung ca 
events 
Person-yrs 
at risk 
Rate per 100,000 
p/y (95% CI) 
Incidence rate 
ratios (95% CI) § 
Townsend index of deprivation 
1 (least deprived) 2069 72.0 28.7 (27.5 - 30.0) 1.00 
2 2243 61.4 36.5 (35.1 - 38.1) 1.20 (1.12-1.27) 
3 2439 58.1 42.0 (40.4 - 43.7) 1.49 (1.41-1.59) 
4 2653 51.4 51.7 (49.8 - 53.7) 1.86 (1.75-1.98) 
5 (most deprived) 2245 36.4 61.5 (59.1 - 64.1) 2.16 (2.02-2.31) 
missing 484 14.0 34.5 (31.5 - 37.7) 1.29 (1.14-1.46) 
Mosaic Public Sector™ group 
A (Symbols of success) 690 27.9 24.7 (23.0 - 26.6) 1.62 (1.45-1.81) 
B (Happy families) 613 34.9 17.6 (16.2 - 19.0) 1.00 
C (Suburban comfort) 1700 46.7 36.4 (34.7 - 38.1) 2.22 (2.02-2.44) 
D (Ties of community) 1608 40.0 40.2 (38.2 - 42.2) 2.17 (1.97-2.38) 
E (Urban intelligence) 233 11.4 20.5 (18.0 - 23.3) 1.01 (0.86-1.19) 
F (Welfare borderline) 566 9.0 62.6 (57.6 - 68.0) 2.81 (2.49-3.17) 
G (Municipal dependency) 1008 15.4 65.5 (61.6 - 70.0) 3.23 (2.91-3.59) 
H (Blue collar enterprise) 1791 33.4 53.7 (51.2 - 56.2) 3.10 (2.83-3.41) 
I (Twilight subsistence) 866 6.7 129.3 (121.0 - 138.2) 6.65 (5.98-7.39) 
J (Grey perspectives) 1239 20.4 60.7 (57.4 - 64.2) 3.45 (3.12-3.83) 
K (Rural isolation) 425 14.1 30.0 (27.3 - 33.0) 1.80 (1.58-2.05) 
99 (Missing) 1394 33.3 41.9 (39.8 - 44.2) 1.95 (1.73-2.20) 
§ Townsend Index incidence rate ratios adjusted for age, sex and general practice 
    Mosaic Public Sector group incidence rate ratios adjusted for general practice 
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3.3.2.4.2  Lung cancer incidence rates by Mosaic Public Sector TM groups and 
types 
Compared with Townsend Index quintiles, there were wider variations in the 
incidence of lung cancer across Mosaic Public Sector™ groups (Table 3.4, Figure 
3.4). The highest lung cancer incidence rate of 129.3 per 100,000 person-years 
(95% CI 121.0-138.2) was found in Mosaic Public Sector™ group I (Twilight 
subsistence). Mosaic Public Sector™ groups F, G and J also had high rates of 
lung cancer incidence. After adjusting for any effects due to the variable 
reporting of general practices, the lung cancer incidence rate in Mosaic group I 
where incidence was highest, was 6.6 times higher when compared with the rate 
in Mosaic group B where the incidence of lung cancer was lowest (IRR 6.65, 95% 
CI 6.0-7.4). 
 
 
Reference groups (Mosaic group B ; Townsend quintile 1) 
 
Figure 3.4: Lung cancer incidence rate ratios by Mosaic Public Sector TM groups 
and by Townsend quintiles (adjusted for age, sex and practice) 
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Analyses of the 61 Mosaic Public Sector™ types (Table 3.5 & Figure 3.5) showed 
the highest lung cancer incidence rate of 191.7 per 100,000 person-years (95% 
CI 173.8-211.5) in Mosaic Public Sector™ type I50 (Cared for pensioners). The 
next highest incidence rate of 174.2 per 100,000 person-years (95% CI 151.1-
200.7) was found in Mosaic Public Sector™ type I48 (Old people in flats). Lung 
cancer incidence was lowest for people in Mosaic Public Sector™ type B10 
(Upscale new owners) with a rate of 6.2 per 100,000 person-years (95% CI 4.4-
8.7). The incidence rate of lung cancer in Mosaic type I50 was 31.2 times higher 
(IRR 31.2, 95% CI 21.9-44.5) when compared to the rate in Mosaic type B10.  
Table 3.6 summarizes the typical characteristics of the Mosaic Public Sector™ 
groups and types where lung cancer incidences were highest in the UK. 
 
Table 3.5. Incidence rates (per 100,000 person years) by mosaic types 
 
Mosaic type 
 
Lung ca events 
 
Person-yrs at risk 
 
Rate per 100,000 
p/y (95%CI) 
A01 Global connections 
A02 Cultural leadership 
A03 Corporate chieftains 
A04 Golden empty nesters 
A05 Provincial privilege 
A06 High technologists 
A07 Semi-rural seclusion 
10 
41 
59 
114 
165 
134 
167 
0.38 
2.19 
3.62 
3.50 
4.41 
7.53 
6.28 
26.0 (14.0 - 48.4) 
17.8 (13.8 - 25.5) 
16.3 (12.6 - 21.0) 
32.6 (27.1 - 39.2) 
37.4 (32.1 - 43.6) 
17.8 (15.0 - 21.1) 
26.6 (22.9 - 31.0) 
B08 Just moving in 
B09 Fledgling nurseries 
B10 Upscale new owners 
B11 Families making good 
B12 Middle rung families 
B13 Burdened optimists 
B14 In military quarters 
5 
38 
33 
139 
273 
120 
5 
0.64 
4.56 
5.34 
7.46 
10.74 
5.86 
0.32 
7.8 (3.2 - 18.7) 
8.3 (6.1 - 11.5) 
6.2 (4.4 - 8.7) 
18.3 (15.8 - 22.0) 
25.4 (22.6 - 28.6) 
20.5 (17.1 - 24.5) 
15.6 (6.5 - 37.5) 
C15 Close to retirement 
C16 Conservative values 
C17 Small time business 
C18 Sprawling subtopia 
C19 Original suburbs 
C20 Asian enterprise 
298 
395 
305 
392 
223 
87 
10.29 
7.46 
8.75 
9.13 
7.69 
3.42 
29.0 (25.9 - 32.4) 
53.0 (48.0 - 58.5) 
34.9 (31.2 - 39.0) 
42.9 (38.9 - 47.4) 
29.0 (25.4 - 33.1) 
25.4 (20.6 - 31.3) 
D21 Respectable rows 
D22 Affluent blue collar 
D23 Industrial grit 
D24 Coronation street 
D25 Town centre refuge 
D26 South Asian industry 
D27 Settled minorities 
228 
426 
445 
262 
140 
14 
93 
6.82 
9.63 
10.65 
6.03 
2.84 
0.78 
3.30 
33.4 (29.4 - 38.1) 
44.3 (40.2 - 48.7) 
41.8 (38.1 - 45.8) 
43.5 (38.5 - 49.1) 
49.4 (41.8 - 58.3) 
17.9 (10.6 - 30.3) 
28.2 (23.0 - 34.6) 
104 
 
E28 Counter cultural mix 
E29 City adventurers 
E30 New urban colonists 
E31 Caring professionals 
E32 Dinky developments 
E33 Town gown transition 
E34 University challenge 
40 
22 
47 
51 
34 
31 
8 
1.43 
1.30 
2.46 
2.10 
2.00 
1.36 
0.71 
27.9 (20.5 - 38.1) 
17.0 (11.2 - 25.8) 
19.1 (14.4 - 25.4) 
24.3 (18.5 - 32.0) 
17.0 (12.1 - 23.8) 
22.8 (16.0 - 32.4) 
11.2 (5.6 - 22.5) 
F35 Bedsit beneficiaries 
F36 Metro multiculture 
F37 Upper floor families 
F38 Tower block living 
F39 Dignified dependency 
F40 Sharing a staircase 
26 
61 
135 
30 
243 
71 
0.82 
1.80 
3.24 
0.41 
2.08 
0.70 
31.8 (21.7 - 46.7) 
33.9 (26.4 - 43.6) 
41.7 (35.2 - 49.3) 
72.8 (50.9 - 104.2) 
117.1 (103.3 - 132.8) 
100.9 (80.0 - 127.3) 
G41 Families on benefits 
G42 Low horizons 
G43 Ex-industrial legacy 
76 
401 
531 
3.21 
6.43 
5.75 
23.7 (18.9 - 29.6) 
62.4 (56.6 - 68.8) 
92.4 (84.9 - 100.6) 
H44 Rustbelt resilience  
H45 Older right to buy 
H46 White van culture 
H47 New town materialism 
529 
487 
486  
289 
8.61 
6.23 
10.44 
8.10 
61.4 (56.4 - 66.9) 
78.2 (71.6 - 85.5) 
46.6 (42.6 - 50.9) 
35.7 (31.8 - 40.1) 
I48 Old people in flats 
I49 Low income elderly 
I50 Cared for pensioners 
191 
277 
398 
1.10 
3.52 
2.08 
174.2 (151.1 - 200.7) 
78.6 (69.9 - 88.4) 
191.7 (173.8 - 211.5) 
J51 Sepia memories 
J52 Childfree serenity 
J53 High spending elders 
J54 Bungalow retirement 
J55 Small town seniors 
J56 Tourist attendants 
124 
119 
258 
268 
405 
65 
1.32 
2.74 
4.49 
3.18 
7.41 
1.28 
93.8 (78.6 - 111.8) 
43.4 (36.3 - 51.9) 
57.5 (50.9 - 64.9) 
84.3 (74.8 - 95.0) 
54.7 (49.6 - 60.3) 
50.8 (39.9 - 64.8) 
K57 Summer playgrounds 
K58 Greenbelt guardians 
K59 Parochial villagers 
K60 Pastoral symphony 
K61 Upland hill farmers 
0 (no data) 
99 (unclassified) 
43 
137 
134 
91 
20 
261 
52 
0.76 
5.33 
4.09 
3.19 
0.78 
6.36 
1.34 
56.4 (41.8 - 76.0) 
25.7 (21.7 - 30.4) 
32.8 (27.7 - 38.9) 
28.5 (23.2 - 35.0) 
25.8 (16.6 - 39.9) 
41.0 (36.3 - 46.3) 
38.8 (29.6 - 50.9) 
 
 
 
Table 3.6. Mosaic groups and types with the highest incidence of lung 
cancer 
 
Mosaic groups 
 
I Twilight subsistence Older people living in social housing with high care needs 
G Municipal dependency Low income families living in estate based social housing 
F Welfare borderline People living in social housing with uncertain unemployment in 
deprived areas 
Mosaic types  
I50 Cared-for pensioners Older people receiving care in homes or sheltered 
accommodation 
I48 Old people in flats Older people living in small council and housing association 
flats 
F39 Dignified dependency Low income couples and pensioners living in crowded 
apartments in high density social housing 
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Figure 3.5: Lung cancer incidence by Mosaic Public Sector™ type 
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The estimated lung cancer incidence rates in each UK Primary Care Trust was 
derived using the THIN incidence rates of lung cancer for the different Mosaic 
types and the population of each Mosaic type in the different Primary Care Trusts 
(PCTs) in the UK. Figure 3.6 shows the estimated lung cancer incidence rates in 
the different regions in the UK. 
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Figure 3.6: Estimated number of people in each primary care trust (PCT) in the 
UK likely to have lung cancer.  
This was calculated using the population of each Mosaic type in the PCTs and the THIN 
lung cancer incidence rate by Mosaic type.  
(Mapping by Experian UK)  
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3.3.3  Lung cancer survival in THIN 
3.3.3.1  Overall survival 
Among the 12,135 lung cancer cases studied, 8,885 (73.2%) died during the 
study period. Six months after diagnosis, 57% of the cases were still alive; one 
year after, 37% of the cases were alive and five years after, only 11% of the 
cases were alive. The median survival for the cases was 232 days (IQR: 76-630 
days). This was only slightly better than survival in the National Lung Cancer 
Audit database (LUCADA)231 where the median survival was 203 days with a one 
year survival of 32%.  
 
3.3.3.2  Lung cancer survival by age and sex 
Lung cancer survival worsened with increasing age at diagnosis (Table 3.7). For 
patients diagnosed at 40 years of age or less, the 1-year and 5-year survival 
were 52% and 31% respectively. One year and five year survival after lung 
cancer diagnosis at ages between 80 to 90 years were 29% and 6% 
respectively. 
 
Table 3.7. Survival of lung cancer patients by age at diagnosis  
Age at 
diagnosis 
Median survival 
in days (IQR) 
6 months 
survival  
1-year 
survival 
5-year 
survival 
Unadjusted 
hazards ratio 
95% CI p-value 
<40  
40-50  
50-60  
60-70 
70-80   
80-90 
>90 
457 (248- .) 
341 (148-1150) 
287 (116-830) 
274 (85-736) 
218 (72-604) 
164 (54-443) 
147 (46-403) 
85% 
70% 
65% 
61% 
55% 
47% 
40% 
52% 
48% 
42% 
42% 
36% 
29% 
26% 
31% 
17% 
15% 
13% 
9% 
6% 
- 
1.00 
1.35 
1.54 
1.68 
1.94 
2.41 
2.72 
- 
0.92-1.97 
1.08-2.20 
1.18-2.40 
1.36-2.77 
1.69-3.45 
1.85-4.01 
- 
0.126 
0.018 
0.004 
<0.001 
<0.001 
<0.001 
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Male lung cancer patients died earlier than female patients with a median 
survival for males of 221 days (IQR: 72-580 days) compared with 251 days 
(IQR: 83-709 days) for females (Figure 3.7).  
 
 
Figure 3.7: Kaplan-Meier survival plots showing lung cancer survival by sex 
 
 
The percentages of males alive at 6 months, 1 year and 5 years after diagnosis 
were 55%, 36% and 10% respectively. Survival for females on the other hand at 
6 months, 1 year and 5 years were 59%, 40% and 12% respectively (Table 3.8). 
Survival for patients in THIN was better than survival in the cancer registry16, 
where the one year lung cancer survival was 27% for men and 30% for women. 
After adjusting for the effect of age at diagnosis, male lung cancer patients in 
THIN had 11% worse survival than female lung cancer patients (Hazards ratio 
for death - 1.11, 95% CI 1.06 to 1.16). 
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 Table 3.8. Survival of lung cancer patients by sex  
Lung cancer follow-up period Males females 
6 months 0.55 (55%) 0.59 (59%) 
1 year 0.36 (36%) 0.40 (40%) 
5 years 0.10 (10%) 0.12 (12%) 
 
 
3.3.3.2  Lung cancer survival by deprivation 
Using the Townsend index deprivation quintile as a measure of socioeconomic 
status, survival did not differ across socioeconomic groups (Figure 3.8 & Table 
3.9) 
 
Figure 3.8: Kaplan-Meier survival plots showing lung cancer survival by 
Townsend deprivation quintiles 
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Table 3.9. Survival of lung cancer patients by Townsend deprivation quintiles 
Townsend 
quintile 
Median survival 
in days (IQR) 
6 months 
survival  
1-year 
survival 
5-year 
survival 
Unadjusted 
hazards ratio 
95% CI p-value 
 
1 
2 
3 
4 
5 
missing 
223 (78-593) 
232 (79-640) 
224 (67-587) 
242 (76-666) 
221 (72-608) 
296 (116-1032) 
56% 
57% 
56% 
58% 
55% 
64% 
37% 
36% 
36% 
39% 
37% 
44% 
9.7% 
10% 
9.9% 
12% 
10% 
18% 
1.00 
0.98 
1.03 
0.94 
1.01 
0.78 
- 
0.91-1.05 
0.96-1.10 
0.88-1.01 
0.94-1.09 
0.68-0.88 
- 
0.53 
0.46 
0.10 
0.82 
<0.001 
 
 
 
         
3.4  Discussion 
The overall incidence of lung cancer recorded in THIN general practices was 41.4 
per 100,000 person-years between 2000 and 2009, however incidence from 
2000-2002 was lower than in the latter periods of the study. This compares 
favourably with findings from a previous study which showed that the observed 
recording rates of pancreatic, colorectal and lung cancers in THIN prior to 2004 
were lower than expected based on the national cancer registry data but 
increased and were more comparable to registry rates after 2004209. It has been 
suggested that a large increase in the recruitment of general practices to THIN in 
2003 associated with receipt of training in data entry, experience in using the 
Vision software, and the institution of cancer quality improvement measures by 
the national Health Service in 2003 may have all contributed to the increase in 
recording of these cancers209. The introduction of the Quality and Outcomes 
Framework (QOF)233 in 2004 which encourages general practitioners to record all 
new cases of cancer may also partly explain the increase in cancer recording in 
THIN. After comparing the lung cancer incidence rate in THIN with incidence rate 
recorded by the national cancer registry230, this study confirms that THIN 
captures a higher proportion of lung cancer incidence in more recent years. 
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3.4.1 Lung cancer Incidence 
There are two reliable national lung cancer databases in the UK against which 
THIN data were compared to assess its completeness and representativeness. 
These are the National Lung Cancer Audit database (LUCADA)231 which has been 
shown to be highly representative of people with lung cancer in England84; and 
the national cancer registry data reported by the Office for National Statistics 
(ONS)234 which is a good source of information on lung cancer incidence. Data 
reported by the ONS are systematically collected from all regional cancer 
registries in England, Wales, Scotland and Northern Ireland.  
Reassuringly, the sex distribution of lung cancer cases in THIN, the median age 
at diagnosis and at death, and the increasing incidence with greater 
socioeconomic deprivation were all comparable to findings from LUCADA84. 
Comparison of the lung cancer incidence rate in THIN with the incidence rate 
reported by the national cancer registry230, showed the incidence rate in THIN to 
be over 93% of the cancer registry incidence rate. Geographical variations in 
lung cancer incidence in THIN were also mostly similar to registry data. The 
highest incidence rates were in the North-West of England, North-East of 
England and Scotland while the South East Coast and London had the lowest 
incidence. Cancer registry data however, shows incidence in London to be 
exceptionally high compared to other SHA regions in southern England. This is in 
contrast to THIN where the lowest incidence of lung cancer was in London, which 
may be due to THIN’s over recruitment of practices covering slightly more 
affluent areas216 217. The population of THIN also has an over-representation of 
practices from the South-East of England where incidence rates are among the 
lowest so it is therefore unsurprising that the crude overall lung cancer incidence 
in THIN is marginally lower than the incidence rates based on registry data. The 
difference between THIN and registry incidence rates may also be partly 
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attributed to the fact that about 6.8% of cases included in the UK cancer 
registries are from death certificates only18. 
 
3.4.2  Societal distribution of lung cancer 
The association that was found between lung cancer incidence and greater 
socioeconomic deprivation was independent of age, sex and general practice and 
is consistent with findings from other studies90 96. Variations in lung cancer 
incidence were however, more marked in the Mosaic groups and types than in 
Townsend deprivation quintiles. Mosaic Public Sector™ segmentation classifies 
UK households and postcodes into several lifestyle groups and types based on 
finer characteristics which has enabled the identification of much higher 
incidence rates of lung cancer in specific sectors of society. Mosaic Public 
Sector™ types I50 (Cared for pensioners), I48 (Old people in flats) and F39 
(Dignified dependency) had the highest lung cancer incidence rates and this was 
unsurprising considering the fact that these Mosaic Public Sector™ types are 
characterised mostly by older people who have poor levels of education, are 
mostly reliant on state benefits and live relatively less healthy lifestyles including 
above average smoking rates. 
Mosaic classification is done at the household as well as the postcode level and 
although about half (54%) of the data used for Mosaic profiling are sourced from 
the 2001 Census, the other 46% are derived from sources such as the Experian 
Lifestyle Survey, consumer credit databases, the electoral roll, shareholder 
registers, Land registry data, Council Tax information, the Hospital Episode 
Statistics, the British Crime Survey, Expenditure and Food Survey and other 
sources222. Mosaic profiling is therefore based on an exchange of information 
which enhances a deeper understanding of the characteristics of people in the 
various groups and types226 unlike the Townsend Index which uses a less 
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complex classification of postcodes based on measures of socioeconomic 
deprivation from Census data221. To accurately target public health resources 
and develop tailored public health campaigns and interventions, the differing 
needs of deprived populations have to be identified and understood and in this 
regard, Mosaic classification is particularly valuable. 
 
3.4.3  Lung cancer survival 
Median survival for people with lung cancer in THIN was only slightly better than 
survival in LUCADA84. The survival estimates in THIN and LUCADA were 
marginally higher when compared with survival in the cancer registry16 and most 
likely reflect the different methods of case ascertainment141; in particular, the 
registry ascertains cases with a diagnosis of lung cancer only on a death 
certificate whilst these cases, having no supporting clinical data prior to death, 
may not have been recorded in THIN nor LUCADA.  
Socioeconomic deprivation did not affect survival of people with lung cancer in 
THIN and this is consistent with the findings from LUCADA84. This lack of 
association may reflect the dismal prognosis of lung cancer in general and the 
lack of effective treatments for most people with lung cancer. 
 
3.4.4  Strengths and limitations of this study 
Some of the limitations of using general practice data such as THIN for this study 
include the limited scope of data recording and variation in the diagnostic criteria 
for medical conditions that were previously discussed in Chapter 2 (Section 2.1.3 
- strengths and weaknesses of THIN). Although it was considered necessary to 
explore the survival of lung cancer patients in THIN in relation to the cancer 
histology and patients' performance status, there were insufficient data on these 
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variables to enable these analysis. Performance status records were available for 
only 14 patients with lung cancer (1.15% of lung cancer patients in THIN) and 
despite retrieving some histology records from the medical free text comments, 
histology records were available for only 1704 patients overall (14% of patients 
in the dataset). Due to the lack of power that may result from analysis of these 
few numbers, the effect of performance status and histology on lung cancer 
survival were therefore not explored. 
Detailed information about how Mosaic groups and types are derived are not 
disclosed by Experian and this limits the ability to assess the validity of their 
methods. Some health information have also been used in deriving the Mosaic 
classifications and this may confound the identification of groups with the highest 
lung cancer incidence. By using data from 400 variables to profile all postcodes 
in the UK into 61 Mosaic types, it is not likely that any postcode or household will 
conform with all of the values characteristic of its type and in fact, a few 
postcodes may not fall into any category. However, it is worth noting that Mosaic 
types identify groups of individuals and households that are as similar as 
possible to each other and as different as possible to other groups101.  
A major strength of this study is that this is the first lung cancer study to 
incorporate the Experian's Mosaic Public Sector™ classification tool  and this tool 
provides a finer and more detailed classification of the UK population than any 
other socio-demographic classification markers such as Townsend deprivation 
index221 and therefore allows programs and interventions to be tailored to the 
specific needs of the population.  
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3.5  Conclusion 
The analyses in this study have shown that general practice data from THIN are 
representative of lung cancer in the UK and capture the vast majority of cases 
from cancer registries. UK general practice data are thus a potentially valuable 
tool for lung cancer research as they are the only source of detailed 
prospectively collected health information available at a population level both 
before and after lung cancer diagnosis. Linkage of patients’ records to Experian's 
Mosaic Public Sector™ classification has also provided a more refined knowledge 
of the sectors of society where lung cancer incidence is highest in the UK. As 
such, Mosaic could be used outside general practice as an important tool to 
reduce lung cancer-related health inequalities by enabling tailored public health 
campaigns and interventions to be more precisely and thus effectively targeted 
geographically to specific lifestyle groups in society.  
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4. Chapter 4.   The use of a matched case-control 
dataset to explore differences in the smoking-
associated risk of lung cancer  
The previous chapter assessed the validity of lung cancer records in THIN 
database concluding that it was representative of lung cancer in the UK and 
therefore a valid source of data for lung cancer research. In this chapter, a 
dataset of lung cancer cases and controls, matched on age (year of birth), sex 
and general practice is developed with the primary aim of piloting the methods 
for the development of a lung cancer risk-prediction score, including the 
assessment of the timing of symptoms and other clinical features that are likely 
to be predictive of lung cancer. The chapter goes on to describe several studies 
that were conducted using the matched case-control dataset to investigate the 
association between cigarette smoking and lung cancer in different subgroups of 
patients in general practice. In particular, socioeconomically deprived individuals 
and those with depression were studied because these are subgroups of people 
with particularly high smoking prevalence and high levels of cigarette smoke 
addiction. Since age and sex are associated with lung cancer incidence (shown in 
results in Chapter 3, section 3.3.2.2 - Lung cancer incidence by age groups and 
sex), performing these analyses in a population of cases and controls matched 
by age, sex and general practice allows the confounding effects of age, sex and 
the variable recording in general practices, to be dealt with during the design 
stage of the study.  
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4.1 Derivation of the matched case-control dataset 
4.1.1  Criteria for selection of cases  
The cases included in this matched case-control dataset were the incident cases 
of lung cancer derived in Chapter 2 (section 2.3). As mentioned earlier, only 
incident cases of lung cancer first diagnosed between the 1st of January 2000 
and the 28th of July 2009 were included in the study. The eligibility criteria for 
case selection are as summarised below: 
 First coded diagnosis of lung cancer between the 1st of January 
2000 and the 28th of July 2009 
 Actively registered in the GP practice for at least 1 year before 
diagnosis 
 Exclusion of cases without a month of diagnosis, cases with a date 
of diagnosis more than 31 days after death, diagnosis more than 
31 days after the finish date and cases with a recorded date of 
death more than 31 days after the finish date. 
The total number of eligible cases that were identified in THIN database were 
12,135. Lung cancer is rare in individuals less than 40 years and analysis of the 
THIN dataset in this thesis has shown lung cancer to be rare in individuals less 
than 40 years (59 patients less than 40 years; 0.49% of the case population). 
Based on this, subsequent analysis in this thesis excluded patients less than 40 
years. In total, 12,076 eligible cases were available to develop the matched 
case-control dataset for the analyses in the following studies.  
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4.1.2  Criteria for selection of controls  
Each case in the dataset was matched with up to four controls randomly selected 
from the patient population in THIN. Controls were matched to cases using the 
following criteria. 
 Same sex as their matched case 
 Same age (year of birth) as the matched case 
 Registered at the same general practice as the case 
 Have general practice records for at least 1 year prior to the date of lung 
cancer diagnosis in the matched case  (also known as the index date) 
 No record of lung cancer or mesothelioma in their record 
 Alive and contributing to THIN at the time of lung cancer diagnosis in the 
matched case 
 
4.1.3 Overall matched case-control population 
A total of 5,256 cases were matched with 4 controls each, 4,008 cases matched 
with 3 eligible controls each, 1,933 controls matched with 2 controls each and 
691 cases each had only 1 eligible control. In total therefore, there were 49,493 
patients in the case-control population comprising of 11,888 cases and 37,605 
controls. There were 188 cases who did not have any eligible controls to match 
with and these cases were excluded from further analyses in this study. All cases  
and controls were derived from 445 UK general practices. 
There were 7,025 male and 4,863 female lung cancer cases in the dataset, 
making up 59.1% and 40.9% of the lung cancer population respectively. The 
median age of lung cancer diagnosis was 72.5 years (IQR 64.5 to 78.8 years). 
The median follow-up time prior to lung cancer diagnoses was similar in the 
cases and controls at 9.5 years (IQR 5.5 years to 13.5 years) and 9.4 years (IQR 
5.4 years to 13.2 years) respectively. 
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 4.2  Factors to be investigated in this chapter 
The following sections in this chapter describe studies that firstly explore the 
features of general practice patients before lung cancer diagnosis and then 
investigate several hypotheses on the variation in lung cancer risk among 
different sub-groups of smokers. 
Section 4.4 uses the matched case-control dataset to identify factors that are 
predictive of lung cancer in general practice.  
Section 4.5 investigates whether the association between cigarette smoking and 
lung cancer differs between individuals of different socioeconomic groups. 
Section 4.5 investigates whether there is variation in the risk of lung cancer 
among smokers with a history of depression compared to those who have no 
history of depression in general practice. 
Section 4.6 summarises the result from another research project which was done 
using the dataset created in this thesis, to investigate whether the risk of lung 
cancer differs between men and women with the same recorded quantity of 
cigarettes smoked.  
 
4.3 Definition of variables analysed in this chapter 
This section describes the variables that were analysed in the studies in this 
chapter. While some variables were exclusive to one study, others were common 
to more than one study. Detailed analyses for the different studies are discussed 
in the relevant sections.  
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4.3.1  Age and sex 
Demographic information such as date of birth and sex are available for all 
patients in THIN database. Children up to the age of 15 years of age have their 
month and year of birth recorded in THIN, however on reaching the age of 15, 
only the year of birth is recorded. For the purpose of analyses, the date of birth 
of individuals over the age of 15 years in THIN was assumed as the 1st of July of 
the recorded year of birth. The following studies in this thesis have included only 
patients aged 40 years of age or older and age was defined as age on the index 
date of lung cancer. Since the cases and controls in this chapter were matched 
on age and sex, these variables were identical for all patients in a matched set.  
 
4.3.2  Deprivation 
Townsend quintile of deprivation was previously described in Chapter 2 (Section 
2.1.5). All patients in THIN are assigned to a Townsend quintile corresponding to 
their level of deprivation, and these quintiles are made available with the 
demographic records of patients in the database.  The Townsend quintiles range 
from 1 to 5, with quintile 1 representing the least deprived quintile and quintile 5 
representing the most deprived quintile. 
 
4.3.3  Smoking 
All records of smoking status were retrieved from patient's records using the 
smoking Read codes listed in Appendix I. Patients were categorised according to 
their smoking status prior to lung cancer, as current, ex or non smokers. 
Records of daily cigarette consumption prior to the diagnosis of lung cancer were 
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also retrieved from patients who were "current- " or "ex-" smokers. Two types of 
records of daily cigarette consumption were extracted from the patients' notes: 
 The last record of daily consumption prior to the lung cancer index date 
 The highest ever recorded daily consumption prior to the index date 
In obtaining the quantity of cigarettes smoked, all smoking records made within 
the six months before lung cancer diagnosis were excluded to account for a 
possible change in the cases' cigarette consumption in the months preceding 
lung cancer diagnosis. Based on their cigarette consumption, patients were 
classified as: non-smokers, trivial/light smokers (1 to 9 cigarettes smoked daily), 
moderate smokers (10 to 19 cigarettes smoked daily) and heavy/very heavy 
smokers (20+ cigarettes per day). Current smokers who had no record of their 
daily cigarette consumption were recorded as such - (smoker with no recorded 
quantity) and patients who had no recorded smoking information and who were 
not known to be non-smokers were included in a separate category (missing 
smoking records).  
 
4.3.4 Clinical features 
The symptoms and diagnoses that were analysed in cases and controls were 
defined using two sources. Firstly, the symptoms recommended by the NICE 
guidelines147 for referral of suspected cases of lung cancer and indications for 
chest x-ray; These were cough, haemoptysis, chest/shoulder pain, voice 
hoarseness, dyspnoea and weight loss. In addition, the six most common 
symptoms and diagnoses in the records of patients with lung cancer other than 
the symptoms in the NICE guidelines (complete list of most common symptoms 
and diagnoses in the medical records of patients with lung cancer is shown in 
Appendix II)  were assessed; These were upper respiratory tract infections 
(URTI), lower respiratory tract infections (LRTI), non-specific chest infections, 
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constipation, depressive disorders and Chronic Obstructive Pulmonary Disease 
(COPD). Records of these symptoms and diagnoses prior to lung cancer 
diagnosis, were extracted from patients' datasets using lists of Read codes for 
the different conditions (Read codes listed in Appendix I). 
Records of chest x-rays, blood tests and general practice consultations for 
symptoms other than those already assessed, were also retrieved from the 
patients' records.  
 
 
4.4 The use of a matched case-control dataset to 
identify the factors predictive of lung cancer  
 
As stated in chapter 1, a major objective of this thesis is to develop a lung 
cancer risk-prediction score using patient features in primary care that are 
predictive of lung cancer before diagnosis. In order to ensure that the timing of 
clinical features for the development of the score were accurately determined,  it 
was considered a worthwhile exercise to pilot the methods for identifying the 
lung cancer predictors using the matched case-control dataset developed in this 
chapter prior to the score development with a different dataset. Since the cases 
and controls in the dataset in this chapter have been matched on age and sex, 
the effect of these variables in predicting lung cancer cannot be assessed. 
However, this pilot study enabled the identification of other predictors in general 
practice as well as allow the timing of symptoms and other clinical features to be 
determined.  
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4.4.1 Methods 
Conditional logistic regression was used to estimate the relative odds and 95% 
CI for lung cancer, by smoking status, daily cigarette consumption and 
deprivation. Before conducting analyses on patients' clinical features, the median 
period of general practice follow-up for the cases and controls were assessed to 
ensure that they were comparable. The pattern and frequency of symptom 
presentation in cases and controls prior to lung cancer diagnosis were then 
assessed by way of frequency plots for the different symptom records. This 
allowed an estimation of the time periods when symptom consultation patterns 
differed in the cases and when they could be used to predict a future diagnosis 
of lung cancer. To identify the precise time periods when clinical factors were 
independently associated with lung cancer,  conditional logistic regression 
analyses were done to estimate the odds ratio and 95% CI for lung cancer with 
the different clinical factors firstly in the 0-6 months and the 6-24 month 
periods, and then over shorter 6-monthly time periods: 0-6 months, 6-12 
months, 12-18 months and the 18-24 months before diagnosis. To determine 
the independent predictors of lung cancer, multivariate analyses were done 
using the smoking, deprivation and clinical variables that were associated with 
lung cancer in univariate analyses at the 6-24 month period before diagnosis 
using a statistical significance cut-off level of p<0.05. Variables that were not 
significant in multivariate analysis were removed from the model and those 
variables that were previously not associated with lung cancer in univariate 
analysis were again checked for significance in the final model. 
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4.4.2 Results 
4.4.2.1 Socioeconomic deprivation and smoking characteristics of cases 
and controls 
 
Using the Townsend deprivation quintiles as a measure of socioeconomic 
deprivation, increasing deprivation was associated with a greater likelihood of 
lung cancer (Table 4.1).  
Smoking status of patients prior to lung cancer diagnosis were available for 
34,313 controls (91.2% of controls) and 11,383 cases (95.8% of cases). In total 
therefore, there were smoking records for 45,696 out of the 49,493 patients in 
the dataset (92.3% of patients). Results in Table 4.1 show that a higher 
proportion of controls were non smokers compared to cases (39.2% and 10.6% 
respectively). Compared to controls, the likelihood of a case being a current 
smoker was 11.43 (95% CI 10.59-12.34) and the likelihood of a case being an 
ex-smoker was 5.33 (95% CI 4.95-5.75). Patients with lung cancer smoked 
more cigarettes per day compared to controls and controls were more likely to 
be trivial smokers of less than 1 cigarette per day.  
Analysis of the highest and the latest recorded quantity of cigarettes smoked 
daily by cases and controls up to 6 months before diagnosis shows that in the 
period before lung cancer diagnosis, there was a reduction in the proportion of  
cases who were heavy and very heavy smokers as well as an increase in the 
proportion of  cases who were moderate, light and trivial smokers. Although the 
controls showed a similar decrease in heavy cigarette consumption over time, 
these were not as marked as in the cases. Based on this finding and taking into 
account the fact that individuals' smoking consumption can change over time, 
the highest ever recorded daily cigarette consumption was used as a proxy 
marker of patients' cigarette exposure in all subsequent analyses. 
126 
 
Analysis using a combination of patients' smoking status and daily cigarette 
consumption showed an increase in the odds ratio for lung cancer with an 
increase in the daily cigarette consumption and the odds were greater in current 
smokers compared to ex smokers. The odds ratio for lung cancer among current 
smokers of 40+ cigarettes per day was 21.97 (95% CI 18.65-25.88) whereas 
the odds ratio among ex smokers of 40+ cigarettes per day was 8.56 (95% CI 
7.08-10.34).  
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Table 4.1 Socioeconomic deprivation and smoking status of cases and 
controls 
 Control n(%) 
n=37,605 
Case n(%) 
n=11,888 
Unadjusted odds ratio for 
lung cancer (95% CI) 
 
Townsend deprivation quintile 
5 (most deprived) 
4 
3 
2 
1 (least deprived) 
Missing Townsend records 
5,064 (13.47) 
6,742 (17.93) 
7,420 (19.73) 
8,187 (21.77) 
8,735 (23.23) 
1,457 (3.87) 
2,196 (18.47) 
2,609 (21.95) 
2,380 (20.02) 
2,200 (18.51) 
2,037 (17.13) 
466 (3.92) 
2.26  (2.08-2.44) 
1.88  (1.75-2.03) 
1.48  (1.38-1.59) 
1.19  (1.11-1.28) 
1.00 
1.65  (1.41-1.94 
 
Smoking status prior to lung cancer diagnosis 
Current smoker 
Ex smoker 
Non smoker 
Missing smoking records 
7,369 (19.60) 
12,403 (32.98) 
14,541 (38.67) 
3,292 (8.75) 
5,458 (45.91) 
4,748 (39.94) 
1,177 (9.90) 
505 (4.25) 
11.43  (10.59-12.34) 
5.33  (4.95-5.75) 
1.00 
1.89  (1.67-2.13) 
 
Daily cigarette consumption up to 6 months before diagnosis  
Highest record of cig/day 
Very heavy (40+/day) 
Heavy (20-39/day) 
Moderate (10-19/day) 
Light (1-9/day) 
Trivial (<1/day) 
Smoker, no quantity recorded 
Non smoker 
Missing smoking records 
 
730 (1.94) 
3,949 (10.50) 
3,720 (9.89) 
2,234 (5.94) 
143 (0.38) 
8,460 (22.50) 
14,729 (39.17) 
3,640 (9.68) 
 
685 (5.76) 
3,607 (30.34) 
2,410 (20.27) 
983 (8.27) 
20 (0.17) 
2,169 (18.25) 
1,260 (10.60) 
754 (6.34) 
 
15.06  (13.21-17.16) 
14.02  (12.91-15.22) 
9.04  (8.31-9.84) 
5.86  (5.30-6.49) 
1.95  (1.20-3.20) 
3.23  (2.98-3.51) 
1.00 
2.38  (2.14-2.65) 
Latest record of cig/day 
Very heavy (40+/day) 
Heavy (20-39/day) 
Moderate (10-19/day) 
Light (1-9/day) 
Trivial (<1/day) 
Smoker, no quantity recorded 
Non smoker 
Missing smoking records 
 
459 (1.22) 
2,935 (7.80) 
3,940 (10.48) 
3,257 (8.66) 
185 (0.49) 
8,460 (22.50) 
14,729 (39.17) 
3,640 (9.68) 
 
376 (3.16) 
2,482 (20.88) 
2,852 (23.99) 
1,957 (16.46) 
38 (0.32) 
2,169 (18.25) 
1,260 (10.60) 
754 (6.34) 
 
13.02  (11.11-15.26) 
12.80  (11.73-13.97) 
10.20  (9.40-11.08) 
8.24  (7.55-8.99) 
2.86  (1.97-4.16) 
3.22  (2.97-3.49) 
1.00 
2.41  (2.16-2.68) 
 
Smoking status and highest daily cigarette consumption  
Current V heavy (40+/d) 
Current Heavy (20-39/d) 
Current Mod (10-19/d) 
Current Light (1-9/d) 
Current Trivial (<1/d) 
 
Ex V heavy (40+/d) 
Ex Heavy (20-39/d) 
Ex Mod (10-19/d) 
Ex Light (1-9/d) 
Ex Trivial (<1/d) 
Non-smoker 
Smoker, no quantity recorded 
Missing smoking records 
340 (0.90) 
2,389 (6.35) 
2,028 (5.39) 
1,138 (3.03) 
46 (0.12) 
 
390 (1.04) 
1,560 (4.15) 
1,692 (4.50) 
1,096 (2.91) 
97 (0.26) 
14,729 (39.17) 
8,460 (22.50) 
3,640 (9.68) 
465 (3.91) 
2,578 (21.69) 
1,645 (13.84) 
597 (5.02) 
7 (0.06) 
 
220 (1.85) 
1,029 (8.66) 
765 (6.44) 
386 (3.25) 
13 (0.11) 
1,260 (10.60) 
2,169 (18.25) 
754 (6.34) 
21.97  (18.65-25.88) 
16.90  (15.44-18.49) 
11.41  (10.37-12.54) 
7.19  (6.36-8.13) 
2.30  (1.00-5.27) 
 
8.56  (7.08-10.34) 
9.70  (8.71-10.80) 
6.02  (5.38-6.74) 
4.37  (3.80-5.02) 
1.73  (0.94-3.17) 
1.00 
3.20  (2.95-3.47) 
2.41  (2.17-2.69) 
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4.4.2.2  Clinical features prior to lung cancer diagnosis 
4.4.2.2.1  Duration of registration in general practice 
To ensure that the clinical records of cases and controls were comparable, the 
average period of their registration in general practice prior to the index date of 
lung cancer were determined. Cases had a median general practice registration 
duration of 9.5 years (IQR 5.5 years to 13.5 years) while controls had a 
registration duration of 9.4 years (IQR 5.4 years to 13.2 years) before lung 
cancer diagnosis in their matched case. 
 
4.4.2.2.2 Overall pattern of consultations by cases and controls 
The median number of consultations per case in the 5 years before lung cancer 
diagnosis was 287 (IQR 142 to 510) and the median number of consultations per 
control within the same period was 198 (IQR 79 to 393). Within the 2 years 
before diagnosis, the median number of consultations per case was 168 (IQR 89 
to 278) and the median number per control was 107 (IQR 42 to 204). Plots of 
the frequency of consultations among patients in the dataset within the 5 year 
and 2 year periods before diagnosis (Figure 4.1 & Figure 4.2), show a similar 
pattern of consultation in the cases and controls up to the year before lung 
cancer diagnosis when there is a considerable increase in the consultation 
frequency for cases. 
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Figure 4.1 General consultations by cases and controls, 5 years before lung 
cancer diagnosis 
(the height of the bars are scaled so that the sum of their height equals 100) 
 
 
Figure 4.2 General consultation by cases and controls, 2 years before lung 
cancer diagnosis 
(the height of the bars are scaled so that the sum of their height equals 100) 
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4.4.2.2.2 Pattern of symptom consultations prior to lung cancer diagnosis 
As shown in Figure 4.3a, there was a considerable increase in the frequency of 
symptom presentation by cases, for all the lung cancer symptoms detailed in the 
NICE guidelines. This increase in symptom presentation in general practice are 
shown to have occurred within the year before lung cancer diagnosis. Plots of 
the most commonly recorded symptoms and diagnosis in the dataset of lung 
cancer cases - constipation, depression, URTI, LRTI, chest infections and COPD, 
also show an increase in the general practice presentation of these symptoms 
before lung cancer diagnosis (Figure 4.3b). However, among the most commonly 
recorded symptoms in the case dataset, the increase in the pattern of general 
practice presentation were more marked for LRTI, chest infections, depression 
and COPD. 
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Cough 
 
 
Haemoptysis 
 
 
Chest pain 
 
 
Voice hoarseness 
 
Dyspnoea 
 
Weight loss 
 
Figure 4.3a  Plots showing the frequency of symptom records* in cases and controls, 5 years before lung cancer diagnosis 
*Symptoms recommended by the NICE guidelines for indications for chest x-ray or referral of suspected cases of lung cancer 
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Constipation 
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Upper Respiratory Tract Infections 
 
Lower respiratory Tract Infections 
 
Chest infections 
 
Chronic Obstructive Pulmonary Disease 
 
Figure 4.3b Plots showing the frequency of symptom records** in cases and controls, 5 years before lung cancer diagnosis 
**six of the most commonly recorded symptoms and diagnosis in the medical records of cases before lung cancer diagnosis  
    (the height of the bars are scaled so that the sum of their height equals 100) 
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4.4.2.2.3 Pattern of clinical investigations before lung cancer diagnosis 
Figure 4.4 shows an increase in the frequency of chest x-rays and blood 
investigations among cases compared to controls, before the diagnosis of lung 
cancer was made. 
Chest x-ray 
 
 
Blood investigations 
 
Figure 4.4 The frequency of chest x-ray and blood investigations, 5 
years before lung cancer diagnosis  
(the height of the bars are scaled so that the sum of their height equals 100) 
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4.4.2.2.4 Symptoms and investigations associated with lung cancer in general 
practice  
Table 4.2 shows the univariate association between lung cancer and patients' 
clinical features in the 0-6 and 6-24 month periods before diagnosis. Results 
from the 6-monthly sub-analysis of the 6-24 month clinical records are also 
shown. The largest proportion of symptoms and investigations by cases were 
made in the 0-6 month period before diagnosis and the symptoms with the 
largest odds ratio for lung cancer were haemoptysis and weight loss while the 
investigation that was most strongly associated with lung cancer was chest 
investigations. The majority of records made 6-24 months before diagnosis were 
made in the 6-12 month period before diagnosis. 
Table 4.2 Univariate association between lung cancer and general 
practice symptoms and investigations up to 24 months before diagnosis   
Symptom before lung 
cancer 
Control n(%) 
N=37,605 
Case n(%) 
N=11,888 
Unadjusted OR for 
lung cancer (95% C) 
Cough  
0-6 months  
6-24 months 
6-12 months  
12-18 months  
18-24 months 
 
2,259 (6.01) 
4,722 (12.56) 
2,009 (5.34) 
1,949 (5.18) 
1,848 (4.91) 
 
3,232 (27.19) 
2,589 (21.78) 
1,386 (11.66) 
1,072 (9.02) 
937 (7.88) 
 
6.15 (5.77-6.55) 
1.95 (1.85-2.07) 
2.33 (2.17-2.51) 
1.76 (1.63-1.91) 
1.64 (1.51-1.79) 
Haemoptysis 
0-6 months 
6-24 months 
6-12 months 
12-18 months 
18-24 months 
 
54 (0.14) 
128 (0.34) 
46 (0.12) 
38 (0.10) 
48 (0.13) 
 
1,108 (9.32) 
272 (2.29) 
161 (1.35) 
82 (0.69) 
56 (0.47) 
 
75.52 (56.21-101.48) 
6.82 (5.50-8.44) 
11.12 (7.99-15.47) 
6.76 (4.56-10.01) 
3.66 (2.48-5.41) 
Chest/shoulder pain 
0-6 months 
6-24 months 
6-12 months 
12-18 months 
18-24 months 
 
1,330 (3.54) 
3,330 (8.86) 
1,315 (3.50) 
1,301 (3.46) 
1,253 (3.33) 
 
1,953 (16.43) 
1,463 (12.31) 
697 (5.86) 
548 (4.61) 
476 (4.00) 
 
5.69 (5.26-6.15) 
1.46 (1.36-1.56) 
1.74 (1.58-1.92) 
1.34 (1.21-1.49) 
1.21 (1.09-1.36) 
Voice hoarseness 
0-6 months 
6-24 months 
6-12 months 
12-18 months 
18-24 months 
 
65 (0.17) 
189 (0.50) 
69 (0.18) 
68 (0.18) 
63 (0.17) 
 
227 (1.91) 
95 (0.80) 
42 (0.35) 
29 (0.24) 
31 (0.26) 
 
10.93 (8.26-14.46) 
1.56 (1.22-2.00) 
1.90 (1.29-2.81) 
1.30 (0.84-2.02) 
1.50 (0.97-2.32) 
Dyspnoea 
0-6 months  
6-24 months 
6-12 months  
12-18 months  
18-24 months 
 
1,020 (2.71) 
2,119 (5.63) 
930 (2.47) 
889 (2.36) 
760 (2.02) 
 
2,465 (20.74) 
1,439 (12.10) 
720 (6.06) 
587 (4.94) 
511 (4.30) 
 
10.01 (9.19-10.90) 
2.26 (2.10-2.43) 
2.44 (2.20-2.70) 
2.06 (1.85-2.30) 
2.08 (1.85-2.34) 
Weight loss 
0-6 months  
6-24 months 
6-12 months  
12-18 months  
18-24 months 
 
125 (0.33) 
297 (0.79) 
105 (0.28) 
92 (0.24) 
111 (0.30) 
 
629 (5.29) 
239 (2.01) 
118 (0.99) 
89 (0.75) 
52 (0.44) 
 
17.17 (14.03-21.02) 
2.45 (2.05-2.92) 
3.54 (2.71-4.62) 
2.85 (2.11-3.84) 
1.36 (0.98-1.91) 
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Constipation 
0-6 months  
6-24 months 
6-12 months  
12-18 months  
18-24 months 
 
623 (1.66) 
1,384 (3.68) 
588 (1.56) 
539 (1.43) 
486 (1.29) 
 
762 (6.41) 
626 (5.27) 
285 (2.40) 
239 (2.01) 
208 (1.75) 
 
4.05 (3.62-4.53) 
1.38 (1.25-1.53) 
1.47 (1.27-1.71) 
1.33 (1.14-1.56) 
1.27 (1.07-1.50) 
Depression 
0-6 months 
6-24 months 
6-12 months 
12-18 months 
18-24 months 
 
678 (1.80) 
1,526 (4.06) 
640 (1.70) 
651 (1.73) 
629 (1.67) 
 
431 (3.63) 
640 (5.38) 
285 (2.40) 
255 (2.15) 
251 (2.11) 
 
2.06 (1.82-2.34) 
1.36 (1.24-1.50) 
1.46 (1.26-1.68) 
1.25 (1.08-1.45) 
1.30 (1.12-1.51) 
URTI 
0-6 months 
6-24 months 
6-12 months 
12-18 months 
18-24 months 
 
731 (1.94) 
1,975 (5.25) 
708 (1.88) 
771 (2.05) 
665 (1.77) 
 
417 (3.51) 
735 (6.18) 
284 (2.39) 
270 (2.27) 
258 (2.17) 
 
1.86 (1.64-2.10) 
1.19 (1.08-1.30) 
1.27 (1.10-1.47) 
1.09 (0.95-1.26) 
1.24 (1.07-1.43) 
LRTI 
0-6 months 
6-24 months 
6-12 months 
12-18 months 
18-24 months 
 
529 (1.41) 
1,267 (3.37) 
493 (1.31) 
465 (1.24) 
446 (1.19) 
 
926 (7.79) 
835 (7.02) 
348 (2.93) 
306 (2.57) 
280 (2.36) 
 
6.40 (5.70-7.17) 
2.22 (2.02-2.44) 
2.34 (2.03-2.71) 
2.13 (1.83-2.47) 
1.99 (1.71-2.33) 
Chest infections 
0-6 months  
6-24 months 
6-12 months  
12-18 months  
18-24 months 
 
1,457 (3.87) 
3,291 (8.75) 
1,354 (3.60) 
1,352 (3.60) 
1,261 (3.35) 
 
2,145 (18.04) 
1,994 (16.77) 
1,022 (8.60) 
804 (6.76) 
747 (6.28) 
 
5.91 (5.48-6.38) 
2.16 (2.03-2.31) 
2.54 (2.33-2.78) 
1.94 (1.77-2.13) 
1.94 (1.76-2.14) 
COPD 
0-6 months  
6-24 months 
6-12 months  
12-18 months  
18-24 months 
 
660 (1.76) 
1,234 (3.28) 
659 (1.75) 
595 (1.58) 
504 (1.34) 
 
1,183 (9.95) 
1.403 (11.80) 
748 (6.29) 
670 (5.64) 
576 (4.85) 
 
6.31 (5.70-6.99) 
4.01 (3.69-4.36) 
3.82 (3.42-4.27) 
3.73 (3.33-4.19) 
3.76 (3.32-4.26) 
Chest x-rays 
0-6 months  
6-24 months 
6-12 months  
12-18 months  
18-24 months 
 
1153 (3.07) 
2,752 (7.32) 
1,042 (2.77) 
984 (2.62) 
940 (2.50) 
 
5,990 (50.39) 
1,870 (15.73) 
893 (7.51) 
682 (5.74) 
564 (4.74) 
 
39.48 (35.83-43.51) 
2.41 (2.25-2.57) 
2.87 (2.61-3.16) 
2.24 (2.02-2.48) 
1.93 (1.73-2.15) 
Blood investigations 
0-6 months  
6-24 months 
6-12 months  
12-18 months  
18-24 months 
 
12,923 (34.37) 
20,047 (53.31) 
12,042 (32.02) 
11,221 (29.84) 
10,488 (27.89) 
 
6,967 (58.61) 
7,071 (59.48) 
4,338 (36.49) 
3,985 (33.52) 
3,723 (31.32) 
 
2.88 (2.75-3.01) 
1.24 (1.18-1.30) 
1.17 (1.12-1.22) 
1.13 (1.08-1.18) 
1.12 (1.06-1.17) 
 
 
In mutivariate analysis of all the socio-demographic and clinical records of 
patients associated with lung cancer in the 6-24 months before diagnosis (Table 
4.3),  voice hoarseness, constipation, depression and upper respiratory tract 
infections were found not to be associated with lung cancer in the 6-24 month 
period and were excluded from the final model. In conducting this analysis, the 
highest daily cigarette consumption ever recorded (after exclusion of records 
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made 6 months prior to diagnosis) was used as a proxy marker for patients' 
cigarette exposure. 
 
Table 4.3 Multivariate modelling of the clinical features associated with 
lung cancer 6-24 months before diagnosis  
 
 
Univariate OR 
 
p-value Adjusted OR (95% 
CI) 
 p-value § 
Smoked qty(highest) 
Current V heavy (40+/d) 
Current Heavy (20-39/d) 
Current Mod (10-19/d) 
Current Light (1-9/d) 
Current Trivial (<1/d) 
 
Ex V heavy (40+/d) 
Ex Heavy (20-39/d) 
Ex Mod (10-19/d) 
Ex Light (1-9/d) 
Ex Trivial (<1/d) 
Non-smoker 
Smoker, no qty recorded 
Missing smoking records 
 
21.97  (18.65-25.88) 
16.90  (15.44-18.49) 
11.41  (10.37-12.54) 
7.19  (6.36-8.13) 
2.30  (1.00-5.27) 
 
8.56  (7.08-10.34) 
9.70  (8.71-10.80) 
6.02  (5.38-6.74) 
4.37  (3.80-5.02) 
1.73  (0.94-3.17) 
1.00 
3.20  (2.95-3.47) 
2.41  (2.17-2.69) 
 
 
 
<0.001 
 
18.02 (15.24-21.31) 
14.40 (13.13-15.79) 
10.32 (9.36-11.38) 
6.75 (5.95-7.65) 
2.16 (0.93-4.99) 
 
6.67 (5.48-8.11) 
7.70 (6.89-8.60) 
4.98 (4.43-5.59) 
3.73 (3.23-4.30) 
1.61 (0.86-3.00) 
1.00 
2.97 (2.74-3.23) 
2.52 (2.26-2.82) 
 
 
 
 
<0.001 
Townsend score 
5 (most deprived) 
4 
3 
2 
1 (least deprived) 
9(no record) 
 
2.26  (2.08-2.44) 
1.88  (1.75-2.03) 
1.48  (1.38-1.59) 
1.19  (1.11-1.28) 
1.00 
1.65  (1.41-1.94 
 
 
<0.001 
 
1.47 (1.34-1.61) 
1.36 (1.25-1.48) 
1.25 (1.16-1.36) 
1.15 (1.06-1.24) 
1.00 
1.15 (0.96-1.39) 
 
 
<0.001 
 
Cough 
 
1.95 (1.85-2.07) 
 
<0.001 
 
1.36 (1.26-1.45) 
 
<0.001 
 
Haemoptysis 
 
6.82 (5.50-8.44) 
 
<0.001 
 
3.72 (2.90-4.77) 
 
<0.001 
 
Chest pain 
 
1.46 (1.36-1.56) 
 
<0.001 
 
1.12 (1.04-1.22) 
 
0.004 
 
Dyspnoea 
 
2.26 (2.10-2.43) 
 
<0.001 
 
1.20 (1.10-1.32) 
 
<0.001 
 
Weight loss 
 
2.45 (2.05-2.92) 
 
<0.001 
 
1.60 (1.30-1.97) 
 
<0.001 
 
LRTI 
 
2.22 (2.02-2.44) 
 
<0.001 
 
1.28 (1.15-1.43) 
 
<0.001 
 
Chest infections 
 
2.16 (2.03-2.31) 
 
<0.001 
 
1.30 (1.20-1.40) 
 
<0.001 
 
COPD 
 
4.01 (3.69-4.36) 
 
<0.001 
 
1.69 (1.53-1.87) 
 
<0.001 
 
Chest x-rays 
 
2.41 (2.25-2.57) 
 
<0.001 
 
1.27 (1.27-1.50) 
 
<0.001 
 
Blood tests 
 
1.24 (1.18-1.30) 
 
<0.001 
 
1.07 (1.01-1.13) 
 
<0.001 
§ P-values for binary variables were obtained using the Wald's test of significance. In variables with 
more than 2 categories, p-values were obtained from the likelihood ratio test 
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4.4.3 Discussion and conclusion 
This study has identified the socio-demographic and clinical predictors of lung 
cancer in general practice up to two years before diagnosis and also identified 
the timing before diagnosis when patients' features can be used to predict a 
future diagnosis of lung cancer.  
There was an increase in the frequency of general consultations, consultations 
for clinical symptoms of lung cancer and clinical investigations in cases up to two 
years before lung cancer diagnosis and this was most marked within the year 
before diagnosis. After excluding records made in the 6 months before lung 
cancer diagnosis, patients' socio-demographic and clinical features were found to 
be independently associated with lung cancer  6-24 months before diagnosis. 
The socio-demographic features associated with lung cancer were patients' 
smoking status, daily cigarette consumption and deprivation (measured using 
Townsend deprivation quintiles).  Since the cases and controls in the dataset 
were matched on age and sex, the effect of age and sex could not be accounted 
for. Clinical features that were independently associated with lung cancer were 
cough, haemoptysis, chest/shoulder pain, dyspnoea, weight loss, lower 
respiratory tract infections, chest infections, Chronic Obstructive Pulmonary 
Disease (COPD), chest x-rays and blood investigations. Despite being predictive 
of lung cancer, the majority of symptom records were relatively uncommon in 
the records of cases. 
As previously stated, this study was done to pilot the methods for the 
development of a lung cancer predictive score and results from the study will be 
used to inform decisions on the relevant time periods when clinical symptoms 
can be used to reliably develop a predictive score. In the next chapter, a similar 
but more detailed study will be conducted using a case-control study that has 
not been matched on age and sex which will enable the identification of lung 
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cancer predictors including age and sex. Results of that study will then be 
applied in developing a predictive score for lung cancer. 
 
 
4.5  Is there variation in the smoking associated 
risk of lung cancer by deprivation? 
4.5.1 Introduction 
Previous studies as well as results from this thesis have shown an increase in 
lung cancer risk among individuals of lower socioeconomic status92. Smoking is 
strongly associated with lung cancer incidence and it is highly prevalent among 
individuals of lower socioeconomic status235. Evidence from a meta-analysis 
however shows that the socioeconomic differences in lung cancer incidence 
remains even after adjusting for the level of cigarette smoke consumption90. 
Studies have also shown that self-reported smoking only accounts for 15% to 
50% of the socioeconomic variation in lung cancer risk93 236 237. Although the 
differential exposure to factors such as diet and occupational exposure are 
known to account for some of the socioeconomic differences in lung cancer 
incidence, a substantial part of the inequalities remain even after these have 
been adjusted for and they do not fully account for the difference in lung cancer 
risk97. Fidler et al.99 demonstrated that at similar levels of reported daily 
cigarette consumption, the saliva cotinine levels among individuals with higher 
levels of deprivation were higher than the cotinine levels in less deprived 
individuals. Results of the study may be explained by possible misclassification of 
smoking status or a difference in smoking behaviour between individuals of 
different socioeconomic groups. It however suggests the possibility that 
individuals of different socioeconomic status may be exposed to different 
smoking-associated risks per cigarette smoked.  
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This study uses the matched case-control dataset developed in this chapter to 
test the hypothesis that for each stratum of smoking, the dose-related risk of 
lung cancer is higher in individuals of lower socioeconomic status compared to 
individuals of higher socioeconomic status.   
 
4.5.2 Methods 
Conditional logistic regression analyses were performed to estimate the odds 
ratios and 95% CI for lung cancer associated with socioeconomic status and 
smoking. The odds ratio for lung cancer by smoking was stratified by Townsend 
quintiles to assess whether the overall risk of lung cancer differed among 
smokers from different socioeconomic groups ; and this was also assessed in 
males and females separately. Interaction terms were used to assess for any 
interaction between smoking and socio-economic status. Statistical significance 
was assumed at p<0.05 using the Wald's test of significance. 
 
4.5.3  Results 
In all the Townsend quintiles, smoking prevalence was higher among lung cancer 
cases than controls. Also, daily cigarette consumption increased with increasing 
levels of deprivation. Table 4.4 shows the distribution of cases and controls in 
the different Townsend quintiles and by category of smoking. 
Table 4.5 shows an increase in the odds ratio for lung cancer with higher daily 
cigarette consumption. Compared to individuals who had never smoked, the 
odds for lung cancer in individuals who smoked 10 to 19 cigarettes daily was 
9.04 (95% CI 8.30-9.83) and this increased to 14.17 (95% CI 13.07-15.35) in 
individuals who smoked 20 or more cigarettes daily. After stratifying this 
analysis by Townsend quintiles, there remained an increase in the odds of lung 
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cancer with a higher number of cigarettes smoked daily across all Townsend 
quintiles. The odds ratio for lung cancer among smokers in the different 
Townsend quintiles did not show a significant trend of increasing lung cancer risk 
with increasing deprivation and the findings were similar in males and females 
(Table 4.6), however the overall risk of lung cancer among smokers was greater 
in females than males.  
Further investigation of the odds ratios for lung cancer among never smokers in 
the different Townsend quintiles showed that among never smokers, the risk of 
lung cancer increased with increasing deprivation such that individuals from 
Townsend quintile 5 had a 60% increase in lung cancer risk compared to 
individuals in Townsend quintile 1 (odds ratio 1.60; 95% CI 1.16-2.20). The lung 
cancer odds ratio for trend with increasing deprivation among non-smokers was 
1.08 (95% CI 1.01-1.14). 
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Table 4.4. The distribution of cases and controls in the Townsend quintiles and by smoking category 
  
Townsend 1 (n=10,772) 
 
Townsend 2 (n=10,387) 
 
Townsend 3 (n=9,800) 
 
Townsend 4 (n=9,351) 
 
Townsend 5 (n=7,260) 
Daily cigarettes 
smoked 
Controls (%) 
n=8,735  
Cases (%) 
n=2,037 
Controls (%) 
n=8,187 
Cases (%) 
n=2,200 
Controls (%) 
n=7,420 
Cases (%) 
n=2,380 
Controls (%) 
n=6,742 
Cases (%) 
n=2,609 
Controls (%) 
n=5,064 
Case (%) 
n=2,196 
Heavy/very heavy  773 (8.9) 617 (30.3) 798 (9.8) 707 (32.1) 908 (12.2) 839 (35.3) 1,052 (15.6) 1,019 (39.1) 941 (18.6) 936 (42.6) 
Moderate smoker 691 (7.9) 363 (17.8) 737 (9.0) 395 (18.0) 719 (9.7) 492 (20.7) 761 (11.3) 585 (22.4) 652 (12.9) 471 (21.5) 
Trivial/light smoker 514 (5.9) 197 (9.7) 489 (6.0) 197 (8.9) 486 (6.6) 191 (8.0) 438 (6.5) 213 (8.2) 352 (7.0) 166 (7.6) 
Non-smoker 3,916 (44.8) 307 (15.1) 3,573 (43.6) 280 (12.7) 2,903 (39.1) 232 (9.8) 2,303 (34.2) 222 (8.5) 1,522 (30.1) 170 (7.7) 
Smoker (no quantity) 2,037 (23.3) 440 (21.6) 1,886 (23.0) 466 (21.2) 1,651 (22.3) 464 (19.5) 1,521 (22.6) 412 (15.8) 1,052 (20.8) 315 (14.3) 
No smoking records 804 (9.2) 113 (5.5) 704 (8.6) 155 (7.1) 753 (10.2) 162 (6.8) 667 (9.9) 158 (6.1) 545 (10.8) 138 (6.3) 
 
 
Table 4.5. The odds ratio for lung cancer by smoking category and stratified by Townsend quintiles 
 Overall OR 
(n=49,493)* 
Townsend 1 
(n=10,772) 
Townsend 2 
(n=10,387) 
Townsend 3 
(n=9,800) 
Townsend 4 
(n=9,351) 
Townsend 5 
(n=7,260) 
Daily cigarettes smoked       
Heavy/very heavy  14.17 (13.07-15.35) 13.49 (10.31-17.66) 16.78 (12.39-22.74) 20.65 (14.83-28.77) 13.94 (10.40-18.67) 10.86 (7.97-14.80) 
Moderate smoker 9.04 (8.30-9.83) 6.99 (5.34-9.15) 9.81 (7.14-13.49) 12.75 (9.12-17.82) 8.81 (6.49-11.95) 7.19 (5.21-9.94) 
Trivial/light smoker 5.63 (5.09-6.22) 4.40 (3.25-5.96) 6.25 (4.37-8.94) 5.89 (4.04-8.58) 5.28 (3.66-7.64) 4.54 (3.08-6.68) 
Non-smoker 1.00 1.00 1.00 1.00 1.00 1.00 
Smoker (no quantity) 3.23 (2.98-3.50) 2.61 (2.07-3.29) 3.29 (2.50-4.32) 4.48 (3.29-6.10) 3.03 (2.27-4.04) 2.78 (2.00-3.87) 
No smoking records 2.38 (2.14-2.65) 1.55 (1.11-2.18) 2.54 (1.78-3.61) 2.66 (1.79-3.95) 2.17 (1.49-3.15) 1.85 (1.23-2.79) 
* includes those with missing records on Townsend quintile 
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Table 4.6. The odds ratio for lung cancer by smoking category in males and females, stratified by Townsend quintiles 
Males 
Daily cigarettes 
smoked 
Overall OR 
(n=28,991)* 
Townsend 1 
(n=6,591) 
Townsend 2 
(n=6,169) 
Townsend 3 
(n=5,714) 
Townsend 4 
(n=5,337) 
Townsend 5 
(n=4,095) 
Heavy/very heavy  11.24 (10.11-12.51) 12.11 (8.58-17.09) 12.06 (8.27-17.57) 15.86 (10.33-24.37) 9.30 (6.39-13.51) 8.04 (5.27-12.28) 
Moderate smoker 7.62 (6.78-8.55) 6.38 (4.47-9.10) 8.41 (5.60-12.64) 9.62 (6.19-14.94) 6.57 (4.35-9.93) 4.40 (2.80-6.92) 
Trivial/light smoker 5.00 (4.38-5.70) 5.81 (3.95-8.56) 5.36 (3.41-8.43) 4.90 (2.98-8.05) 3.91 (2.43-6.27) 3.45 (2.01-5.94) 
Non-smoker 1.00 1.00 1.00 1.00 1.00 1.00 
Smoker (no quantity) 3.09 (2.78-3.44) 3.15 (2.35-4.22) 2.78 (1.99-3.88) 4.65 (3.09-6.99) 2.28 (1.57-3.31) 2.48 (1.58-3.89) 
No smoking records 2.20 (1.91-2.53) 1.64 (1.07-2.50) 2.32 (1.48-3.64) 2.52 (1.54-4.15) 1.64 (1.00-2.67) 1.20 (0.70-2.06) 
Females 
 n=20,502* n=4,181 n=4,218 n=4,086 n=4,014 n=3,165 
Heavy/very heavy  19.60 (5.41-7.42) 19.03 (11.92-30.81) 30.32 (17.63-52.14) 32.08 (18.47-55.71) 23.56 (14.59-39.06) 14.49 (9.12-23.03) 
Moderate smoker 10.91 (9.63-12.37) 8.99 (5.78-14.00) 11.42 (6.78-19.22) 19.48 (11.35-33.43) 12.11 (7.60-19.30) 11.58 (7.20-18.60) 
Trivial/light smoker 6.34 (5.41-7.42) 2.61 (1.58-4.31) 7.93 (4.35-14.46) 7.78 (4.28-14.11) 7.21 (3.99-13.00) 5.70 (3.25-10.00) 
Non-smoker 1.00 1.00 1.00 1.00 1.00 1.00 
Smoker (no quantity) 3.07 (2.70-3.50) 1.69 (1.14-2.51) 4.22 (2.57-6.94) 3.75 (2.31-6.09) 4.14 (2.60-6.57) 2.75 (1.67-4.52) 
No smoking records 2.47 (2.08-2.94) 1.47 (0.83-2.62) 2.72 (1.53-4.83) 2.55 (1.31-4.98) 2.88 (1.59-5.19) 2.99 (1.56-5.72) 
 * includes those with missing records on Townsend quintile 
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4.5.4 Discussion and conclusion 
 
In this study, there was no evidence to support the hypothesis that the risk of 
lung cancer associated with smoking increases with increasing deprivation. At 
increasing levels of cigarette consumption, there was an increase in the risk of 
lung cancer and this risk was similar across the Townsend quintiles. Cigarette 
consumption was however higher among individuals from more deprived 
Townsend quintiles and a higher proportion of cases who smoked were from 
more deprived quintiles. The finding of the lack of a difference in the risk of lung 
cancer among smokers from different socioeconomic groups was consistent in 
both males and females. However, the increased risk of lung cancer associated 
with smoking was higher in females than males.  
A major strength of this study is the large size of the THIN dataset which 
provides sufficient power to the study. By using patients' highest ever smoking 
record up to 6 months before lung cancer diagnosis, any effect due to a change 
in cigarette consumption in the months leading up to lung cancer diagnosis has 
been minimised in this study.  
The reliance on patients' reported smoking consumption may introduce bias due 
to a possible underestimation of smoking status by certain patients. Also, the 
misclassification of smoking status by GPs may introduce residual confounding 
into the study, although any effect due to misclassification would affect the cases 
and controls similarly and should therefore not make a difference to the study 
results.  Information on risk factors such as occupational exposure, diet and 
alcohol consumption which may be higher among and therefore increase the  
risk of lung cancer in individuals of lower socioeconomic groups, were not 
available in THIN database and could not be adjusted for in the study. 
Nonetheless, the finding of an increase in the baseline risk of lung cancer among 
non-smokers who were deprived compared to non-deprived non-smokers 
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suggests that these factors may marginally increase the risk of lung cancer 
among deprived individuals and supports findings from other studies that factors 
such as diet, occupational, environmental exposures and other lifestyle factors  
contribute to the association between socioeconomic status and lung cancer risk. 
The increase in lung cancer risk among female smokers compared to non-
smokers is an interesting finding which warrants further exploration and this will 
be explored in another study in this chapter. 
In conclusion, the findings of this study fail to provide support for the hypothesis 
that the risk of lung cancer is higher in more deprived smokers compared to less 
deprived smokers with similar levels of reported daily cigarette consumption; 
and suggests contrary to previous studies236 237, that most of the socioeconomic 
difference in lung cancer risk are due to smoking.  The socioeconomic gradient in 
lung cancer incidence is therefore driven by the greater smoking prevalence 
among people of lower socioeconomic status and to tackle these inequalities, 
smoking cessation programs targeted to socioeconomically deprived 
communities need to be intensified. 
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4.6  Is there an increase in smoking-associated risk 
of lung cancer in depressed compared to non-
depressed smokers?  
 
4.6.1 Introduction 
Despite the fact that cigarette smoking is the most important risk factor for lung 
cancer25 38, certain host factors increase the susceptibility of people to start and 
continue smoking, to smoke more heavily and to develop lung cancer238. 
Smoking prevalence is higher among individuals with depression239-241, perhaps 
in part because nicotine from cigarettes has been reported to provide temporary 
relief from the symptoms of depression242 243. Compared to smokers without 
reported depression, smokers with depression also have a higher risk of being 
nicotine dependent244, they are less likely to quit smoking245 and they have a 
greater likelihood of smoking relapse246. Depression may also cause an alteration 
in the body's immune system and consequently increases the risk of immune-
related conditions such as cancer104 247.  
It has been suggested that depression increases the risk of several cancers 
including lung cancer, yet evidence from the few studies that have examined this 
association is not consistent. In a  Finnish cohort study, depression was found to 
modify the effect of smoking on lung cancer risk in men such that the relative 
risk of lung cancer among smokers compared with non-smokers was 
considerably higher for those with elevated depressiveness scores (19.67; 95% 
CI 2.57-150.7) than for men at normal depressiveness scores (3.38; 95% CI 
1.09-10.52)107. In another prospective study in the United States, depression 
was positively associated with smoking-related cancers in individuals who 
smoked at least 15 cigarettes daily108. A prospective cohort study of persons 
aged 71 years and older in Massachusetts, USA, found an increase in the risk of 
several cancers including lung cancer among chronically depressed individuals 
regardless of their smoking status 105.  
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Using the thesis matched case-control dataset of patients in THIN, this study 
examined the association between depression and subsequent lung cancer risk in 
UK general practice patients. In doing this, the association between smoking and 
lung cancer was stratified by depression to determine whether people with 
depression are more at risk from the adverse effects of smoking.  
 
4.6.2 Methods 
Records of depression up to one year before the lung cancer index date were 
obtained from the cases and controls. Depression records made in the year 
preceding diagnosis were excluded to ensure that records related to patients' 
imminent diagnosis of lung cancer were not included in the analyses. Also, the 
highest recorded daily cigarette consumption for patients were obtained 
(detailed in section 4.3). Conditional logistic regression analyses were used to 
estimate the odds ratios and 95% confidence intervals (CIs) for lung cancer 
associated with depression and smoking. The odds ratio for lung cancer with 
depression was also obtained after adjusting for the effects of smoking. To 
estimate the increase in lung cancer risk among smokers with depression and 
those without depression, the analysis of the association between lung cancer 
and smoking were stratified by depression. Interaction terms were used to 
assess for any interaction between smoking and depression. Statistical 
significance was assumed at 0.05 using the Wald's test of significance. 
  
4.6.3 Results 
Records of depression were present in the general practice notes of 20.9% of 
cases and 17.1% of controls prior to one year before the cases' lung cancer 
index date. Univariate analysis of depression and lung cancer showed that 
depression was associated with a 30% increased odds of lung cancer (OR 1.30; 
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95% CI 1.24 - 1.38)(Table 4.7). Smoking was also associated with an increase 
in the odds ratio for lung cancer and the odds increased with an increase in daily 
cigarette consumption. On adjusting the association between depression and 
lung cancer by smoking, the odds ratio for lung cancer among people with 
depression decreased to 1.06 (95% CI 0.99-1.12).  
Table 4.8 shows the association between cigarette smoking and lung cancer 
stratified by depression. Compared to individuals with no record of depression, 
individuals with a history of depression were more likely to smoke and to smoke 
more heavily, with a higher proportion of them being moderate and heavy/very 
heavy smokers. The increase in the odds ratio for lung cancer with higher daily 
cigarette consumption was similar in both depressed and non-depressed groups 
of patients. There was no effect modification by a diagnosis of depression on the 
association between smoking habit and lung cancer risk. 
To ensure that results from the stratified matched analyses using conditional 
logistic regression were not distorted due to the large number of missing 
depression values which would have resulted in some dropped cases or controls, 
these analyses were repeated by breaking the matching and using unconditional 
logistic regression adjusted for age and sex.  The results from these analyses 
were very similar to those of the matched analyses. 
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                    Table 4.7.  Frequency of depression and smoking prevalence among cases and controls  
Variable  Controls n(%) 
n=37,605 
Cases n(%) 
n=11,888 
Total n(%) Unadjusted 
odds ratio for 
lung cancer 
95% confidence 
intervals 
Depression 
History of depression 
No history of depression 
 
  
  6,436 (17.1) 
31,169 (82.9) 
 
 
2,487 (20.9) 
9,401 (79.1) 
 
 
8,923 (18.0) 
40,570 (82.0) 
 
 
1.30 
1.00 
 
1.24 - 1.38 
Smoking  
Heavy/very heavy smoker 
Moderate smoker 
Trivial/light smoker 
Non smoker 
Smoker, no record of quantity 
Missing smoking records  
 
  4,679 (12.4) 
  3,720 (9.9) 
    2,377 (6.3) 
14,729 (37.2) 
8,460 (22.5) 
3,640 (9.7) 
 
4,292 (36.1) 
2,410 (20.3) 
1,003 (8.4) 
1,260 (10.6) 
2,169 (18.3) 
754 (6.3) 
 
8,971 (18.1) 
6,130 (12.4) 
3,380 (6.8) 
15,989 (32.3) 
10,629 (21.5) 
4,394 (8.9) 
 
14.17 
9.04 
5.63 
1.00 
3.23 
2.38 
 
13.07 - 15.35 
8.30 - 9.83 
5.09 - 6.22 
- 
2.98 - 3.50 
2.14 - 2.65 
                                 Odds ratio for lung cancer with depression after adjusting for smoking was 1.06 (95% CI 0.99-1.12) 
         
                           Table 4.8. Association between smoking and lung cancer, stratified by depression 
 No history of depression History of depression 
 
Smoking status 
controls n(%) 
n=31,169 (100) 
cases n(%) 
n=9,401 (100) 
Odds ratio for lung 
cancer (95% CI) 
controls (%) 
n=6,436 (100) 
cases (%) 
n=2,487 (100) 
Odds ratios for lung 
cancer (95% CI) 
Heavy/very heavy smoker 
Moderate smoker 
Trivial/light smoker 
Non smoker 
Smoker, no record of qty 
Missing smoking records 
3,524 (11.3) 
2,939 (9.4) 
1,942 (6.2) 
12,393 (39.8) 
7,043 (22.6) 
3,328 (10.7) 
3,179 (33.8) 
1,848 (19.7) 
816 (8.7) 
1,051 (11.2) 
1,820 (19.4) 
687 (7.3) 
13.5 (12.3-14.8) 
8.8 (8.0-9.7) 
5.7 (5.1-6.4) 
1.00 
3.3 (3.0-3.7) 
2.3 (2.1-2.6) 
1,155 (18.0) 
781 (12.1) 
435 (6.8) 
2,336 (36.3) 
1,417 (22.0) 
312 (4.9) 
1,113 (44.8) 
562 (22.6) 
187 (7.5) 
209 (8.4) 
349 (14.0) 
67 (2.7) 
14.8 (11.0-20.0) 
9.2 (6.8-12.6) 
4.6 (3.1-6.9) 
1.00 
2.8 (2.0-3.8) 
1.7 (0.9-3.0) 
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4.6.4 Discussion and conclusion 
In this study, patients with a history of depression were found to have a 30% 
increased risk of lung cancer compared with patients with no history of 
depression and this increased lung cancer risk was explained by cigarette 
smoking. Cigarette smoking was higher among patients with a recorded history 
of depression compared to those with no history of depression, and they were 
more likely to smoke more heavily. On stratified analysis, a history of depression 
did not appear to make people more vulnerable to the carcinogenic effects of 
smoking.  
As previously mentioned in chapter 2, a strength of THIN database - the data 
source for this study, is its large size, providing data on a vast number of 
patients and enabling the study of associations between different exposures and 
rare outcomes such as lung cancer. Records of depression and smoking in the 
database were collected during routine consultation in general practice and the 
results are therefore applicable to UK general practices. By matching cases and 
controls in our study by age, sex and general practice, any confounding due to 
these variables were controlled for during the design stage of the study.   
The study is limited by the fact that the diagnosis of depression was not based 
on standardised psychiatric criteria but on the assessment of GPs. Patients were 
noted to have a history of depression when they had records of a previous 
diagnosis of depression in their general practice notes up to one year prior to the 
lung cancer index date. Although this is not an ideal way to assess clinical 
depression, findings from these analyses consequently reflect the association 
between these assessments of depression in general practice and subsequent 
lung cancer incidence. Patients with lung cancer are known to commonly have 
psychological distress and depressive symptoms which is related with their 
functional limitations and symptoms248 and this can lead to the possibility of 
reverse causation in the association between depression and lung cancer. To 
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minimise any effect due to reverse causality in this study, records of depression 
that were made within the year before lung cancer diagnosis were excluded. 
Since evidence from previous studies show that the majority of patients with 
lung cancer have symptoms for a median of 12 months before diagnosis112, it is 
unlikely that the diagnosis of depression among the cases in this study were 
related to their impending lung cancer diagnosis.  
Previous studies have shown an increase in lung cancer risk among depressed 
compared to non-depressed smokers107 108 and it has been suggested that there 
may be differences in the smoking behaviour such as much deeper inhalation or 
smoking more of the cigarette in depressed compared to non-depressed 
smokers249. It has also been argued that depression modifies the effect of 
smoking on lung cancer107. In this study however, there was no difference in 
smoking-associated risk of lung cancer between depressed and non-depressed 
individuals who smoked similar quantities of cigarettes daily, suggesting that the 
increased risk of lung cancer observed among depressed individuals is mostly 
explained by their higher prevalence of cigarette smoking and more heavy 
smoking. 
The small non-significant 6% excess risk of lung cancer with depression which 
remained after adjusting for smoking may partly be due to residual confounding 
due to possible misclassification of smoking in the general practice records, or 
passive smoking. It has been proposed that depression alters the body's immune 
functions and suppresses cellular immunity through activation of the 
Hypothalamic-Pituitary-Adrenal axis and the ensuing abnormal secretion of 
adrenal steroids104 250. This impaired cellular immunity has however been noted 
to promote the development and progression of certain cancers associated with 
viruses but there is no known evidence as yet, to show that it increases the risk 
of lung cancer. Certain behavioural factors such as low levels of physical activity, 
poor dietary habits and high alcohol consumption are also known to increase the 
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risk of lung cancer72 79 80, and the less healthy behaviours of depressed people 
may be another mechanism by which lung cancer risk is slightly increased in 
these individuals. 
In conclusion therefore, this study found an increase in lung cancer risk among 
general practice patients with a history of depression and this was largely 
explained by smoking. Smoking increased the risk of lung cancer in depressed 
and non-depressed individuals and there was no evidence to support a 
significantly higher smoking-associated risk of lung cancer in depressed 
compared to non-depressed individuals. The possibility that an interplay of 
genetic factors and other behavioural risk factors  such as high alcohol 
consumption and poor dietary intake may marginally increase the risk of lung 
cancer among individuals with depression cannot be excluded. However given 
the fact that depression and other mental health conditions are associated with a 
higher prevalence of cigarette smoking and as a consequence, lung cancer,  it is 
important that smoking-cessation interventions are incorporated into the NICE 
guidelines for the management of patients with depression251 in order to prevent 
lung cancer and other chronic conditions in the long term. 
 
 
4.7  The association between smoking quantity and lung 
cancer in men and women 
This section summarizes the results of a study252 which investigated whether the 
risk of lung cancer differs between men and women with the same recorded 
quantity of cigarettes smoked. The study was conducted as part of a PhD project 
by Dr Helen Powell, a clinical fellow in the Division of Epidemiology and Public 
Health. The study used the matched case-control dataset developed by Barbara 
Iyen-Omofoman and which has been described in this thesis chapter. The initial 
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data management and extraction of the variables for the study were done by 
Barbara Iyen-Omofoman while Helen Powell carried out the data organisation 
and performed the statistical analyses.  
 
4.7.1 Study summary 
Previous evidence had shown that women who smoke have a 25% greater risk 
of coronary heart disease than male smokers253 and even though an examination 
of this relationship in lung cancer had shown conflicting results87 89 254 255, no 
study had assessed the effect in a UK population. The study also tested the 
hypothesis that if women are at higher risk of smoking-related lung cancer, it 
may be because they have smaller lung volumes than men. 
Using conditional logistic regression, odds ratios for lung cancer were calculated 
according to the highest recorded daily cigarette consumption in men and 
women separately. Results showed that in women, there was a 19-fold increase 
in the risk of lung cancer (odds ratio 19.10; 95% CI 16.98-21.49) in heavy 
smokers compared to never-smokers. This was more than for men smoking the 
same quantity (odds ratio 12.81; 95% CI 11.52-14.24). A test for interaction 
showed strong evidence of a difference in effect of cigarette quantity smoked on 
lung cancer between men and women (interaction p<0.001) and this effect 
remained even after adjusting for height ( a proxy marker for lung volume). 
Based on the results of this study, it was concluded that moderate and heavy 
smoking carry a higher risk of lung cancer in women than men and this 
difference is not explained by a difference in their lung volumes. Extrapolating 
risk estimates for lung cancer in men to women will therefore underestimate the 
adverse impact of smoking in women. 
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5. Chapter 5.   The use of an unmatched case-
control dataset to identify the socio-demographic 
and early clinical features predictive of lung 
cancer in general practice  
In the previous chapter, the study used a case-control dataset matched on age, 
sex and general practice to pilot the methods to identify the independent 
predictors of lung cancer and determine the timing of clinical features before 
lung cancer diagnosis. Also using the same dataset, studies were conducted to 
investigate variations in the smoking-associated risk of lung cancer in certain 
groups of general practice patients while controlling for the confounding effects 
of age, sex and variability in general practice recording. The next phase of this 
study entails the identification of lung cancer predictors that can be used to 
develop a predictive score for lung cancer. To develop a predictive score that is 
robust and widely applicable, the effects of age and sex have to be accounted 
for. This chapter therefore uses a case-control dataset that has not been 
matched on age or sex, to identify the socio-demographic and early clinical 
features predictive of lung cancer and that can be used to develop a predictive 
score for lung cancer. 
 
5.1 introduction 
Most lung cancer patients experience symptoms before diagnosis114 and in a 
study of recently diagnosed patients, symptoms were recalled starting between 4 
months and 2 years before diagnosis112. In the UK where the GP is the 
gatekeeper to specialised health care, most patients present with symptoms to 
their GP before the diagnosis of lung cancer is made112 113. A case-control study 
of patients from 21 general practices in Exeter, UK113 showed that GP records of 
haemoptysis, dyspnoea, abnormal spirometry and smoking were independently 
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associated with lung cancer up to 180 days before diagnosis. Although the UK 
NICE referral guidelines147 were developed to facilitate urgent referral of 
suspected lung cancer cases, the evidence base for this has been questioned112 
134 142. Because many lung cancer symptoms are non-specific, GPs face a difficult 
challenge in deciding which patients merit investigation. A key step is to 
estimate the risk of lung cancer by taking into account a combination of socio-
demographic features and clinical symptoms. 
This study aims to use the thesis dataset of cases and unmatched controls to 
identify the pattern and frequency of early pre-diagnostic symptoms, clinical 
investigations and patients' socio-demographic factors that are independently 
associated with lung cancer.  
 
5.2  Methods 
5.2.1  Cases and controls  
The cases included in this matched case-control dataset were the incident cases 
of lung cancer derived in Chapter 2 (section 2.3). The eligibility criteria for case 
selection have also been detailed in section 4.1.1. Similar to the matched case-
control study in chapter 4, the 59 lung cancer cases less than 40 years of age 
(0.49% of cases) were excluded from the analyses in this chapter. In total, there 
were 12,076 eligible cases for this study. 
For each case, 10 randomly selected controls were selected. The controls were 
selected and assigned to cases using the following criteria 
 Controls had to be registered in the same general practice as the case 
 At least 40 years or older on the date of diagnosis of the case 
 Alive and contributing to THIN on the lung cancer index date of the case  
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 Have at least 1 year of active data prior to the case index date  
Ten eligible controls were randomly assigned to each case and when there were 
less than 10 eligible controls for a case, all eligible controls were assigned. 
 
5.2.2  Socio-demographic and clinical features 
The socio-demographic information analysed were: age, sex, Townsend 
deprivation quintiles (measure of socio-economic status) and smoking history. 
Definition of the variables - Age, sex, Townsend deprivation quintiles and 
smoking, as well as the data extraction process for these variables were as 
described in the previous chapter for the matched case-control dataset (section 
4.3). In the dataset analysed in the previous chapter, age and sex were used as 
matching variables. In the case-control dataset analysed in this chapter, 
patients' age was categorised into 5-year age bands and in addition to sex, was 
included in the analyses. 
Based on the highest ever recorded number of cigarettes smoked daily, the 
smoking records of current or ex-smokers were further categorised as trivial 
(less than 1 cigarette daily), light (1-9 cigarettes daily), moderate (10-19 
cigarettes daily), heavy (20-39 cigarettes daily) or very heavy (40+ cigarettes 
daily). As detailed in the previous chapter, current or ex-smokers who had no 
records of daily cigarette consumption were recorded as such (smoker with no 
recorded quantity) and patients who had no recorded smoking information and 
who were not known to be non-smokers were included in a separate category 
(missing smoking records).  
All consultations made by the cases and controls in their registered general 
practices were retrieved from the database. Details of the symptoms analysed, 
chest x-rays and blood investigations have been described in the previous 
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chapter (section 4.3 4). In extracting and categorising records of blood tests for 
this study, blood investigations were classified based on the outcome of the tests 
into: normal result, abnormal result, test done with no recorded result and no 
record of blood tests. In addition, the frequency of general practice consultations 
for symptoms and diagnoses other than those already assessed in the study 
were retrieved from patients' records.  
The Read codes used to extract patients' records of symptoms, chest x-rays and 
blood tests are listed in Appendix I. 
 
5.2.3  Timing of clinical records 
Similar to the method described in the study in the previous chapter, all 
symptoms, diagnoses and investigations over the 2-year period before lung 
cancer diagnosis (or the diagnosis date of the matched case, for controls) were 
retrieved from patients' records. Since a chest x-ray is the initial investigation for 
suspected lung cancer147, the timing of chest x-rays prior to lung cancer 
diagnosis in cases and prior to the pseudo-date in controls were determined and 
compared, as a means of determining the time period before diagnosis when GPs 
started preliminary investigations for suspected lung cancer in cases. There was 
a steep increase in the chest x-ray frequency in cases (but not controls) within 
the 4 months prior to diagnosis, so all symptoms, blood tests and other 
consultations recorded within this period were excluded.  
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5.2.4  Statistical analysis 
Univariate logistic regression models were used to calculate the relative odds of 
lung cancer by socio-demographic factors (age, sex and Townsend deprivation 
quintiles), smoking, symptoms, diagnoses, blood tests and number of 
consultations in the 2 years before diagnosis. These analyses were done 
separately for records made in the 4-12 and the 13-24 month periods prior to 
diagnosis. Multivariate modelling was done using only variables that were 
associated with lung cancer in univariate analysis, using a significance cut-off 
level of p<0.05. Variables that were not statistically significant in the 
multivariate analysis were removed from the model and those that previously 
showed no association with lung cancer in the univariate model were re-checked 
for significance in the final model.  
 
5.3  Results 
5.3.1  Population socio-demographic characteristics  
Of the 12,076 cases eligible for this study, 12,073 cases were assigned 10 
controls each, 2 cases did not have any eligible controls and were excluded, and 
the remaining case had only 1 eligible control, giving a total of 132,805 patients 
in the study population which comprised of 12,074 cases and 120,731 controls. 
Compared to controls, people with lung cancer were more likely to be male, be 
older, live in households located in more deprived areas and they were more 
likely to have a current or ex smoking history (Table 5.1)  
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Table 5.1.  Socio-demographic characteristics and smoking status of 
lung cancer cases and controls 
 
 
Case n(%) 
n =12,074 
Control n(%) 
n = 120,731 
Unadjusted odds ratio for 
lung cancer (95% CI) 
Age at diagnosis (years)  
>80 2,639 (21.86) 10,797 (8.94) 48.80   (39.72-59.97) 
75-80 2,305 (19.09) 8,191 (6.78) 56.19   (45.69-69.10) 
70-75 2,212 (18.32) 9,940 (8.23) 44.43   (36.13-54.64) 
65-70 1,750 (14.49) 11,201 (9.28) 31.20   (25.34-38.40) 
60-65 1,488 (12.32) 13,475 (11.16) 22.05   (17.90-27.16) 
55-60 896 (7.42) 15,439 (12.79) 11.59   (9.37-14.33) 
50-55 469 (3.88) 15,963 (13.22) 5.87     (4.70-7.32) 
45-50 220 (1.82) 16,756 (13.88) 2.62     (2.06-3.34) 
40-45 95 (0.79) 18,969 (15.71) 1.00      
Sex  
Male 7,154 (59.25) 58,034 (48.07) 1.57       (1.51-1.63) 
Female 4,920 (40.75) 62,697 (51.93) 1.00 
Townsend deprivation quintile  
5 (most deprived) 2,234 (18.50) 15,997 (13.25) 1.94      (1.82-2.07) 
4 2,640 (21.87) 21,071 (17.45) 1.74      (1.64-1.85) 
3 2,421 (20.05) 23,791 (19.71) 1.41      (1.33-1.50) 
2 2,236 (18.52) 26,540 (21.98) 1.17      (1.10-1.25) 
1 (least deprived) 2,064 (17.09) 28,681 (23.76) 1.00 
Missing Townsend records 479 (3.97) 4,651 (3.85) 1.43      (1.29-1.59) 
Smoking status and qty 
Current V heavy (40+/d) 471    (3.90) 1,466   (1.21) 12.52    (11.14-14.09) 
Current Heavy (20-39/d) 2,589 (21.44) 10,928 (9.05) 9.24      (8.61-9.90) 
Current Mod (10-19/d) 1,665 (13.79) 8,247   (6.83) 7.87      (7.29-8.49) 
Current Light (1-9/d) 607    (5.03) 3,765   (3.12) 6.28      (5.68-6.96) 
Current Trivial (<1/d) 7        (0.06) 144      (0.12) 1.89      (0.89-4.05) 
Current, no qty recorded  439    (3.64) 4,495   (3.72) 3.81      (3.40-4.26 
Ex V Heavy (40+/d) 221     (1.83) 841      (0.70) 10.24    (8.75-12.00) 
Ex Heavy (20-39/d) 1,043  (8.64) 4,258   (3.53) 9.55      (8.75-10.42) 
Ex Mod (10-19/d) 777     (6.44) 4,394   (3.64) 6.89      (6.27-7.57) 
Ex Light (1-9/d) 399     (3.30) 2,837   (2.35) 5.48      (4.87-6.17) 
Ex Trivial (<1/d) 13       (0.11) 289      (0.24) 1.75      (1.00-3.06) 
Ex, no qty recorded 1,780  (14.74) 16,027 (13.27) 4.33      (4.02-4.66) 
Non smoker 1,300  (10.77) 50,676 (41.97) 1.00 
Missing smoking records 763     (6.32) 12,364 (10.24) 2.41       (2.20-2.64) 
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5.3.2 Duration of registration in the general practices 
The  average period of follow-up in the general practices prior to the lung cancer 
index date (defined in the cases as the date of lung cancer diagnosis and defined 
in controls as the date of lung cancer diagnosis in the matching case) was similar 
in cases and controls. The median follow-up for the cases was 9.5 years (inter-
quartile range 5.5 years to 13.5 years) and the median follow-up for controls 
was 9.1 years (inter-quartile range 5.2 years to 13.2 years).  
 
5.3.3 Overall consultation by cases and controls 
For the entire duration of being registered in the general practices, the median 
number of consultations per case was 421 and the median number of 
consultations per control was 192. In the two years before lung cancer diagnosis 
in cases, the median number of consultations by the cases and controls were 
170 and 64 consultations respectively. Plots of the consultation pattern in cases 
and controls over the 5-year and 2-year periods prior to lung cancer diagnosis 
(Figure 5.1 and Figure 5.2) showed a similar consultation pattern in cases and 
controls up to the year before diagnosis, when the consultation frequency in 
cases increased considerably. 
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Figure 5.1: Plot of general consultation by controls and lung cancer cases, 5 
years before lung cancer diagnosis 
(the height of the bars are scaled so that the sum of their height equals 100) 
 
 
 
 
 
 
Figure 5.2:  Plot of general consultation by controls and lung cancer cases, 2 
years before lung cancer diagnosis 
(the height of the bars are scaled so that the sum of their height equals 100) 
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5.3.4 Timing of chest x-rays prior to lung cancer diagnosis 
A plot of the frequency of chest x-ray investigations in cases and controls before 
lung cancer diagnosis showed a fairly similar chest x-ray frequency in both 
groups of patients up to the 4th month preceding lung cancer diagnosis (Figure 
5.3). During the 4 months before lung cancer diagnosis, there was a steep 
increase for cases implying that investigations for lung cancer were initiated by 
GPs at this time. Based on this finding, it was considered logical to exclude all 
symptoms, blood tests and other consultations recorded within the 4 month 
period from further analyses, so that the early-stage factors associated with lung 
cancer could be determined.  
 
Figure 5.3. Plots showing the frequency distribution of chest x-rays in general 
practice prior to the diagnosis of lung cancer 
(the height of the bars are scaled so that the sum of their height equals 100) 
Odds ratio (95% CI) for chest x-ray within the 12 months among cases compared to 
controls was 28.63 (27.34-29.98); P<0.001 
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5.3.5  Clinical features associated with lung cancer   
Analysis of the symptoms, diagnoses, blood tests and number of consultations 
within the 4-12 and 13-24 month periods preceding diagnosis (Table 5.2 & Table 
5.3) showed that the symptoms with the highest frequency among cases were 
cough, non-specific chest infections, dyspnoea, chest pain and COPD. In the 4-
12 month period before diagnosis, these symptoms were recorded among 16%, 
12%, 9%, 8% and 8% of cases respectively compared to 6%, 4%, 2%, 4% and 
1% of controls respectively. Although haemoptysis records were made for only 
2% of cases within the 4-12 month period, the odds ratio for lung cancer among 
people who had haemoptysis within this period was 20.15 (95% CI 16.24-
25.01). 
Compared to the controls, cases consulted their GPs for other symptoms more 
often before diagnosis. Using fewer than 10 consultations as a reference value, 
the odds ratio for cases to consult their GPs 21 times or more was 3.56 (95% CI 
3.41-3.73) in the 13-24 month period and 4.45 (95% CI 4.24-4.68) in the 4-12 
month period. Depression was a commonly recorded symptom in the records of 
patients with lung cancer however, depression records within the 24 months 
before diagnosis was found not to be associated with lung cancer. There were 
also more blood investigations among cases than controls within the 4-12 and 
13-24 month periods before diagnosis, with an increase in the number of normal 
and abnormal test results. The odds ratios for lung cancer were greater with all 
the symptoms recorded within the 4-12 month period than the 13-24 month 
period. 
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Table 5.2 :  Symptoms, blood investigations and number of general practice consultations recorded among cases and controls within the 4 to 12 month 
period prior to lung cancer diagnosis  
Variable in GP record 4-12 months 
before lung cancer diagnosis 
Cases n(%) 
N=12,074 
Controls n(%) 
N=120,731 
Unadjusted OR 
for lung cancer 
95% CI p-value § 
 
Cough 
 
1,938 (16.05) 
 
7,088 (5.87) 
 
3.07 
 
2.90-3.24 
 
<0.001 
 
Haemoptysis 
 
247  (2.05) 
 
125    (0.10) 
 
20.15 
 
16.24-25.01 
 
<0.001 
 
Chest/shoulder pain 
 
1,002 (8.30) 
 
4,880 (4.04) 
 
2.15 
 
2.00-2.31 
 
<0.001 
 
Voice hoarseness 
 
66   (0.55) 
 
219    (0.18) 
 
3.02 
 
2.30-3.99 
 
<0.001 
 
Dyspnoea 
 
1,091 (9.04) 
 
2,479 (2.05) 
 
4.74 
 
4.40-5.10 
 
<0.001 
 
Weight loss 
 
197  (1.63) 
 
323    (0.27) 
 
6.18 
 
5.17-7.39 
 
<0.001 
 
Constipation 
 
423  (3.50) 
 
1,469 (1.22) 
 
2.95 
 
2.64-3.29 
 
<0.001 
 
Depressive disorders 
 
365  (3.02) 
 
3,365 (2.79) 
 
1.09 
 
0.97-1.21 
 
0.135 
 
URTI 
 
426  (3.53) 
 
3,082 (2.55) 
 
1.40 
 
1.26-1.55 
 
<0.001 
 
LRTI 
 
516  (4.27) 
 
1,585 (1.31) 
 
3.36 
 
3.03-3.71 
 
<0.001 
 
Non-specific chest infections 
 
1,398 (11.58) 
 
4,350 (3.60) 
 
3.50 
 
3.29-3.73 
 
<0.001 
 
COPD 
 
978  (8.10) 
 
1,349 (1.12) 
 
7.80 
 
7.17-8.49 
 
<0.001 
 
Outcome of blood tests  
No blood test record 
Test without results 
Abnormal 
Normal 
 
 
6,406 (53.06) 
5,431 (44.98) 
107  (0.89) 
130  (1.08) 
 
 
84,997 (70.40) 
34,295 (28.41) 
528   (0.44) 
911   (0.75) 
 
 
1.00 
2.10 
2.69 
1.89 
 
 
 
2.02-2.18 
2.18-3.31 
1.57-2.28 
 
 
 
 
<0.001 
 
Number of GP consultations  
0-10 
11-20 
21 or more 
 
 
4,316 (35.75) 
4,373 (36.22) 
3,385 (28.04) 
 
 
77,720 (64.37) 
29,327 (24.29) 
13,684 (11.33) 
 
 
1.00 
2.69 
4.45 
 
 
 
2.57-2.81 
4.24-4.68 
 
 
 
<0.001 
§ p-values for binary variables were obtained using the Wald's test of significance. In variables with more than  2 categories, p-values were obtained from the likelihood ratio test 
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Table 5.3:  Symptoms, blood investigations and number of general practice consultations recorded among cases and controls within the 13 to 24 month 
period prior to lung cancer diagnosis  
Variable in GP record 13-24 months 
before lung cancer diagnosis 
Cases n(%) 
N=12,074 
Controls n(%) 
N=120,731 
Unadjusted OR 
for lung cancer 
95% CI p-value § 
 
Cough 
 
1,774 (14.69) 
 
9,087 (7.53) 
 
2.12 
 
2.00-2.24 
 
<0.001 
 
Haemoptysis 
 
  133  (1.10) 
 
191    (0.16) 
 
7.03 
 
5.63-8.78 
 
<0.001 
 
Chest/shoulder pain 
 
   959 (7.94)  
 
6,540 (5.42) 
 
1.51 
 
1.40-1.62 
 
<0.001 
 
Voice hoarseness 
 
   56   (0.46) 
 
326    (0.27) 
 
1.72 
 
1.30-2.29 
 
<0.001 
 
Dyspnoea 
 
   992 (8.22) 
 
3,047 (2.52) 
 
3.46 
 
3.21-3.72 
 
<0.001 
 
Weight loss 
 
  139  (1.15) 
 
416    (0.34) 
 
3.37 
 
2.78-4.09 
 
<0.001 
 
Constipation 
 
    421  (3.49) 
 
1,848 (1.53) 
 
2.32 
 
2.09-2.59 
 
<0.001 
 
Depressive disorders 
 
  449  (3.72) 
 
4,705 (3.90) 
 
0.95 
 
0.86-1.05 
 
0.333 
 
URTI 
 
    497  (4.12) 
 
4,274 (3.54) 
 
1.17 
 
1.06-1.29 
 
<0.001 
 
LRTI 
 
    566  (4.69) 
 
2,218 (1.84) 
 
2.63 
 
2.39-2.89 
 
<0.001 
 
Non-specific chest infections 
 
1,356 (11.23) 
 
5,856 (4.85) 
 
2.48 
 
2.33-2.64 
 
<0.001 
 
COPD 
 
  1,024 (8.48) 
 
1,553 (1.29) 
 
7.11 
 
6.56-7.71 
 
<0.001 
 
Outcome of blood tests  
No blood test record 
Test without results 
Abnormal 
Normal 
   
 
6,136  (50.82) 
5,632  (46.65) 
127   (1.05) 
179   (1.48) 
 
 
79,446 (65.80) 
39,255 (32.51) 
       752  (0.62) 
1,278   (1.06) 
 
 
1.00 
1.86 
2.19 
1.81 
 
 
 
1.79-1.93 
1.81-2.64 
1.55-2.13 
 
 
 
<0.001 
 
Number of GP consultations  
0-10 
11-20 
21 or more 
 
 
3,491 (28.91) 
3,492 (28.92) 
5,091 (42.16) 
 
 
64,881 (53.74) 
29,296 (24.27) 
26,554 (21.99) 
 
 
1.00 
2.22 
3.56 
 
 
 
2.11-2.33 
3.41-3.73 
 
 
 
<0.001 
§ p-values for binary variables were obtained using the Wald's test of significance. In variables with more than  2 categories, p-values were obtained from the likelihood ratio test  
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In multivariate analysis (Table 5.4), age, sex, Townsend deprivation quintiles, 
smoking (status and highest daily cigarette consumption), number of general 
practice consultations as well as symptom presentations of cough, haemoptysis, 
dyspnoea, weight loss, LRTI, non-specific chest infections and COPD were 
independently associated with lung cancer up to 24 months before diagnosis. 
Chest pain, voice hoarseness and URTI were associated with lung cancer in the 
4-12 months but not in the 13-24 months before diagnosis. Constipation, 
depression and blood tests were not independently associated with lung cancer 
in either the 4-12 or the 13-24 month periods. 
Compared with the univariate model, the association of age, sex and smoking 
with lung cancer were almost unchanged in the multivariate model. The 
association with deprivation was slightly attenuated in the multivariate model 
but remained significantly associated with lung cancer. The odds of lung cancer 
increased with increasing number of daily cigarettes smoked and this effect was 
stronger among current than ex-smokers. 
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Table 5.4:  Multivariate model of factors associated with lung cancer before diagnosis 
 
 
Risk factor variable 
 
   13-24 months before diagnosis 
 
   4-12 months before diagnosis 
 
Adjusted odds ratio 
(95% CI) 
 
P-value § 
 
Adjusted odds ratio 
(95% CI) 
 
p-value § 
 
Age at diagnosis (yrs) 
40-45 
45-50 
50-55 
55-60 
60-65 
65-70 
70-75 
75-80 
>80 
 
 
1.00 
2.55 (2.00-3.26) 
5.50  (4.40-6.88) 
10.88  (8.78-13.48) 
20.74 (16.80-25.61) 
30.58 (24.78-37.74) 
47.87 (38.80-59.06) 
65.60 (53.13-80.99) 
72.53 (58.76-89.53) 
 
 
 
 
 
<0.001 
 
 
1.00 
2.50 (1.96-3.19) 
5.42  (4.34-6.78) 
10.67  (8.61-13.22) 
19.59 (15.86-24.18) 
28.61 (23.17-35.32) 
44.74 (36.26-55.21) 
60.03 (48.62-74.12) 
65.55 (53.10-80.93) 
 
 
 
 
 
<0.001 
 
Sex 
Male 
Female 
 
 
1.59 (1.53-1.66) 
1.00 
 
 
<0.001 
 
 
1.62 (1.55-1.69) 
 
 
<0.001 
 
Townsend score 
5(most deprived) 
4  
3 
2 
1 (least deprived) 
Missing Townsend records 
 
 
1.13 (1.05-1.21) 
1.14 (1.05-1.21) 
1.07 (1.00-1.14) 
1.01 (0.94-1.08) 
1.00 
1.01 (0.90-1.13) 
 
 
 
0.0001 
 
 
1.10 (1.02-1.18) 
1.12 (1.05-1.20) 
1.07 (1.00-1.14) 
1.00 (0.93-1.07) 
1.00 
1.01 (0.90-1.13) 
 
 
 
0.0017 
 
Smoking status and qty  
Current V heavy (40+/d) 
Current Heavy (20-39/d) 
Current Mod (10-19/d) 
Current Light (1-9/d) 
Current Trivial (<1/d) 
Current, no qty recorded  
 
Ex V Heavy (40+/d) 
Ex Heavy (20-39/d) 
Ex Mod (10-19/d) 
Ex Light (1-9/d) 
Ex Trivial (<1/d) 
Ex, no qty recorded 
 
Missing smoking records 
Non smoker 
 
 
16.61 (14.53-18.98) 
13.65 (12.63-14.75) 
9.85 (9.07-10.70) 
6.09 (5.46-6.79) 
2.64 (1.20-5.81) 
3.48 (3.09-3.92) 
 
5.70 (4.80-6.76) 
7.15 (6.50-7.86) 
4.72 (4.27-5.21) 
3.75 (3.31-4.25) 
1.29 (0.73-2.28) 
2.69 (2.49-2.91) 
 
2.56 (2.33-2.82) 
1.00 
 
 
 
 
 
<0.001 
 
 
15.91 (13.90-18.21) 
13.45 (12.44-14.54) 
9.82 (9.04-10.68) 
5.98 (5.36-6.68) 
2.68 (1.21-5.90) 
3.47 (3.08-3.91) 
 
5.33 (4.48-6.35) 
6.67 (6.06-7.35) 
4.50 (4.07-4.98) 
3.54 (3.12-4.02) 
1.21 (0.68-2.17) 
2.57 (2.38-2.78) 
 
2.70 (2.45-2.97) 
1.00 
 
 
 
 
 
<0.001 
 
Cough 
 
1.22 (1.14-1.30) 
 
<0.001 
 
1.63 (1.53-1.75) 
 
<0.001 
Haemoptysis  3.40 (2.59-4.45) <0.001 8.70 (6.75-11.20) <0.001 
Dyspnoea 1.18 (1.08-1.29) <0.001 1.41 (1.29-1.55) <0.001 
Weight loss 1.78 (1.43-2.23) <0.001 2.66 (2.16-3.29) <0.001 
LRTI 1.40 (1.26-1.53) <0.001 1.56 (1.38-1.76) <0.001 
Chest infections 1.24 (1.15-1.33) <0.001 1.55 (1.44-1.68) <0.001 
COPD 1.79 (1.63-1.97) <0.001 1.61 (1.46-1.78) <0.001 
Chest/shoulder pain*   1.39 (1.28-1.51) <0.001 
Voice hoarseness*   1.79 (1.28-2.49) 0.001 
URTI*   1.15 (1.02-1.30) 0.020 
 
No. of GP consultations 
0-10 
11-20 
21 or more 
 
 
1.00 
1.14 (1.07-1.20) 
1.17 (1.10-1.24) 
 
 
 
<0.001 
 
 
1.00 
1.23 (1.16-1.29) 
1.36 (1.28-1.44) 
 
 
 
<0.001 
§ p-values for binary variables were obtained using the Wald's test of significance. In variables with 
more than  2 categories, p-values were obtained from the likelihood ratio test 
*symptoms not associated with lung cancer in the 13-24 month period before diagnosis 
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5.4 Discussion  
5.4.1 Main findings  
Similar to the earlier findings from the study using the case-control dataset that 
was matched on age and sex, this study has shown an increase in symptom 
reporting to GPs by patients up to 2 years before lung cancer diagnosis but the 
overall increase in consultation frequency by cases was shown to occur mostly 
within the year before diagnosis. There was an increase in the frequency of chest 
x-ray investigations in cases which occurred at about the 4th month before lung 
cancer diagnosis implying that investigations were initiated by GPs at this time. 
After excluding symptoms recorded in the 4 month period prior to lung cancer 
diagnosis, symptoms that were more commonly reported in the 2 years before 
diagnosis were cough, non-specific chest infections, dyspnoea, chest pain and 
COPD. On taking account of the combined effects of patients' socio-demographic 
factors, smoking and number of consultations, the symptoms that were found to 
be independently associated with lung cancer within the 4-24 months before 
diagnosis were cough, haemoptysis, dyspnoea, weight loss, LRTI, chest 
infections and COPD. Chest pain, voice hoarseness and URTI remained 
associated with lung cancer only within the 4-12 months before diagnosis.  
Socio-demographic characteristics found to be independently associated with 
lung cancer were age, sex, deprivation and smoking. These findings were 
comparable to findings in the UK national lung cancer audit database84 and other 
populations90. Smoking is the most important risk factor for lung cancer25 38 and 
this was reflected in the general practice population in THIN.  
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5.4.2 Comparison with other studies 
This is the first large study that uses a combination of patients' socio-
demographic characteristics and general practice records while excluding 
symptoms in the final months before diagnosis, to identify the early predictors of 
lung cancer. A few studies have explored the symptoms of lung cancer in general 
practice112 114 134  but only one study so far has excluded symptoms in the final 
months before diagnosis as a means of identifying the early-stage symptoms 
associated with lung cancer113. This study of 247 lung cancer cases and 1235 
controls explored symptoms of lung cancer but did not identify the socio-
demographic characteristics associated with lung cancer113. A more recent study 
used a combination of baseline risk factors and primary care symptoms up to 
diagnosis to develop an algorithm to predict lung cancer192. In identifying lung 
cancer predictors for this algorithm, this study included symptoms up to 
diagnosis which GPs may already be investigating, so the algorithm developed 
using these predictors may not be able to predict lung cancer early enough to 
improve clinical outcomes. 
Apart from COPD and chest infections (URTI, LRTI and non-specific chest 
infections), the symptoms which were found to be associated with lung cancer in 
this study are comparable to those found in the study by Hamilton et al.113 as 
well as the NICE guideline recommendations147. The association between COPD 
and lung cancer in this study, although not investigated by Hamilton et al., is 
similar to the finding by Hippisley-Cox et al.192. However, in contrast to 
Hippisley-Cox et al. where dyspnoea, pneumonia and voice hoarseness were not 
associated with lung cancer, this study found dyspnoea and LRTI to be 
associated with lung cancer up to 24 months before diagnosis and voice 
hoarseness was associated with lung cancer up to 12 months before diagnosis.  
The majority of these symptoms, except haemoptysis, can be found in benign 
conditions and present frequently in general practice116 256. The association 
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between URTI and lung cancer in the 4-12 months before diagnosis is likely 
explained by GPs making URTI diagnoses following complaints of cough and 
other non-specific respiratory symptoms in the year before diagnosis. Chest pain 
and voice hoarseness were also associated with lung cancer in the 4-12 months 
before diagnosis and this may be because these symptoms are indicative of 
intra-thoracic spread110 and therefore characteristic of the later stages of 
disease. 
 
5.4.3 Strengths and limitations 
This study was done using lung cancer cases in the thesis dataset which had 
previously been validated against UK national lung cancer databases (Chapter 
3), hence the results can be generalised to and are widely representative of the 
early interactions between GPs and lung cancer patients in the UK. As previously 
highlighted in chapter 2 (section 2.1.4), the database is large and therefore has 
considerable statistical power. Also, all records that have been used for analyses 
are routinely collected in general practice and therefore freely available to GPs.  
A drawback in this study is the unavailability of information on cigarette pack-
years for defining patients' lifetime cigarette exposure. As a proxy, patients' 
cigarette consumption were categorised using the highest recorded number of 
cigarettes smoked daily which provided the highest possible daily consumption 
for the patients. The results from analyses using these categories fit broadly with 
existing literature. In conducting these analyses, the recorded date of lung 
cancer diagnosis in THIN was assumed to be the patients' date of diagnosis. In 
practice however, lung cancer diagnosis is either made in general practice 
following investigations in primary care, or following diagnosis by a chest 
physician in secondary care. This leads to the possibility that a patients' actual 
date of lung cancer diagnosis is earlier than the diagnosis date recorded in the 
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GP's notes. Despite this limitation, the general characteristics and survival 
estimates for patients with lung cancer in THIN have been shown to be 
representative and highly comparable to the lung cancer population in the UK. 
 
5.4.4 Conclusion 
Although there is an increase in symptom reporting up to 2 years before lung 
cancer diagnosis, a considerable amount of consultation for these symptoms 
were made within the year before diagnosis and suggests the need for more 
efforts to educate the public and especially smokers on the key symptoms of 
lung cancer and the need to seek medical care as and when they have these 
symptoms. The warning symptoms identified 4-12 months and even 13-24 
months before diagnosis were comparable to the NICE guideline 
recommendations147 indicating that some patients with lung cancer could have 
been investigated or diagnosed earlier.  
A combination of early-stage symptoms in general practice, smoking and 
socioeconomic characteristics were found to be associated with lung cancer and 
could be used to develop a predictive score to aid earlier identification of patients 
at increased lung cancer risk who will benefit from further investigations such as 
chest x-rays. However, in view of the fact that GPs start chest x-ray 
investigations for suspected lung cancer at about 4 months before diagnosis and 
since the increase in general consultation frequency by cases occurs mostly 
within the year before diagnosis, it seems logical that the optimal time period 
during which patients' general practice records could be used to reliably predict 
lung cancer in enough time to improve clinical outcomes is the 4-12 month 
period before diagnosis. The following chapter will use the variables which were 
independently associated with lung cancer in the 4-12 months before diagnosis 
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to develop and validate a lung cancer prediction score for use in general 
practice. 
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6. Chapter 6.  The derivation and validation 
of a general practice risk prediction model 
for lung cancer 
 
In the previous chapter, the socio-demographic and early clinical features 
independently associated with lung cancer in general practice were identified.  
This chapter describes the use of these variables to develop a risk prediction 
model for lung cancer as well the validation of this model in an independent 
THIN dataset. 
  
6.1 Introduction 
As previously discussed in chapter 1 (section 1.6.2), there are several risk 
prediction models which have been developed to estimate  the risk of lung 
cancer189-192 194. Only one risk-prediction algorithm so far has been developed 
using a combination of patients' baseline risk factors and symptoms recorded in 
primary care192. This model development incorporated patients' symptoms up to 
the period immediately before lung cancer diagnosis when GPs will be 
investigating for suspected lung cancer and may therefore not detect lung cancer 
early enough to improve clinical outcomes.  
Using the combination of patients' early pre-diagnostic symptoms and features in 
general practice, smoking and socioeconomic characteristics which had been 
shown in the previous chapter to be independently associated with lung cancer, 
this chapter aims to develop and validate a lung cancer risk-prediction model 
that could be used to aid earlier diagnosis of lung cancer in general practice.  
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6.2 Methods 
 
6.2.1 Derivation of the risk  model 
 
In the previous chapter, the socio-demographic and clinical features 
independently associated with lung cancer in the 4-12 and the 13-24 month 
periods before lung cancer diagnosis were determined using multivariate logistic 
regression analyses. These variables were derived using the unmatched dataset 
developed in chapter 5, hereafter referred to as the derivation dataset. 
Based on the findings that the increase in frequency of general consultations 
among cases occurs within the first year before lung cancer diagnoses and that 
chest x-rays are initiated by GPs at about 4 months before diagnosis, the 4-12 
month period was decided to be an optimal period during which variables 
independently associated with lung cancer could be used to develop a lung 
cancer prediction model that would reliably predict lung cancer and aid earlier 
diagnosis of cases. 
In developing the risk probabilities for lung cancer, the method used to develop 
the Thoracic Surgery Scoring System (Thoracoscore)257 was applied by assigning 
the β-Coefficient values (log odds ratio) from multivariate logistic regression 
model to the respective variables, as a means of ensuring that variables were 
weighted according to the strength of their association with lung cancer in the 
model. Aggregate scores were then computed for individual patients in the 
dataset. 
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6.2.2 Validation cohort 
The last date of data collection in the version of THIN which has been used so far 
in this thesis was July 28th 2009. To ensure that the risk-prediction model is 
validated using a dataset of patients in THIN with records spanning over a 
different period from the derivation period, a more recent version of the dataset 
which had records of patients up to a last data collection date of September 
22nd 2010, was obtained for this purpose. 
Since the last date of data collection in the derivation dataset was the 28th of 
July 2009, the 29th of July 2009 was taken as the date following which the 
outcome - incidence of lung cancer, could be used to assess the model validation 
in the validation cohort. The validation cohort comprised of all patients in THIN 
who were aged 39 years of age or older and free from lung cancer on the 29th of 
July 2009, the validation start date. Eligibility in this cohort was limited to 
patients who had at least one year of general practice follow-up before and after 
the 29th of July 2009.  
 
6.2.3 Validation of the risk model 
A lung cancer risk probability score was computed for all patients in the dataset 
on the basis of the socio-demographic characteristics and symptoms in their 
records. The β-Coefficient values (log odds ratio) derived from multivariate 
logistic regression modelling were used to compute aggregate risk probabilities 
for individual patients in the dataset using the equation: 
Risk score = constant + sum of β coefficients at different values of the exposure variables. 
The actual number of incident lung cancer cases within the year after the 29th of 
July 2009 were identified and then the performance of the model was assessed 
by comparing the sensitivity and specificity at different cut-offs. Additionally, a 
comparison of the sensitivity and specificity of the model with those of the NICE 
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guideline symptoms was made. The discriminatory power of the model was 
assessed by means of a receiver operating characteristic (ROC) curve and then 
the area under the curve (AUC) statistic was calculated. 
 
6.3 Results 
6.3.1 Risk prediction model for lung cancer 
Based on the analyses and results in the previous chapter, variables that were 
found to be independently associated with lung cancer in the 4-12 month period 
and therefore included in the final model were age, sex, Townsend deprivation 
quintiles, smoking (status and highest record of cigarettes smoked daily), 
number of other GP consultations as well as symptom presentations of cough, 
haemoptysis, dyspnoea, weight loss, LRTI, non-specific chest infections, COPD, 
chest/shoulder pain, voice hoarseness and URTI (Table 6.1). The odds of lung 
cancer increased with increasing age, male sex, greater socioeconomic 
deprivation and higher daily cigarette consumption. Haemoptysis and weight loss 
were the symptoms associated with the greatest risk of lung cancer. For 
example, a general practice record of haemoptysis was associated with an 8.7 
fold higher risk of lung cancer (odds ratio 8.70; 95% CI 6.75-11.20) and weight 
loss was associated with a 2.7 fold higher risk of lung cancer (odds ratio 2.66; 
95% CI 2.16-3.29). 
The β-Coefficient values derived from multivariate logistic regression modelling 
in the derivation dataset are also detailed in Table 6.1.  
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Table 6.1.  Factors independently associated with lung cancer in the derivation dataset, 4 
to 12 months before diagnosis (n=132,805) 
 
Risk factor variable 
 
Adjusted odds ratio (95% CI) 
 
p-value 
 
β coefficient 
Age at diagnosis (yrs) 
40-45 
45-50 
50-55 
55-60 
60-65 
65-70 
70-75 
75-80 
>80 
 
1.00 
2.50 (1.96-3.19) 
5.42  (4.34-6.78) 
10.67  (8.61-13.22) 
19.59 (15.86-24.18) 
28.61 (23.17-35.32) 
44.74 (36.26-55.21) 
60.03 (48.62-74.12) 
65.55 (53.10-80.93) 
 
 
 
 
<0.001 
 
 
0.9164 
1.6900 
2.3669 
2.9746 
3.3534 
3.8006 
4.0944 
4.1828 
Sex 
Male 
Female 
 
1.62 (1.55-1.69) 
 
<0.001 
 
0.4805 
Townsend score 
5(most deprived) 
4  
3 
2 
1 (least deprived) 
Missing Townsend records 
 
1.10 (1.02-1.18) 
1.12 (1.05-1.20) 
1.07 (1.00-1.14) 
1.00 (0.93-1.07) 
1.00 
1.01 (0.90-1.13) 
 
 
0.0017 
 
0.0932 
0.1157 
0.0640 
-0.0009 
 
0.0099 
Smoking status and 6m qty  
Current V heavy (40+/d) 
Current Heavy (20-39/d) 
Current Mod (10-19/d) 
Current Light (1-9/d) 
Current Trivial (<1/d) 
Current, no qty recorded  
 
Ex V Heavy (40+/d) 
Ex Heavy (20-39/d) 
Ex Mod (10-19/d) 
Ex Light (1-9/d) 
Ex Trivial (<1/d) 
Ex, no qty recorded 
 
Missing smoking records 
Non smoker 
 
15.91 (13.90-18.21) 
13.45 (12.44-14.54) 
9.82 (9.04-10.68) 
5.98 (5.36-6.68) 
2.68 (1.21-5.90) 
3.47 (3.08-3.91) 
 
5.33 (4.48-6.35) 
6.67 (6.06-7.35) 
4.50 (4.07-4.98) 
3.54 (3.12-4.02) 
1.21 (0.68-2.17) 
2.57 (2.38-2.78) 
 
2.70 (2.45-2.97) 
1.00 
 
 
 
 
<0.001 
 
2.7664 
2.5984 
2.2845 
1.7885 
0.9851 
1.2432 
 
1.6742 
1.8980 
1.5045 
1.2636 
0.1943 
0.9455 
 
0.9922 
Cough 1.63 (1.53-1.75) <0.001 0.4915 
Haemoptysis 8.70 (6.75-11.20) <0.001 2.1630 
Dyspnoea 1.41 (1.29-1.55) <0.001 0.3449 
Weight loss 2.66 (2.16-3.29) <0.001 0.9794 
LRTI 1.56 (1.38-1.76) <0.001 0.4414 
Chest infections 1.55 (1.44-1.68) <0.001 0.4393 
COPD 1.61 (1.46-1.78) <0.001 0.4786 
Chest/shoulder pain 1.39 (1.28-1.51) <0.001 0.3296 
Voice hoarseness 1.79 (1.28-2.49) 0.001 0.5806 
URTI 1.15 (1.02-1.30) 0.020 0.1417 
No. of GP consultations 
0-10 
11-20 
21 or more 
 
1.00 
1.23 (1.16-1.29) 
1.36 (1.28-1.44) 
 
 
<0.001 
 
 
0.2032 
0.3069 
Logistic regression constant    -7.2295 
§ p-values for binary variables were obtained using the Wald's test of significance. In variables with 
more than  2 categories, p-values were obtained from the likelihood ratio test 
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6.3.2 Model validation in an independent THIN dataset 
There were 1,897,742 patients in THIN who had no history of lung cancer up to 
the 29th of July 2009 and with at least one year of follow-up data after the 29th 
of July 2009. A total of 71,449 patients had less than one year of follow-up in 
their general practices before the 29th of July 2009 and were excluded. The final 
validation cohort therefore comprised of 1,826,293 patients which was made up 
of 939,299 females (51.4%) and 886,994 males (48.6%). There were 1,728 
incident diagnoses of lung cancer (0.09% of the cohort) identified during the 
one-year of follow-up from the 29th of July 2009. 
Risk probability scores were computed for all patients in the validation dataset 
using the β-coefficient values in Table 6.1 and the number of patients identified 
by the score as well as the sensitivity and specificity of the risk model at 
different cut-off values are shown in Table 6.2. 
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            Table 6.2.  Performance of the risk model at different cut-off values in the validation population (n=1,826,293) 
Cut-off value Patients at risk of lung 
cancer based on risk model 
Patients not requiring a chest 
x-ray based on risk model 
Number of True 
positives 
Number of 
True negatives  
Sensitivity*  Specificity§  
-3 737,390 1,088,903 1,624 1,088,799 93.98% 59.67% 
-2.5 541,074 1,285,219 1,526 1,285,017 88.31% 70.43% 
-2 388,040 1,438,253 1,375 1,437,900 79.57% 78.81% 
-1.5 255,788 1,570,505 1,182 1,569,959 68.40% 86.05% 
-1.25 192,433 1,633,860 1,063 1,633,195 61.52% 89.51% 
-1 144,523 1,681,770 917 1,680,959 53.07% 92.13% 
-0.5 72,883 1,752,292 610 1,752,292 35.30% 96.04% 
0 30,994 1,795,299 367 1,793,938 21.24% 98.32% 
0.5 11,860 1,814,433 174 1,812,879 10.07% 99.36% 
                                          * sensitivity = True positives/(true positives + false negatives) 
                                           §specificity = true negatives/ (true negatives + false positives) 
 
            Table 6.3.  Sensitivity and specificity of NICE guideline symptoms alone in the validation population (n=1,826,293) 
symptom Patients requiring a chest x-
ray based on NICE guideline 
Patients not requiring a chest 
x-ray based on NICE guideline 
Number of 
True positives 
Number of True 
negatives 
Sensitivity Specificity 
Haemoptysis 1843 1,824,450 24 1,822,746 1.39% 99.90% 
Cough 175,290 1,651,003 413 1,649,688 23.90% 90.42% 
Chest/shoulder pain 107,753 1,718,540 192 1,717,004 11.11% 94.10% 
Dyspnoea 61,631 1,764,662 315 1,763,249 18.23% 96.64% 
Weight loss 7,679 1,818,614 26 1,816,912 1.50% 99.58% 
Voice hoarseness 5,209 1,821,084 9 1,819,365 0.52% 99.72% 
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Using only the NICE guidelines symptoms, the number of patients who will be 
identified to be at risk of lung cancer and hence require a chest x-ray, the 
number of true positives and the sensitivity and specificity of the guideline 
symptoms in predicting lung cancer risk are shown in Table 6.3.  Using 
Haemoptysis alone as a trigger for chest x-rays, only 24 cases of lung cancer in 
the cohort population can be detected. Using the most commonly reported 
symptom cough as a trigger for investigations, 175,290 patients are identified to 
be at risk of lung cancer and 413 of these will be diagnosed with lung cancer. 
Using the NICE symptoms therefore to identify a comparable number of true 
positives as the lung cancer risk model, a higher number of patients are required 
to undergo chest x-rays than the risk model. For example, at a cut-off to identify 
610 cases of lung cancer in the validation cohort, the risk model identified 
72,883 patients at high risk of lung cancer for whom chest x-ray investigations 
are indicated, yet using a weighted combination of all the NICE symptoms, a 
total of 305,137 patients will have to undergo chest-ray investigations to identify 
724 cases of lung cancer. 
The receiver operating characteristic curve obtained from the application of the 
risk model in the validation cohort is shown in Figure 6.1. The area under the 
curve (AUC) is 0.88. Using a weighted combination of the NICE guideline 
symptoms to identify patients at high risk of lung cancer, the area under the 
receiver operating characteristic curve is 0.64 (Figure 6.2). 
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Figure 6.1. Receiver operating characteristic curve for the lung cancer risk 
prediction model.  
The area under the curve is 0.88. the diagonal line represents  the discrimination  
expected by chance alone  
 
 
 
Figure 6.2. Receiver operating characteristic curve for a lung cancer risk model 
developed using a weighted combination of the NICE guideline symptoms 
The area under the curve is 0.64 
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6.4 Discussion 
6.4.1 Main findings from study 
In this chapter, a lung cancer risk prediction model was developed using a 
combination of patients' socio-demographic and clinical records which were 
found to be independently associated with lung cancer in the 4-12 month period 
before diagnosis. On validating this model in an independent dataset, it 
performed well and showed good discrimination with an area under the receiver 
operating characteristic curve of 0.88. 
 
6.4.2 Strengths and limitations 
Strengths of THIN database such as the large size and representativeness of the 
UK lung cancer population are as discussed in previous sections. The information 
which have been incorporated into the risk model development are readily 
available to GPs so the application of the score in practice will be relatively easy 
and at no extra cost to GPs. In developing this risk model, records made in the 4 
months before diagnosis were excluded to avoid the inclusion of symptoms, 
diagnoses and investigations attributable to lung cancer instead of predictive of 
it. This ensures that the model can aid earlier diagnosis and improve clinical 
outcomes for people with lung cancer. 
Limitations of this study include the lack of relevant information for example 
family history of lung cancer and occupational exposure to carcinogens such as 
asbestos, which were unavailable in THIN and so could not be included in the 
model. Although inclusion of these variables may improve the performance of 
the model, the validation analyses using the currently available variables have 
shown good discrimination and the model performed substantially better than 
the current NICE guidelines147 when validated in an independent dataset.  
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In prospective analyses to assess the model performance in the validation 
cohort, patients' clinical data were collected at different time periods during the 
year before the 28th of July 2009 and the outcome of lung cancer incidence was 
measured at different time periods after the 29th of July 2009. By doing this, it 
was not possible to identify and exclude an appropriate 4 month period before 
lung cancer diagnosis in the validation cohort. However, further analyses was 
done to assess the model performance after excluding 580 incident lung cancer 
diagnosis made during the 4 months after the 29th of July 2009 and the results 
showed a similar model discrimination with an area under the ROC curve of 0.88. 
Analysis of the risk model in the validation cohort showed that a considerable 
number of patients need to undergo chest x-ray investigations to diagnose lung 
cancer cases. The positive predictive value of the model is therefore not as high 
as the positive predictive value of the NICE guideline symptoms, as previously 
reported by a study142. This is unsurprising considering that lung cancer was rare 
in the population and was only diagnosed in 1,728 patients (0.09% of the 
population). As previously noted, positive predictive values are not good 
measures of model accuracy particularly with rare outcomes as they are usually 
low even with good sensitivity and specificity158. A similar finding was shown in 
the randomised Danish lung cancer screening trial where 980 CT scans were 
done in order to identify 69 lung cancer cases258. This model however compared 
quite favourably with the NICE guideline symptoms, with less than a quarter of 
chest x-rays required to detect a comparable number of lung cancers even than 
a weighted combination of the NICE guideline symptoms. 
 
6.4.3 Comparison with other studies 
As previously discussed in chapter 1, a number of models including the Bach189, 
Spitz194 and the Liverpool Lung Project (LLP)191 have been developed to predict 
the risk of lung using patients' baseline risk factors. A study which compared the 
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discriminatory power of these three models found an AUC statistic of 0.69 for 
both the Spitz and LLP models and AUC of 0.66 for the Bach model195 and these 
are substantially lower than the AUC statistic value of 0.88 in this model. The 
LLP model is currently being used to select individuals who have a 5% risk of 
developing  lung cancer over 5 years for inclusion into the UK lung screen 
(UKLS) trial of low dose CT screening for lung cancer128. However, at a cut-off to 
capture 62% of cases of lung cancer, the LLP model falsely identifies 30% of 
non-lung cancer controls and does not perform as well as this risk model which 
for accurately identifying 79.6% of lung cancer cases gives a false positive rate 
of 21.2%. 
The only other model which uses primary care data to predict lung cancer was 
developed using patient records up to a certain point to establish baseline risk, 
after which incident diagnoses of lung cancer over the subsequent 2 years were 
predicted. The model appears to have a good discriminatory power with ROC 
values of 0.92 for males and females, however all GP records of patients 
recorded in the period leading up to lung cancer diagnosis were included in the 
algorithm development so it is likely that many symptoms and smoking records 
included were those after the point at which clinical lung cancer investigations 
were already underway and a diagnosis of lung cancer were actively being 
sought by the GPs. The study in this thesis has shown that in the 4 month period 
leading up to lung cancer diagnosis, the majority of patients with lung cancer 
start undergoing investigations in general practice. It follows therefore that the 
model developed by Hippisley-Cox et al.192 will be predicting lung cancer in 
patients that are already being investigated in general practice and hence it is of 
limited value in diagnosing lung cancer at an earlier stage. 
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6.5 Conclusion 
A combination of the early-stage symptoms of lung cancer presented in general 
practice, smoking status and socioeconomic characteristics associated with lung 
cancer appear to aid earlier identification of patients who are at an increased risk 
of lung cancer and who will benefit from further investigations such as chest x-
rays. The weighting and inclusion of socio-demographic variables - age, sex, 
socioeconomic status and smoking, as well as the weighting and inclusion of 
other clinical diagnoses - upper respiratory tract infections, lower respiratory 
tract infections, non-specific chest infections, COPD and the frequency of general 
practice consultations make this model a huge improvement on the NICE list147 
of symptoms. Evidence from past research has shown that a delay of 18 to 131 
days (median of 54 days)  between diagnosis and curative treatment for lung 
cancer was associated with an increase in cross-sectional tumour size and an 
increased risk of the cancer becoming incurable133. The outcomes of lung cancer 
are likely to be better in patients referred earlier and whose disease is diagnosed 
earlier because they may have earlier stage disease and better performance 
status. Earlier identification of lung cancer would consequently avert disease 
progression and metastases and lead to improved prognosis for people with lung 
cancer. A clinical trial perhaps in conjunction with a screening trial, is needed to 
fully quantify the benefit of the model in practice.  
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Chapter 7  Conclusions and 
recommendations for future research 
 
7.1 Summary of main findings 
 
The main findings of the studies in this thesis are as follows: 
 The characteristics of patients with lung cancer in The Health 
Improvement Network (THIN) are comparable to patient characteristics in 
two reliable UK national lung cancer databases - The UK National Cancer 
Registry230 and the National Lung Cancer Audit Database (LUCADA)231. 
The database was found to capture a high proportion of incident lung 
cancer cases from cancer registries. THIN is therefore highly 
representative of the national UK population of patients with lung cancer 
and is a potentially valuable tool for lung cancer research in the UK. 
 Experian's Mosaic Public Sector™ classification tool linked with patients' 
records in THIN identified wider variations in lung cancer incidence across 
different types and groups than the more widely used socio-economic 
classification marker - Townsend deprivation quintiles. In doing this, it 
was able to identify the specific sectors of the UK population where the 
incidence of lung cancer was highest. 
 There is no trend of increasing smoking-associated risk of lung cancer 
with deprivation and therefore no evidence to suggest that more deprived 
individuals are more vulnerable to the harmful effects of cigarette smoke 
than less deprived individuals. Although the risk of lung cancer is greater 
among individuals of lower socioeconomic groups compared to individuals 
of higher socioeconomic groups, this is largely due to smoking. 
 Depression is associated with an increased risk of lung cancer and this is 
largely explained by the higher prevalence of cigarette smoking among 
people with depression compared to people with no depression. There is 
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no difference in the smoking-associated risk of lung cancer between 
depressed and non-depressed individuals, hence depression does not 
make individuals more vulnerable to the carcinogenic effects of smoking.  
 There is an increase in the frequency of general consultations as well as 
specific consultations for lung cancer symptoms up to two years before 
lung cancer is diagnosed in patients in general practice.  A combination of 
patients' early symptoms in general practice, smoking and 
sociodemographic features was found to be independently associated with 
lung cancer.   
 A lung cancer risk prediction model was developed using the socio-
demographic and clinical records that were independently associated with 
lung cancer in the 4 to 12 month period before lung cancer diagnosis. 
This model showed good discrimination when validated in an independent 
dataset and it performed better than a combination of the NICE guideline 
symptoms alone and also out-performed existing models for lung cancer. 
 
 
7.2 Clinical implications 
The studies in this thesis provide substantial evidence that can inform the care 
pathway of patients who may be at risk of lung cancer in general practice or in 
the general population.  
The Experian's Mosaic public sector TM classification is a useful tool which if 
applied outside general practice, will enable tailored public health lung cancer 
campaigns and interventions to be more effectively targeted to specific groups of 
people in society. 
Although this research provides support to the existing body of evidence on the 
increased risk of lung cancer among individuals of lower socioeconomic status as 
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well as individuals with a history of depression, there was no evidence to suggest 
that these individuals are more susceptible to the effects of smoking compared 
to  individuals of higher socioeconomic status and individuals with no history of 
depression respectively. Since the prevalence of cigarette smoking is typically 
higher in individuals of lower socioeconomic status as well as depressed 
individuals, there is a pressing need for smoking cessation programs to be 
specifically targeted at deprived communities as well as the incorporation of 
smoking cessation interventions into the NICE guidelines for the management of 
patients with depression.  
Findings from this research showed that there is an increase in symptom 
presentation and other clinical activity such as general consultations and blood 
test investigations up to two years before lung cancer diagnosis and especially 
within the year leading up to diagnosis. Most patients with lung cancer do not 
start to present frequently with symptoms until the year before diagnosis and it 
is likely that the majority of them have symptoms for a considerable period of 
time before they present to the GP. To get the maximum benefit from any 
general practice predictive score for lung cancer, it is essential that patients 
present early with their symptoms. There is a public health need therefore for 
more efforts to educate the public and especially smokers on the key symptoms 
of lung cancer and the need to seek medical care as and when they have 
symptoms. During the one year to four months before diagnosis, the symptoms 
which were found to be independently associated with lung cancer were similar 
to the symptoms in the NICE guideline147 and are common symptom 
presentations in general practice.  
The weighting and inclusion of patients' socio-demographic features in addition 
to clinical symptoms performed better than the NICE guidelines symptoms alone 
and will not only aid earlier recognition by GPs of patients at high risk of lung 
cancer who will benefit from further investigations and/or earlier specialist 
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referral, but it will also enable earlier intervention, avert disease progression, 
prevent a substantial number of early lung cancer deaths and consequently 
improve survival of lung cancer. In applying this model clinically, the aim is to 
incorporate the algorithm into GP software  so that at a certain threshold, a hint 
is offered to the GP to investigate the patient for possible lung cancer and as 
such, these would not need to be directly calculated by GPs. Similar methods are 
already being used for the calculation of cardiovascular disease risk and the 
benefits of this as opposed to GPs working out the score for individual patients is 
that rather than making a risk estimation based on information collected by the 
GP during a consultation, the system takes account of all previous recorded data 
for patients including records entered during consultation with other GPs in the 
same practice . 
 
7.3 Suggestions for further research 
7.3.1 The use of Experian's Mosaic tool to target lung cancer 
public health services  
Experian's Mosaic public sector TM variable has been shown to be a useful tool to 
aid more precise targeting of lung cancer-related public health interventions to 
specific sectors of society. A more detailed knowledge of the information used to 
derive the Mosaic groups and types is needed to assess the validity of the tool 
and quantify its benefits over the Townsend deprivation quintiles. Since the 
Mosaic categories that had the highest incidence of lung cancer comprised of the 
elderly and deprived individuals in society, it will therefore be useful to know the 
additional benefits of the Mosaic over an age-adjusted Townsend measure of 
socioeconomic status.  To adequately assess the benefit of Mosaic in identifying 
the particular sectors of society where lung cancer interventions are most 
required, a practical implementation of this tool to deliver tailored lung cancer 
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interventions is needed. One way in which Mosaic can be assessed in practice is 
to run pilot schemes of health promotion strategies in geographical locations, 
some of which would incorporate Mosaic in the planning stage as a means of 
tailoring specific interventions to specific sectors of society. An evaluation of the 
effectiveness of the tool in practice can then be assessed and quantified. 
 
7.3.2 Smoking-associated risk of lung cancer in deprived 
individuals 
The lack of variation in the risk of lung cancer between individuals of lower 
socioeconomic status and individuals of higher socioeconomic status, though not 
entirely surprising, raises the need for further research using general practice 
data to investigate and possibly quantify the contribution of other risk factors 
such as occupational exposure, diet and alcohol consumption to the association 
between socioeconomic status and lung cancer. Lifestyle risk factors are not 
readily available in general practice database, however a possible approach that 
will enable a comprehensive study of risk factor exposures among individuals 
from different socioeconomic groups and an outcome of lung cancer would be a 
nested case control study using a cohort study database which measures 
lifestyle risk factors as the primary exposure with information on other 
confounders such as occupational and environmental factors. 
 
7.3.3 Smoking-associated risk of lung cancer in depressed 
compared to non-depressed individuals 
The finding that there is no difference in the smoking-associated risk of lung 
cancer between individuals with and without a previous history of depression is 
an important addition to the evidence base of lung cancer risk in depressed 
people. The depression records analysed in this thesis were however diagnosis 
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made by GPs during routine consultation in general practice and were not based 
on standardised psychiatric assessments. Although the results from this study 
are applicable in UK general practices, a study which explores the association 
between depressed patients based on psychiatric criteria and the risk of lung 
cancer will be worthwhile and will provide definitive evidence of the true 
difference in lung cancer risk among smokers with depression and smokers with 
no history of depression.  
 
7.3.4 Validation of the general practice prediction model for 
lung cancer  
Validation of the lung cancer risk-prediction model that was developed in this 
thesis was done using a cohort of 1,826,293 patients with only 1,728 incident 
lung cancer diagnosis identified during the follow-up period from July 2009 to 
September 2010 and this was fairly small compared to the model derivation 
population where there were 12,074 incident cases of lung cancer identified over 
a 10 year period from 2000 to 2009. Despite the fact that the validation in an 
independent THIN dataset showed good discrimination of the model with an area 
under the ROC curve of 0.88, validation of the risk model may have been better 
assessed using a larger validation cohort with data collected over a longer time 
period. In practice however, the best way to assess the accuracy as well as 
quantify the benefit of the risk-prediction model would be to do a clinical trial 
using the model to identify patients at risk of lung cancer at a defined time 
period and then to measure an outcome of lung cancer 4 to 12 months 
afterwards. 
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7.3.5  Proportion of patients with lung cancer diagnosed 
following urgent general practice referral 
A Study over a 2 year period at the Bradford hospitals NHS trust had shown that 
only 23% of patients with lung cancer were referred urgently by their GPs142 and 
another study of all 246 patients with primary lung cancers in Exeter, UK showed 
that 45% of the patients were diagnosed following referral to hospital respiratory 
departments for specialist investigation141. There is the need for a large scale 
study to estimate the exact proportion of patients with lung cancer nationally 
who are diagnosed following the general practice urgent referral route. One way 
to achieve this would be a study using a national hospital dataset which provides 
information on whether individual patients have been referred from general 
practice and whether the referral was urgent or non-urgent.  
 
7.4 Conclusion 
The studies in this thesis have demonstrated the usefulness of general practice 
data from THIN for studies to explore the early interaction between GPs and 
patients before lung cancer is diagnosed. Although there is an increase in clinical 
activity of patients before lung cancer is diagnosed, a considerable amount of 
these occur within the year before diagnosis and suggests the need for further 
efforts  to educate the public especially smokers and those from the sectors of 
society where lung cancer incidence is highest, on the need to seek medical care 
when they have symptoms. Using the early features of patients within the year 
up to 4 months before diagnosis, this thesis has been able to develop a risk 
prediction score which has not only out-performed existing scores but compares 
quite favourably with the NICE guidelines and can aid earlier diagnosis of lung 
cancer in future cases.  
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a) List of Read codes for lung cancer 
Read code Description 
B22..00 Malignant neoplasm of trachea, bronchus and lung 
B220.00 Malignant neoplasm of trachea 
B220z00 Malignant neoplasm of trachea NOS 
B221.00 Malignant neoplasm of main bronchus 
B221000 Malignant neoplasm of carina of bronchus 
B221100 Malignant neoplasm of hilus of lung 
B221z00 Malignant neoplasm of main bronchus NOS 
B222.00 Malignant neoplasm of upper lobe, bronchus or lung 
B222.11 Pancoast's syndrome 
B222000 Malignant neoplasm of upper lobe bronchus 
B222100 Malignant neoplasm of upper lobe of lung 
B222z00 Malignant neoplasm of upper lobe, bronchus or lung NOS 
B223.00 Malignant neoplasm of middle lobe, bronchus or lung 
B223000 Malignant neoplasm of middle lobe bronchus 
B223100 Malignant neoplasm of middle lobe of lung 
B223z00 Malignant neoplasm of middle lobe, bronchus or lung NOS 
B224.00 Malignant neoplasm of lower lobe, bronchus or lung 
B224000 Malignant neoplasm of lower lobe bronchus 
B224100 Malignant neoplasm of lower lobe of lung 
B224z00 Malignant neoplasm of lower lobe, bronchus or lung NOS 
B225.00 Malignant neoplasm of overlapping lesion of bronchus & lung 
B22y.00 Malignant neoplasm of other sites of bronchus or lung 
B22z.00 Malignant neoplasm of bronchus or lung NOS 
B22z.11 Lung cancer 
B26..00 Malignant neoplasm, overlap lesion of resp & intrathor orgs 
B2zz.00 Malignant neoplasm of respiratory tract NOS 
B551100 Malignant neoplasm of chest wall NOS 
B551z00 Malignant neoplasm of thorax NOS 
Byu2.00 [X]Malignant neoplasm of respiratory and intrathoracic orga 
Byu2000 [X]Malignant neoplasm of bronchus or lung, unspecified 
Byu2400 [X]Malignant neoplasm/ill-defined sites within resp system 
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b) List of Read codes for histology 
Read code Description 
BB08.00 [M]Malignant tumour, small cell type 
BB17.00 [M]Large cell carcinoma NOS 
BB1J.00 [M]Small cell carcinoma NOS 
BB1L.00 [M]Small cell carcinoma, fusiform cell type 
BB1M.00 [M]Small cell carcinoma, intermediate cell 
BB1N.00 [M]Small cell-large cell carcinoma 
BB2..00 [M]Papillary and squamous cell neoplasms 
BB2..12 [M]Squamous cell neoplasms 
BB25.00 [M]Squamous cell papilloma 
BB26.00 [M]Papillary squamous cell carcinoma 
BB29.00 [M]Squamous cell carcinoma in situ NOS 
BB29.13 [M]Intraepithelial squamous cell carcinoma 
BB2A.00 [M]Squamous cell carcinoma NOS 
BB2B.00 [M]Squamous cell carcinoma, metastatic NOS 
BB2C.00 [M]Squamous cell carcinoma, keratinising type NOS 
BB2D.00 [M]Squamous cell carcinoma, large cell, non-keratinising 
BB2E.00 [M]Squamous cell carcinoma, small cell, non-keratinising 
BB2F.00 [M]Squamous cell carcinoma, spindle cell type 
BB2G.00 [M]Adenoid squamous cell carcinoma 
BB2H.00 [M]Squamous cell ca-in-situ, questionable stromal invasion 
BB2J.00 [M]Squamous cell carcinoma, microinvasive 
BB2z.00 [M]Papillary or squamous cell neoplasm NOS 
BB35.00 [M]Basosquamous carcinoma 
BB5..00 [M]Adenomas and adenocarcinomas 
BB5..11 [M]Adenocarcinomas 
BB51.00 [M]Adenocarcinoma in situ 
BB51000 [M]Adenocarcinoma in situ in villous adenoma 
BB51100 [M]Adenocarcinoma in situ in tubulovillous adenoma 
BB52.00 [M]Adenocarcinoma NOS 
BB52000 [M]Adenocarcinoma in tubulovillous adenoma 
BB53.00 [M]Adenocarcinoma, metastatic, NOS 
BB54.00 [M]Scirrhous adenocarcinoma 
BB56.00 [M]Superficial spreading adenocarcinoma 
BB5F.00 [M]Trabecular adenocarcinoma 
BB5J.11 [M]Cylindroid adenocarcinoma 
BB5M.00 [M]Tubular adenomas and adenocarcinomas 
BB5M100 [M]Tubular adenocarcinoma 
BB5Mz00 [M]Tubular adenoma or adenocarcinoma NOS 
BB5R800 [M]Adenocarcinoid tumour 
BB5S.00 [M]Respiratory tract adenomas and adenocarcinomas 
BB5S200 [M]Bronchiolo-alveolar adenocarcinoma 
BB5S400 [M]Alveolar adenocarcinoma 
BB5Sz00 [M]Respiratory tract adenoma or adenocarcinoma NOS 
BB5T.00 [M]Papillary adenomas and adenocarcinomas 
BB5T100 [M]Papillary adenocarcinoma NOS 
BB5Tz00 [M]Papillary adenoma or adenocarcinoma NOS 
BB5U.00 [M]Villous adenomas and adenocarcinomas 
BB5U100 [M]Adenocarcinoma in villous adenoma 
BB5U200 [M]Villous adenocarcinoma 
BB5Uz00 [M]Villous adenoma or adenocarcinoma NOS 
BB5W.00 [M]Oxyphilic adenomas and adenocarcinomas 
BB5W100 [M]Oxyphilic adenocarcinoma 
BB5W111 [M]Hurthle cell adenocarcinoma 
BB5W112 [M]Oncytic adenocarcinoma 
BB5Wz00 [M]Oxyphilic adenoma or adenocarcinoma NOS 
BB5X.00 [M]Clear cell adenomas and adenocarcinomas 
BB5X100 [M]Clear cell adenocarcinoma NOS 
BB5Xz00 [M]Clear cell adenoma or adenocarcinoma NOS 
BB5c200 [M]Water-clear cell adenocarcinoma 
BB5d.00 [M]Mixed cell adenoma and adenocarcinoma 
BB5d100 [M]Mixed cell adenocarcinoma 
BB5dz00 [M]Mixed cell adenoma or adenocarcinoma NOS 
BB5f600 [M]Papillary and follicular adenocarcinoma 
BB5y.00 [M]Adenoma and adenocarcinoms OS 
BB5y000 [M]Basal cell adenocarcinoma 
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BB5z.00 [M]Adenoma or adenocarcinoma NOS 
BB82.00 [M]Mucinous adenoma and adenocarcinoma 
BB82100 [M]Mucinous adenocarcinoma 
BB82111 [M]Colloid adenocarcinoma 
BB82112 [M]Gelatinous adenocarcinoma 
BB82113 [M]Mucoid adenocarcionoma 
BB82114 [M]Mucous adenocarcinoma 
BB82z00 [M]Mucinous adenoma or adenocarcinoma NOS 
BB84.00 [M]Mucin-producing adenocarcinoma 
BB91000 [M]Intraductal papillary adenocarcinoma with invasion 
BB96.00 [M]Noninfiltrating intraductal papillary adenocarcinoma 
BBB0.00 [M]Adenosquamous carcinoma 
BBB2.00 [M]Adenocarcinoma with squamous metaplasia 
BBB4.00 [M]Adenocarcinoma with spindle cell metaplasia 
BBB5.00 [M]Adenocarcinoma with apocrine metaplasia 
H58y400 Squamous metaplasia of lung 
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c) List of Read codes for Chronic Obstructive Pulmonary Disease  
Read code Description 
66YI.00 COPD self-management plan given 
66YL.00 Chronic obstructive pulmonary disease follow-up 
66YL.11 COPD follow-up 
66YL.12 COAD follow-up 
66YM.00 Chronic obstructive pulmonary disease annual review 
8H2R.00 Admit COPD emergency 
14B3.00 history of COPD 
H3...00 Chronic obstructive pulmonary disease 
H3...11 Chronic obstructive airways disease 
H31..00 Chronic bronchitis 
H310.00 Simple chronic bronchitis 
H310000 Chronic catarrhal bronchitis 
H310z00 Simple chronic bronchitis NOS 
H311.00 Mucopurulent chronic bronchitis 
H311000 Purulent chronic bronchitis 
H311100 Fetid chronic bronchitis 
H311z00 Mucopurulent chronic bronchitis NOS 
H312.00 Obstructive chronic bronchitis 
H312100 Emphysematous bronchitis 
H312200 Acute exacerbation of chronic obstructive airways disease 
H312z00 Obstructive chronic bronchitis NOS 
H313.00 Mixed simple and mucopurulent chronic bronchitis 
H31y.00 Other chronic bronchitis 
H31y100 Chronic tracheobronchitis 
H31yz00 Other chronic bronchitis NOS 
H31z.00 Chronic bronchitis NOS 
H32..00 Emphysema 
H320.00 Chronic bullous emphysema 
H320000 Segmental bullous emphysema 
H320100 Zonal bullous emphysema 
H320200 Giant bullous emphysema 
H320300 Bullous emphysema with collapse 
H320z00 Chronic bullous emphysema NOS 
H321.00 Panlobular emphysema 
H322.00 Centrilobular emphysema 
H32y.00 Other emphysema 
H32y000 Acute vesicular emphysema 
H32y100 Atrophic (senile) emphysema 
H32y111 Acute interstitial emphysema 
H32y200 MacLeod's unilateral emphysema 
H32yz00 Other emphysema NOS 
H32z.00 Emphysema NOS 
H36..00 Mild chronic obstructive pulmonary disease 
H37..00 Moderate chronic obstructive pulmonary disease 
H38..00 Severe chronic obstructive pulmonary disease 
H3y..00 Other specified chronic obstructive airways disease 
H3y..11 Other specified chronic obstructive pulmonary disease 
H3z..00 Chronic obstructive airways disease NOS 
H3z..11 Chronic obstructive pulmonary disease NOS 
Hyu3000 [X]Other emphysema 
Hyu3100 [X]Other specified chronic obstructive pulmonary disease 
H312000 Chronic asthmatic bronchitis 
H312011 Chronic wheezy bronchitis 
H312300 Bronchiolitis obliterans 
H320311 Tension pneumatocoele 
H32yz11 Sawyer - Jones syndrome 
H3y0.00 Chronic obstruct pulmonary disease with acute lower resp infection 
H3y1.00 Chronic obstruct pulmonary dis wth acute exacerbation, unspecified 
 
 
 
197 
 
d) List of smoking status Read codes 
Read code Description Smoking 
category 
137..00 Tobacco consumption see AHD 
137..11 Smoker - amount smoked Current 
1371.00 Never smoked tobacco Never 
1371.11 Non-smoker see AHD 
1372.00 Trivial smoker - < 1 cig/day Current 
1372.11 Occasional smoker Current 
1373.00 Light smoker - 1-9 cigs/day Current 
1374.00 Moderate smoker - 10-19 cigs/d Current 
1375.00 Heavy smoker - 20-39 cigs/day Current 
1376.00 Very heavy smoker - 40+cigs/d Current 
1377.00 Ex-trivial smoker (<1/day) Ex 
1378.00 Ex-light smoker (1-9/day) Ex 
1379.00 Ex-moderate smoker (10-19/day) Ex 
137A.00 Ex-heavy smoker (20-39/day) Ex 
137B.00 Ex-very heavy smoker (40+/day) Ex 
137C.00 Keeps trying to stop smoking Current 
137D.00 Admitted tobacco cons untrue ? Unknown 
137E.00 Tobacco consumption unknown Unknown 
137F.00 Ex-smoker - amount unknown Ex 
137G.00 Trying to give up smoking Current 
137H.00 Pipe smoker Current 
137J.00 Cigar smoker Current 
137K.00 Stopped smoking Ex 
137L.00 Current non-smoker see AHD 
137M.00 Rolls own cigarettes Current 
137N.00 Ex pipe smoker Ex 
137O.00 Ex cigar smoker Ex 
137P.00 Cigarette smoker Current 
137P.11 Smoker Current 
137Q.00 Smoking started Current 
137Q.11 Smoking restarted Current 
137R.00 Current smoker Current 
137S.00 Ex smoker Ex 
137T.00 Date ceased smoking Ex 
137V.00 Smoking reduced Current 
137X.00 Cigarette consumption see AHD 
137Y.00 Cigar consumption see AHD 
137Z.00 Tobacco consumption NOS see AHD 
137a.00 Pipe tobacco consumption see AHD 
137b.00 Ready to stop smoking Current 
137c.00 Thinking about stopping smoking Current 
137d.00 Not interested in stopping smoking Current 
137e.00 Smoking restarted Current 
137f.00 Reason for restarting smoking Current 
137g.00 Cigarette pack-years Unknown 
137h.00 Minutes from waking to first tobacco consumption Current 
13p..00 Smoking cessation milestones Unknown 
13p0.00 Negotiated date for cessation of smoking Current 
13p1.00 Smoking status at 4 weeks Unknown 
13p2.00 Smoking status between 4 and 52 weeks Unknown 
13p3.00 Smoking status at 52 weeks Unknown 
13p4.00 Smoking free weeks Unknown 
13p5.00 Smoking cessation programme start date Current 
13p6.00 Carbon monoxide reading at 4 weeks Unknown 
4I90.00 Expired carbon monoxide concentration Unknown 
6791.00 Health ed. - smoking Current 
67A3.00 Pregnancy smoking advice Current 
67H1.00 Lifestyle advice regarding smoking Current 
6893.00 Tobacco usage screen see AHD 
68T..00 Tobacco usage screen see AHD 
745H.00 Smoking cessation therapy Unknown 
745H000 Nicotine replacement therapy using nicotine patches Current 
745H100 Nicotine replacement therapy using nicotine gum Current 
745H200 Nicotine replacement therapy using nicotine inhalator Current 
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745H300 Nicotine replacement therapy using nicotine lozenges Current 
745H400 Smoking cessation drug therapy Current 
745Hy00 Other specified smoking cessation therapy Current 
745Hz00 Smoking cessation therapy NOS Unknown 
8B2B.00 Nicotine replacement therapy Current 
8B3Y.00 Over the counter nicotine replacement therapy Current 
8B3f.00 Nicotine replacement therapy provided free Current 
8BP3.00 Nicotine replacement therapy provided by community pharmacist Current 
8CAL.00 Smoking cessation advice Current 
8CAg.00 Smoking cessation advice provided by community pharmacist Current 
8H7i.00 Referral to smoking cessation advisor Current 
8HTK.00 Referral to stop-smoking clinic Current 
8I2I.00 Nicotine replacement therapy contraindicated Current 
8I39.00 Nicotine replacement therapy refused Current 
9N2k.00 Seen by smoking cessation advisor Unknown 
9N4M.00 DNA - Did not attend smoking cessation clinic Unknown 
9OO..00 Anti-smoking monitoring admin. Unknown 
9OO..11 Stop smoking clinic admin. Unknown 
9OO..12 Stop smoking monitoring admin. Unknown 
9OO1.00 Attends stop smoking monitor. Unknown 
9OO2.00 Refuses stop smoking monitor Unknown 
9OO3.00 Stop smoking monitor default Unknown 
9OO4.00 Stop smoking monitor 1st letter Unknown 
9OO5.00 Stop smoking monitor 2nd letter Unknown 
9OO6.00 Stop smoking monitor 3rd letter Unknown 
9OO7.00 Stop smoking monitor verb.inv. Current 
9OO8.00 Stop smoking monitor phone inv Current 
9OO9.00 Stop smoking monitoring delete Unknown 
9OOA.00 Stop smoking monitor. check done Unknown 
9OOZ.00 Stop smoking monitor admin.NOS Unknown 
9hG..00 Exception reporting: smoking quality indicators Exception 
9hG0.00 Excepted from smoking quality indicators: Patient unsuitable Exception 
9hG1.00 Excepted from smoking quality indicators: Informed dissent Exception 
E023.00 Nicotine withdrawal Unknown 
E251.00 Tobacco dependence Current 
E251100 Tobacco dependence, continuous Current 
E251300 Tobacco dependence in remission Ex 
E251z00 Tobacco dependence NOS Current 
ZG23300 Advice on smoking Current 
ZRBm200 Fagerstrom test for nicotine dependence Current 
ZRBm211 FTND - Fagerstrom test for nicotine dependence Current 
ZRaM.00 Motives for smoking scale Current 
ZRaM.11 MFS - Motives for smoking scale Current 
ZRao.00 Occasions for smoking scale Current 
ZRh4.00 Reasons for smoking scale Current 
ZRh4.11 RFS - Reasons for smoking scale Current 
ZV11600 [V]Personal history of tobacco abuse Unknown 
ZV4K000 [V]Tobacco use see AHD 
ZV6D800 [V]Tobacco abuse counselling Current 
137j.00 Ex-cigarette smoker Ex 
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e) List of Read codes for records of quantity of cigarettes smoked 
Read code Description Smoking category 
1374.00 Moderate smoker - 10-19 cigs/d current/moderate 
1373.00 Light smoker - 1-9 cigs/day current/light 
1375.00 Heavy smoker - 20-39 cigs/day current/heavy 
1372.00 Trivial smoker - < 1 cig/day current/trivial 
1376.00 Very heavy smoker - 40+cigs/d current/very heavy 
1379.00 Ex-moderate smoker (10-19/day) Ex/moderate 
1378.00 Ex-light smoker (1-9/day) Ex/light 
137A.00 Ex-heavy smoker (20-39/day) Ex/heavy 
1377.00 Ex-trivial smoker (<1/day) Ex/trivial 
137B.00 Ex-very heavy smoker (40+/day) Ex/very heavy 
137..00 Tobacco consumption see AHD 
137Z.00 Tobacco consumption NOS see AHD 
137a.00 Pipe tobacco consumption see AHD 
137Y.00 Cigar consumption see AHD 
137X.00 Cigarette consumption see AHD 
ZV4K000 [V]Tobacco use see AHD 
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f) List of Read codes for Depression 
Read code description 
1B17.00 Depressed 
1B17.11 C/O - feeling depressed 
1B1U.00 Symptoms of depression 
1B1U.11 Depressive symptoms 
1BT..00 Depressed mood 
1BT..11 Low mood 
2257.00 O/E - depressed 
62T1.00 Puerperal depression 
6G00.00 Postnatal depression counselling 
E11..12 Depressive psychoses 
E112.00 Single major depressive episode 
E112.11 Agitated depression 
E112.12 Endogenous depression first episode 
E112.13 Endogenous depression first episode 
E112.14 Endogenous depression 
E112000 Single major depressive episode, unspecified 
E112100 Single major depressive episode, mild 
E112200 Single major depressive episode, moderate 
E112300 Single major depressive episode, severe, without psychosis 
E112400 Single major depressive episode, severe, with psychosis 
E112z00 Single major depressive episode NOS 
E113.00 Recurrent major depressive episode 
E113.11 Endogenous depression - recurrent 
E113000 Recurrent major depressive episodes, unspecified 
E113100 Recurrent major depressive episodes, mild 
E113200 Recurrent major depressive episodes, moderate 
E113300 Recurrent major depressive episodes, severe, no psychosis 
E113400 Recurrent major depressive episodes, severe, with psychosis 
E113700 Recurrent depression 
E113z00 Recurrent major depressive episode NOS 
E118.00 Seasonal affective disorder 
E11y200 Atypical depressive disorder 
E11z200 Masked depression 
E130.00 Reactive depressive psychosis 
E130.11 Psychotic reactive depression 
E135.00 Agitated depression 
E200300 Anxiety with depression 
E204.00 Neurotic depression reactive type 
E204.11 Postnatal depression 
E290.00 Brief depressive reaction 
E290z00 Brief depressive reaction NOS 
E291.00 Prolonged depressive reaction 
E2B..00 Depressive disorder NEC 
E2B0.00 Post-viral depression 
E2B1.00 Chronic depression 
Eu32.00 [X]Depressive episode 
Eu32.11 [X]Single episode of depressive reaction 
Eu32.12 [X]Single episode of psychogenic depression 
Eu32.13 [X]Single episode of reactive depression 
Eu32000 [X]Mild depressive episode 
Eu32100 [X]Moderate depressive episode 
Eu32200 [X]Severe depressive episode without psychotic symptoms 
Eu32211 [X]Single episode agitated depression w'out psychotic symptoms 
Eu32212 [X]Single episode major depression w'out psychotic symptoms 
Eu32300 [X]Severe depressive episode with psychotic symptoms 
Eu32311 [X]Single episode of major depression and psychotic symptoms 
Eu32312 [X]Single episode of psychogenic depressive psychosis 
Eu32313 [X]Single episode of psychotic depression 
Eu32314 [X]Single episode of reactive depressive psychosis 
Eu32400 [X]Mild depression 
Eu32y00 [X]Other depressive episodes 
Eu32y11 [X]Atypical depression 
Eu32z00 [X]Depressive episode, unspecified 
Eu32z11 [X]Depression NOS 
Eu32z12 [X]Depressive disorder NOS 
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Eu32z13 [X]Prolonged single episode of reactive depression 
Eu32z14 [X] Reactive depression NOS 
Eu33.00 [X]Recurrent depressive disorder 
Eu33.11 [X]Recurrent episodes of depressive reaction 
Eu33.12 [X]Recurrent episodes of psychogenic depression 
Eu33.13 [X]Recurrent episodes of reactive depression 
Eu33.14 [X]Seasonal depressive disorder 
Eu33.15 [X]SAD - Seasonal affective disorder 
Eu33000 [X]Recurrent depressive disorder, current episode mild 
Eu33100 [X]Recurrent depressive disorder, current episode moderate 
Eu33200 [X]Recurrent depressive disorder cur epi severe without psyc sympt 
Eu33211 [X]Endogenous depression without psychotic symptoms 
Eu33212 [X]Major depression, recurrent without psychotic symptoms 
Eu33300 [X]Recurrent depress disorder cur epi severe with psychotic symptoms 
Eu33311 [X]Endogenous depression with psychotic symptoms 
Eu33313 [X]Recurr severe episodes/major depression+psychotic symptom 
Eu33314 [X]Recurr severe episodes/psychogenic depressive psychosis 
Eu33315 [X]Recurrent severe episodes of psychotic depression 
Eu33316 [X]Recurrent severe episodes/reactive depressive psychosis 
Eu33y00 [X]Other recurrent depressive disorders 
Eu33z00 [X]Recurrent depressive disorder, unspecified 
Eu33z11 [X]Monopolar depression NOS 
Eu34100 [X]Dysthymia 
Eu34111 [X]Depressive neurosis 
Eu34113 [X]Neurotic depression 
Eu34114 [X]Persistant anxiety depression 
Eu3y111 [X]Recurrent brief depressive episodes 
Eu41200 [X]Mixed anxiety and depressive disorder 
Eu41211 [X]Mild anxiety depression 
Eu53011 [X]Postnatal depression NOS 
Eu53012 [X]Postpartum depression NOS 
R007z13 [D]Postoperative depression 
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g) List of Read codes for cough 
Read code description 
171..00 Cough 
171..11 C/O - cough 
1712.00 Dry cough 
1713.00 Productive cough -clear sputum 
1714.00 Productive cough -green sputum 
1715.00 Productive cough-yellow sputum 
1716.00 Productive cough NOS 
1716.11 Coughing up phlegm 
1717.00 Night cough present 
1719.00 Chesty cough 
1719.11 Bronchial cough 
171A.00 Chronic cough 
171B.00 Persistent cough 
171C.00 Morning cough 
171D.00 Evening cough 
171E.00 Unexplained cough 
171F.00 Cough with fever 
171G.00 Bovine cough 
171H.00 Difficulty in coughing up sputum 
171J.00 Reflux cough 
171K.00 Barking cough 
171Z.00 Cough symptom NOS 
173B.00 Nocturnal cough / wheeze 
H310100 Smokers' cough 
R062.00 [D]Cough 
 
 
 
 
h) List of Read codes for haemoptysis 
Read code description 
172..00 Blood in sputum - haemoptysis 
172..11 Blood in sputum - symptom 
172..12 Haemoptysis - symptom 
4E24.00 Sputum: contains blood 
4E35.00 Sputum: blood cells present 
R063.00 [D]Haemoptysis 
R063000 [D]Cough with haemorrhage 
R063z00 [D]Haemoptysis NOS 
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i) List of Read codes for Dyspnoea 
Read code description 
173..00 Breathlessness 
173..11 Breathlessness symptom 
173..12 Dyspnoea - symptom 
173..13 Shortness of breath symptom 
1732.00 Breathless - moderate exertion 
1733.00 Breathless - mild exertion 
1734.00 Breathless - at rest 
1735.00 Breathless - lying flat 
1735.11 Orthopnoea symptom 
1736.00 Paroxysmal nocturnal dyspnoea 
1738.00 Difficulty breathing 
1739.00 Shortness of breath 
173C.00 Short of breath on exertion 
173C.11 Dyspnoea on exertion 
173C.12 SOBOE 
173D.00 Nocturnal dyspnoea 
173F.00 Short of breath dressing/undressing 
173G.00 Breathless - strenuous exertion 
173I.00 MRC Breathlessness Scale: grade 2 
173J.00 MRC Breathlessness Scale: grade 3 
173K.00 MRC Breathlessness Scale: grade 4 
173L.00 MRC Breathlessness Scale: grade 5 
173N.00 Borg Breathlessness Score: 0.5 very, very slight 
173P.00 Borg Breathlessness Score: 1 very slight 
173Q.00 Borg Breathlessness Score: 2 slight 
173R.00 Borg Breathlessness Score: 3 moderate 
173S.00 Borg Breathlessness Score: 4 somewhat severe 
173T.00 Borg Breathlessness Score: 5 severe 
173V.00 Borg Breathlessness Score: 6 severe (+) 
173W.00 Borg Breathlessness Score: 7 very severe 
173X.00 Borg Breathlessness Score: 8 very severe (+) 
173Y.00 Borg Breathlessness Score: 9 very, very sev (almost maximal) 
173Z.00 Breathlessness NOS 
173a.00 Borg Breathlessness Score: 10 maximal 
173b.00 Unable to complete a sentence in one breath 
2322.00 O/E - dyspnoea 
2323.00 O/E - orthopnoea 
2324.00 O/E - respiratory distress 
2327.00 O/E - accessory resp.m's.used 
232D.00 O/E - sternal recession 
232E.00 O/E - intercostal recession 
232F.00 O/E - subcostal recession 
232G.00 O/E - suprasternal recession 
R060600 [D]Respiratory distress 
R060700 [D]Respiratory insufficiency 
R060800 [D]Shortness of breath 
R060A00 [D]Dyspnoea 
R060D00 [D]Breathlessness 
 
 
j) List of Read codes for weight loss 
Read code description 
1623.00 Weight decreasing 
1625.00 Abnormal weight loss 
1625.11 Abnormal weight loss - symptom 
1D1A.00 Complaining of weight loss 
22A8.00 Weight loss from baseline weight 
R032.00 [D]Abnormal loss of weight 
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k) List of Read codes for Lower Respiratory Tract Infections (LRTI) 
Read code description 
H06..00 Acute bronchitis and bronchiolitis 
H060.00 Acute bronchitis 
H060.11 Acute wheezy bronchitis 
H060000 Acute fibrinous bronchitis 
H060100 Acute membranous bronchitis 
H060200 Acute pseudomembranous bronchitis 
H060300 Acute purulent bronchitis 
H060400 Acute croupous bronchitis 
H060500 Acute tracheobronchitis 
H060600 Acute pneumococcal bronchitis 
H060700 Acute streptococcal bronchitis 
H060800 Acute haemophilus influenzae bronchitis 
H060900 Acute neisseria catarrhalis bronchitis 
H060A00 Acute bronchitis due to mycoplasma pneumoniae 
H060B00 Acute bronchitis due to coxsackievirus 
H060C00 Acute bronchitis due to parainfluenza virus 
H060D00 Acute bronchitis due to respiratory syncytial virus 
H060E00 Acute bronchitis due to rhinovirus 
H060F00 Acute bronchitis due to echovirus 
H060v00 Subacute bronchitis unspecified 
H060w00 Acute viral bronchitis unspecified 
H060x00 Acute bacterial bronchitis unspecified 
H060z00 Acute bronchitis NOS 
H061.00 Acute bronchiolitis 
H061000 Acute capillary bronchiolitis 
H061100 Acute obliterating bronchiolitis 
H061200 Acute bronchiolitis with bronchospasm 
H061300 Acute exudative bronchiolitis 
H061400 Obliterating fibrous bronchiolitis 
H061500 Acute bronchiolitis due to respiratory syncytial virus 
H061600 Acute bronchiolitis due to other specified organisms 
H061z00 Acute bronchiolitis NOS 
H062.00 Acute lower respiratory tract infection 
H06z.00 Acute bronchitis or bronchiolitis NOS 
H06z100 Lower resp tract infection 
H06z112 Acute lower respiratory tract infection 
H2...00 Pneumonia and influenza 
H20..00 Viral pneumonia 
H20..11 Chest infection - viral pneumonia 
H200.00 Pneumonia due to adenovirus 
H201.00 Pneumonia due to respiratory syncytial virus 
H202.00 Pneumonia due to parainfluenza virus 
H20y.00 Viral pneumonia NEC 
H20z.00 Viral pneumonia NOS 
H21..00 Lobar (pneumococcal) pneumonia 
H21..11 Chest infection - pneumococcal pneumonia 
H22..00 Other bacterial pneumonia 
H22..11 Chest infection - other bacterial pneumonia 
H220.00 Pneumonia due to klebsiella pneumoniae 
H221.00 Pneumonia due to pseudomonas 
H222.00 Pneumonia due to haemophilus influenzae 
H222.11 Pneumonia due to haemophilus influenzae 
H223.00 Pneumonia due to streptococcus 
H223000 Pneumonia due to streptococcus, group B 
H224.00 Pneumonia due to staphylococcus 
H22y.00 Pneumonia due to other specified bacteria 
H22y000 Pneumonia due to escherichia coli 
H22y011 E.coli pneumonia 
H22y100 Pneumonia due to proteus 
H22y200 Pneumonia - Legionella 
H22yX00 Pneumonia due to other aerobic gram-negative bacteria 
H22yz00 Pneumonia due to bacteria NOS 
H22z.00 Bacterial pneumonia NOS 
H23..00 Pneumonia due to other specified organisms 
H23..11 Chest infection - pneumonia organism OS 
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H230.00 Pneumonia due to Eaton's agent 
H231.00 Pneumonia due to mycoplasma pneumoniae 
H232.00 Pneumonia due to pleuropneumonia like organisms 
H233.00 Chlamydial pneumonia 
H23z.00 Pneumonia due to specified organism NOS 
H24..00 Pneumonia with infectious diseases EC 
H240.00 Pneumonia with measles 
H241.00 Pneumonia with cytomegalic inclusion disease 
H242.00 Pneumonia with ornithosis 
H243.00 Pneumonia with whooping cough 
H243.11 Pneumonia with pertussis 
H244.00 Pneumonia with tularaemia 
H245.00 Pneumonia with anthrax 
H246.00 Pneumonia with aspergillosis 
H247.00 Pneumonia with other systemic mycoses 
H247000 Pneumonia with candidiasis 
H247100 Pneumonia with coccidioidomycosis 
H247200 Pneumonia with histoplasmosis 
H247z00 Pneumonia with systemic mycosis NOS 
H24y.00 Pneumonia with other infectious diseases EC 
H24y000 Pneumonia with actinomycosis 
H24y100 Pneumonia with nocardiasis 
H24y200 Pneumonia with pneumocystis carinii 
H24y300 Pneumonia with Q-fever 
H24y400 Pneumonia with salmonellosis 
H24y500 Pneumonia with toxoplasmosis 
H24y600 Pneumonia with typhoid fever 
H24y700 Pneumonia with varicella 
H24yz00 Pneumonia with other infectious diseases EC NOS 
H24z.00 Pneumonia with infectious diseases EC NOS 
H25..00 Bronchopneumonia due to unspecified organism 
H25..11 Chest infection - unspecified bronchopneumonia 
H26..00 Pneumonia due to unspecified organism 
H26..11 Chest infection - pnemonia due to unspecified organism 
H260.00 Lobar pneumonia due to unspecified organism 
H261.00 Basal pneumonia due to unspecified organism 
H262.00 Postoperative pneumonia 
H270.00 Influenza with pneumonia 
H270.11 Chest infection - influenza with pneumonia 
H270000 Influenza with bronchopneumonia 
H270100 Influenza with pneumonia, influenza virus identified 
H270z00 Influenza with pneumonia NOS 
H28..00 Atypical pneumonia 
H2y..00 Other specified pneumonia or influenza 
H2z..00 Pneumonia or influenza NOS 
H30..00 Bronchitis unspecified 
H30..11 Chest infection - unspecified bronchitis 
H30..12 Recurrent wheezy bronchitis 
H300.00 Tracheobronchitis NOS 
H302.00 Wheezy bronchitis 
H30z.00 Bronchitis NOS 
H31..00 Chronic bronchitis 
H310.00 Simple chronic bronchitis 
H310000 Chronic catarrhal bronchitis 
H310z00 Simple chronic bronchitis NOS 
H311.00 Mucopurulent chronic bronchitis 
H311000 Purulent chronic bronchitis 
H311100 Fetid chronic bronchitis 
H311z00 Mucopurulent chronic bronchitis NOS 
H312.00 Obstructive chronic bronchitis 
H312000 Chronic asthmatic bronchitis 
H312011 Chronic wheezy bronchitis 
H312100 Emphysematous bronchitis 
H312300 Bronchiolitis obliterans 
H312z00 Obstructive chronic bronchitis NOS 
H313.00 Mixed simple and mucopurulent chronic bronchitis 
H31y.00 Other chronic bronchitis 
H31y000 Chronic tracheitis 
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H31y100 Chronic tracheobronchitis 
H31yz00 Other chronic bronchitis NOS 
H31z.00 Chronic bronchitis NOS 
H530200 Gangrenous pneumonia 
H530300 Abscess of lung with pneumonia 
H540000 Hypostatic pneumonia 
H540100 Hypostatic bronchopneumonia 
H564.00 Bronchiolitis obliterans organising pneumonia 
H56y.00 Other alveolar and parietoalveolar disease 
H56y000 Endogenous lipoid pneumonia 
H56y100 Interstitial pneumonia 
H571.00 Rheumatic pneumonia 
Hyu0800 [X]Other viral pneumonia 
Hyu0900 [X]Pneumonia due to other aerobic gram-negative bacteria 
Hyu0A00 [X]Other bacterial pneumonia 
Hyu0B00 [X]Pneumonia due to other specified infectious organisms 
Hyu0C00 [X]Pneumonia in bacterial diseases classified elsewhere 
Hyu0D00 [X]Pneumonia in viral diseases classified elsewhere 
Hyu0E00 [X]Pneumonia in mycoses classified elsewhere 
Hyu0F00 [X]Pneumonia in parasitic diseases classified elsewhere 
Hyu0G00 [X]Pneumonia in other diseases classified elsewhere 
Hyu0H00 [X]Other pneumonia, organism unspecified 
Hyu1.00 [X]Other acute lower respiratory infections 
Hyu1000 [X]Acute bronchitis due to other specified organisms 
Hyu1100 [X]Acute bronchiolitis due to other specified organisms 
Hyu3.00 [X]Chronic lower respiratory diseases 
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l) List of Read codes for Upper Respiratory Tract Infections (URTI) 
Read code description 
H00..00 Acute nasopharyngitis 
H04..00 Acute laryngitis and tracheitis 
H05..00 Other acute upper respiratory infections 
H050.00 Acute laryngopharyngitis 
H051.00 Acute upper respiratory tract infection 
H052.00 Pharyngotracheitis 
H053.00 Tracheopharyngitis 
H054.00 Recurrent upper respiratory tract infection 
H055.00 Pharyngolaryngitis 
H05y.00 Other upper respiratory infections of multiple sites 
H05z.00 Upper respiratory infection NOS 
H05z.11 Upper respiratory tract infection NOS 
H05z.12 Viral upper respiratory tract infection NOS 
H1...00 Other upper respiratory tract diseases 
H12..00 Chronic pharyngitis and nasopharyngitis 
H13..00 Chronic sinusitis 
H13..11 Chronic rhinosinusitis 
H14..00 Chronic tonsil and adenoid disease 
H14..11 Adenoid disease - chronic 
H14..12 Tonsil disease - chronic 
H15..00 Peritonsillar abscess - quinsy 
H15..11 Quinsy 
H16..00 Chronic laryngitis and laryngotracheitis 
H17..00 Allergic rhinitis 
H17..11 Perennial rhinitis 
H17..12 Allergic rhinosinusitis 
H18..00 Vasomotor rhinitis 
H1y..00 Other specified diseases of upper respiratory tract 
H1y1.12 Nasal vestibulitis 
H1y2.00 Other pharyngeal disease NEC 
H1y2.11 Other nasopharyngeal disease NEC 
H1y7.00 Other diseases of larynx NEC 
H1yz.00 Other upper respiratory tract diseases NOS 
H1yz000 Abscess of trachea 
H1yzz00 Other upper respiratory tract disease NOS 
H1z..00 Upper respiratory tract disease NOS 
H271000 Influenza with laryngitis 
H271100 Influenza with pharyngitis 
H301.00 Laryngotracheobronchitis 
Hyu0.00 [X]Acute upper respiratory infections 
Hyu0000 [X]Other acute sinusitis 
Hyu0100 [X]Acute pharyngitis due to other specified organisms 
Hyu0200 [X]Acute tonsillitis due to other specified organisms 
Hyu0300 [X]Other acute upper respiratory infections/multiple sites 
Hyu0400 [X]Flu+oth respiratory manifestations,'flu virus identified 
Hyu0500 [X]Influenza+other manifestations,influenza virus identified 
Hyu0600 [X]Influenza+oth respiratory manifestatns,virus not identifd 
Hyu0700 [X]Influenza+other manifestations, virus not identified 
Hyu2.00 [X]Other diseases of the upper respiratory tract 
Hyu2000 [X]Other seasonal allergic rhinitis 
Hyu2100 [X]Other allergic rhinitis 
Hyu2200 [X]Other chronic sinusitis 
Hyu2500 [X]Other chronic diseases of tonsils and adenoids 
Hyu2700 [X]Other diseases of larynx 
Hyu2800 [X]Other abscess of pharynx 
Hyu2900 [X]Other diseases of pharynx 
Hyu2A00 [X]Other specified diseases of upper respiratory tract 
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m)  List of Read codes for non-specific chest infections 
Read code description 
H0...00 Acute respiratory infections 
H06z000 Chest infection NOS 
H06z011 Chest infection 
H06z111 Respiratory tract infection 
H06z200 Recurrent chest infection 
H07..00 Chest cold 
H0y..00 Other specified acute respiratory infections 
H0z..00 Acute respiratory infection NOS 
H20y000 Severe acute respiratory syndrome 
H24..11 Chest infection with infectious disease EC 
H271.00 Influenza with other respiratory manifestation 
H271z00 Influenza with respiratory manifestations NOS 
H27y.00 Influenza with other manifestations 
H5yy.11 Respiratory infection NOS 
 
 
n) List of Read codes for chest/shoulder pain 
Read code description 
182..00 Chest pain 
1822.00 Central chest pain 
1823.00 Precordial pain 
1824.00 Anterior chest wall pain 
1825.00 Pleuritic pain 
1826.00 Parasternal pain 
1827.00 Painful breathing -pleurodynia 
1828.00 Atypical chest pain 
1829.00 Retrosternal pain 
182A.00 Chest pain on exertion 
182B.00 Rib pain 
182B000 Costal margin chest pain 
182C.00 Chest wall pain 
182Z.00 Chest pain NOS 
1D22000 Chest wall tenderness 
8HTG.00 Referred to acute chest pain clinic 
8HTJ.00 Referral to rapid access chest pain clinic 
9N0f.00 Seen in rapid access chest pain clinic 
G33z400 Ischaemic chest pain 
N094111 Shoulder joint pain 
N245.17 Shoulder pain 
N245700 Shoulder pain 
R065.00 [D]Chest pain 
R065000 [D]Chest pain, unspecified 
R065011 [D] Retrosternal chest pain 
R065200 [D]Anterior chest wall pain 
R065300 [D]Painful respiration NOS 
R065400 [D]Pleuritic pain 
R065600 [D]Chest discomfort 
R065700 [D]Chest pressure 
R065800 [D]Chest tightness 
R065900 [D]Parasternal chest pain 
R065A00 [D]Musculoskeletal chest pain 
R065B00 [D]Non cardiac chest pain 
R065B14 [D]Non-cardiac chest pain 
R065C00 [D]Retrosternal chest pain 
R065D00 [D]Central chest pain 
R065z00 [D]Chest pain NOS 
Ryu0400 [X]Other chest pain 
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o) List of Read codes for voice hoarseness 
Read code description 
1CA..00 Hoarseness symptom 
1CA..11 Hoarseness - throat symptom 
1CA2.00 Hoarse 
1CA2.11 Voice hoarseness 
1CAZ.00 Hoarseness symptom NOS 
2DE4.00 O/E - hoarseness 
2DE5.00 O/E - dysphonia 
R044300 [D]Change in voice 
R044400 [D]Dysphonia 
R044500 [D]Hoarseness 
ZS2..00 Disorder of voice 
ZS21.00 Dysphonia 
ZT15.00 Change in voice 
 
 
p) List of Read codes for chest x-rays 
Read code description 
535..00 Standard chest X-ray 
535..11 Chest X-ray - routine 
5351.00 Standard chest X-ray requested 
5352.00 Standard chest X-ray normal 
5352.11 Chest X-ray normal 
5353.00 Standard chest X-ray abnormal 
535Z.00 Standard chest X-ray NOS 
536..00 Soft tissue X-ray chest 
5361.00 Soft tiss.X-ray chest normal 
5362.00 Soft tiss.X-ray chest abnormal 
5363.00 X-ray larynx/trachea 
5363.11 Larynx soft tis. X-ray 
5363.12 Trachea soft tis. X-ray 
5364.00 Soft tiss.X-ray lung/bronchus 
5364.11 Bronchus soft tis.X-ray 
5364.12 Lung soft tis. X-ray 
5365.00 Soft tissue X-ray chest wall 
536Z.00 Soft tissue X-ray chest NOS 
545..11 Bronchography 
5451.00 Bronchography requested 
5452.00 Bronchography normal 
5453.00 Bronchography abnormal 
5454.00 Contrast radiog.larynx/trachea 
5454.11 Larynx - contrast radiography 
5454.12 Trachea - contrast radiography 
5455.00 Bilat.transglot.bronchography 
5456.00 Bilat.transcric bronchography 
5457.00 Selective bronchography 
545Z.00 Resp.contrast radiogr.NOS 
5661.00 Serial radiography of lungs 
68C1.00 Screening chest X-ray 
68C1.11 CXR - screening 
7P04200 Plain x-ray of chest 
7P04y00 Other specified diagnostic imaging of chest 
7P04z00 Diagnostic imaging of chest NOS 
ZV72511 [V]Routine chest X-ray 
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q) List of Read codes for blood investigations 
Read code description Blood test status 
4131.00 Blood test requested blood test 
4142.00 Blood sample -> Haematology Lab blood test 
4143.00 Blood sample -> Biochemistry Lab blood test 
4144.00 Blood sample -> Microbiology Lab blood test 
4145.00 Blood sample -> Lab NOS blood test 
41D0.00 Blood sample taken blood test 
421..00 Haematology - general blood test 
4212.00 Haematology test performed blood test 
4213.00 Haematology test requested blood test 
4214.00 Blood sent for haematological test blood test 
4217.00 Haematology res. not back yet blood test 
4218.00 Haematology result normal normal 
4219.00 Haematology result abnormal abnormal 
421A.00 Haematology result borderline normal 
423..00 Haemoglobin estimation blood test 
423..11 Hb estimation blood test 
4232.00 Haemoglobin requested blood test 
4233.00 Haemoglobin - sample sent blood test 
4234.00 Haemoglobin very low abnormal 
4235.00 Haemoglobin low abnormal 
4236.00 Haemoglobin borderline low abnormal 
4237.00 Haemoglobin normal normal 
4238.00 Haemoglobin borderline high abnormal 
4239.00 Haemoglobin high abnormal 
423A.00 Haemoglobin very high abnormal 
423B.00 Haemoglobin abnormal abnormal 
423Z.00 Haemoglobin estimation NOS blood test 
424..00 Full blood count - FBC blood test 
4241.00 Full blood count normal normal 
4242.00 Full blood count borderline normal 
4243.00 Full blood count abnormal abnormal 
424Z.00 Full blood count NOS blood test 
425..00 Haematocrit - PCV blood test 
425..11 Packed cell volume - PCV blood test 
4251.00 Haematocrit - PCV - normal normal 
4252.00 Haematocrit - borderline high abnormal 
4253.00 Haematocrit - PCV - high abnormal 
4254.00 Haematocrit - PCV - low abnormal 
4255.00 Haematocrit - borderline low abnormal 
4256.00 Haematocrit - PCV - abnormal abnormal 
4257.00 Packed cell volume blood test 
4258.00 Haematocrit blood test 
425Z.00 Haematocrit - PCV - NOS blood test 
426..00 Red blood cell (RBC) count blood test 
4261.00 RBC count normal normal 
4262.00 RBC count borderline low abnormal 
4263.00 RBC count low abnormal 
4264.00 RBC count raised abnormal 
4265.00 RBC count borderline raised abnormal 
4266.00 Nucleated red blood cell count blood test 
4267.00 RBC count abnormal abnormal 
426Z.00 RBC count NOS blood test 
428..00 Mean corpusc. haemoglobin(MCH) blood test 
428..11 Mean cell haemoglobin blood test 
4281.00 MCH - normal normal 
4282.00 MCH - borderline low abnormal 
4283.00 MCH - low abnormal 
4284.00 MCH - raised abnormal 
4285.00 MCH - borderline raised abnormal 
4286.00 MCH - abnormal abnormal 
428Z.00 MCH - NOS blood test 
429..00 Mean corpuscular Hb. conc. (MCHC) blood test 
4291.00 MCHC - normal normal 
4292.00 MCHC - borderline low abnormal 
4293.00 MCHC - low abnormal 
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4294.00 MCHC - raised abnormal 
4295.00 MCHC - borderline raised abnormal 
429Z.00 MCHC - NOS blood test 
42A..00 Mean corpuscular volume (MCV) blood test 
42A..11 Mean cell volume blood test 
42A1.00 MCV - normal normal 
42A2.00 MCV - borderline raised abnormal 
42A3.00 MCV - raised abnormal 
42A4.00 MCV - low abnormal 
42A5.00 MCV - borderline low abnormal 
42AZ.00 MCV - NOS blood test 
42B..00 Plasma viscosity blood test 
42B..11 Plasma viscosity - PV blood test 
42B1.00 Plasma viscosity normal normal 
42B2.00 Plasma visc. borderline raised abnormal 
42B3.00 Plasma viscosity raised abnormal 
42B4.00 Plasma viscosity low abnormal 
42B5.00 Plasma visc. borderline low abnormal 
42B6.00 Erythrocyte sedimentation rate blood test 
42B6000 ESR abnormal abnormal 
42B6100 ESR low abnormal 
42B6200 ESR normal normal 
42B6300 ESR raised abnormal 
42B6z00 Erythrocyte sediment rate NOS blood test 
42BZ.00 Plasma viscosity NOS blood test 
42C..00 RBC - red blood cell size blood test 
42C1.00 Red blood cell size normal normal 
42C2.00 RBC's - microcytic abnormal 
42C3.00 RBC's - macrocytic abnormal 
42CZ.00 Red blood cell size NOS blood test 
42D..00 RBC - red blood cell shape blood test 
42D1.00 Red blood cell shape - normal normal 
42G..00 Red blood cell enzymes blood test 
42G1.00 Red blood cell enzymes normal normal 
42G2.00 RBC enzymes abnormal abnormal 
42H..00 Total white cell count blood test 
42H..11 White blood count blood test 
42H..12 White cell count blood test 
42H1.00 White cell count normal normal 
42H2.00 Leucopenia - low white count abnormal 
42H2.11 Leucopenia abnormal 
42H3.00 Leucocytosis -high white count abnormal 
42H3.11 Leucocytosis abnormal 
42H4.00 Agranulocytosis abnormal 
42H5.00 White cell count abnormal abnormal 
42H6.00 Polymorphonuclear leukocyte count blood test 
42H7.00 Total white blood count blood test 
42H8.00 Total WBC (IMM) blood test 
42HZ.00 Total white cell count NOS blood test 
42I..00 Differential white cell count blood test 
42I..11 WCC - differential blood test 
42I1.00 Diff. white cell count normal normal 
42I2.00 Diff. white count abnormal abnormal 
42IZ.00 Diff. white cell count NOS blood test 
42J..00 Neutrophil count blood test 
42J..11 Granulocyte count blood test 
42J1.00 Neutrophil count normal normal 
42J2.00 Neutropenia abnormal 
42J3.00 Neutrophilia abnormal 
42J4.00 Neutrophil count abnormal abnormal 
42JZ.00 Neutrophil count NOS blood test 
42K..00 Eosinophil count blood test 
42K1.00 Eosinophil count normal normal 
42K2.00 Eosinopenia abnormal 
42K3.00 Eosinophil count raised abnormal 
42KZ.00 Eosinophil count NOS blood test 
42L..00 Basophil count blood test 
42L1.00 Basophil count normal normal 
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42L2.00 Basophilia abnormal 
42L3.00 Basophil count abnormal abnormal 
42LZ.00 Basophil count NOS blood test 
42M..00 Lymphocyte count blood test 
42M1.00 Lymphocyte count normal normal 
42M2.00 Lymphocytosis - absolute blood test 
42M3.00 Lymphocytosis - relative blood test 
42M4.00 Abnormal lymphocytes abnormal 
42M5.00 Lymphocyte count abnormal abnormal 
42M6.00 Total T lymphocyte count blood test 
42M7.00 T cell subsets blood test 
42M8.00 Total lymphocyte count (IMM) blood test 
42M9.00 Total B lymphocyte count blood test 
42MA.00 Lymphocyte subsets blood test 
42MB.00 Natural killer cell level blood test 
42MC.00 Prolymphocyte count blood test 
42MD.00 Reactive lymphocyte count blood test 
42ME.00 Hairy cell markers blood test 
42MF.00 Lymphocyte function test blood test 
42MG.00 Leucocyte count blood test 
42MH.00 Population gated lymphocytes blood test 
42MZ.00 Lymphocyte count NOS blood test 
42N..00 Monocyte count blood test 
42N1.00 Monocyte count normal normal 
42N2.00 Monocyte count raised abnormal 
42N3.00 Monocytopenia abnormal 
42N4.00 Abnormal monocytes abnormal 
42N5.00 Monocyte count abnormal abnormal 
42N6.00 Absolute atypical mononuclear cell count blood test 
42N7.00 Percentage atypical mononuclear cell count blood test 
42NZ.00 Monocyte count NOS blood test 
42O..00 Immature white blood cells blood test 
42O1.00 Immature WBC's - non present normal 
42P..00 Platelet count blood test 
42P1.00 Platelet count normal normal 
42P2.00 Thrombocytopenia abnormal 
42P2.11 Auto-immune thrombocytopenia abnormal 
42P3.00 Thrombocythaemia abnormal 
42P4.00 Platelet count abnormal abnormal 
42P5.00 Platelet distribution width blood test 
42P6.00 Platelet/neutrophil ratio blood test 
42P7.00 Percentage reticulated platelet count blood test 
42P8.00 Heparin induced thrombocytopenia screening test blood test 
42P9.00 Plateletcrit blood test 
42PZ.00 Platelet count NOS blood test 
42Q..00 Coagulation/bleeding tests blood test 
42Q..11 Bleeding tests blood test 
42Q..12 Clotting tests blood test 
42Q..13 Coagulation tests blood test 
42Q1.00 Coag./bleeding tests normal normal 
42Q2.00 Coag./bleeding tests abnormal abnormal 
42Q3.00 Bleeding time blood test 
42Q4.00 Whole blood clotting time blood test 
42Q5.00 Prothrombin time blood test 
42Q5000 Prothrombin time abnormal abnormal 
42Q5100 Prothrombin time low abnormal 
42Q5200 Prothrombin time normal normal 
42Q6.00 Partial thromboplastin time blood test 
42Q7.00 Heparin assay blood test 
42Q8.00 Thrombin time blood test 
42Q8000 Thrombin time normal normal 
42Q8100 Thrombin time abnormal abnormal 
42Q9.00 Fibrinogen assay/titre blood test 
42QA.00 Fibrinogen degradation products blood test 
42QB.00 Factor VIII assay blood test 
42QB.11 Plasma factor VIII level blood test 
42QC.00 Factor IX assay blood test 
42QD.00 Serum vitamin K blood test 
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42QE.00 International normalised ratio blood test 
42QE000 INR - international normal ratio normal normal 
42QE100 INR - international normal ratio abnormal abnormal 
42QF.00 Plasma total protein S level blood test 
42QG.00 Plasma free:total protein S ratio blood test 
42QH.00 Plasma free protein S level blood test 
42QI.00 Plasma ristocetin cofactor level blood test 
42QI.11 Plasma von Willebrand factor level blood test 
42QJ.00 Plasma antithrombin III level blood test 
42QK.00 Plasma plasminogen level blood test 
42QL.00 Plasma factor VIII related antigen test blood test 
42QM.00 Plasma factor XII level blood test 
42QN.00 Plasma factor XI level blood test 
42QO.00 Plasma factor X level blood test 
42QP.00 Plasma factor VII level blood test 
42QQ.00 Plasma antithrombin III antigen level blood test 
42QR.00 Plasma factor V level blood test 
42QS.00 Clotting screen blood test 
42QT.00 Plasma factor XIII screening test blood test 
42QU.00 Euglobulin clot lysis time blood test 
42QV.00 Thrombophilia screen blood test 
42QW.00 Kaolin cephalin clotting time blood test 
42QX.00 Dilute Russell viper venom ratio blood test 
42QY.00 Ivy bleeding time blood test 
42QZ.00 Coag./bleeding test NOS blood test 
42Qa.00 Protein C function estimate blood test 
42Qb.00 Protein S function estimate blood test 
42Qc.00 Plasma activated protein C resistance blood test 
42Qd.00 Plasma protein C antigen level blood test 
42Qe.00 Factor V Leiden genotype blood test 
42Qf.00 D-Dimer level blood test 
42Qg.00 Factor II level blood test 
42Qh.00 Factor IX inhibitor activity blood test 
42Qi.00 Factor IX related antigen level blood test 
42Qj.00 Factor VIII inhibitor activity blood test 
42Qk.00 Factor VIII related antigen level blood test 
42Ql.00 Factor VIII von Willebrands Factor ratio blood test 
42Qm.00 Factor VIIIc level blood test 
42Qn.00 Fibrinogen level blood test 
42Qo.00 High molecular weight kininogen level blood test 
42Qp.00 Prekallikrein level blood test 
42Qq.00 Protein C level blood test 
42Qr.00 Prothrombin consumption blood test 
42Qs.00 von Willebrand factor level blood test 
42Qt.00 Partial thromboplastin time ratio blood test 
42Qu.00 Activated partial thromboplastin time ratio blood test 
42Qv.00 Prothrombin time - reference blood test 
42Qw.00 APTT - reference blood test 
42Qx.00 von Willebrand factor activity blood test 
42Qy.00 Thrombin time reference blood test 
42Qz.00 APTR actin FSL ratio blood test 
42R..00 Serum iron tests blood test 
42R..11 Serum iron level blood test 
42R1.00 Serum iron normal normal 
42R2.00 Serum iron low abnormal 
42R3.00 Serum iron raised abnormal 
42R4.00 Serum ferritin blood test 
42R4.11 Ferritin - serum blood test 
42R4.12 TIBC - serum blood test 
42R4100 Ferritin level low abnormal 
42R4200 Serum ferritin normal normal 
42R4300 Serum ferritin high abnormal 
42R5.00 Serum TIBC blood test 
42R5000 TIBC - Total iron binding capacity normal normal 
42R5100 TIBC - Total iron binding capacity low abnormal 
42R6.00 Serum iron abnormal abnormal 
42R7.00 Serum iron level blood test 
42R8.00 Unsaturated iron binding capacity blood test 
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42R9.00 Saturation of iron binding capacity blood test 
42RA.00 Percentage iron saturation blood test 
42RZ.00 Serum iron tests NOS blood test 
42S..00 Iron kinetics blood test 
42S1.00 Iron kinetics normal normal 
42S2.00 Iron kinetics abnormal abnormal 
42S3.00 Iron absorption blood test 
42S4.00 Iron clearance blood test 
42S5.00 Iron utilisation blood test 
42SZ.00 Iron kinetics NOS blood test 
42T..00 Serum vitamin B12 blood test 
42T1.00 Serum vitamin B12 normal normal 
42T2.00 Serum vitamin B12 low abnormal 
42T3.00 Serum vit B12 borderline normal 
42TZ.00 Serum vitamin B12 NOS blood test 
42U..00 Blood folate blood test 
42U..11 Folate blood level blood test 
42U1.00 Serum folate normal normal 
42U2.00 Serum folate low abnormal 
42U3.00 Serum folate borderline normal 
42U4.00 Red blood cell folate blood test 
42U4.11 Folate - RBC blood test 
42U5.00 Serum folate blood test 
42U6.00 Whole blood folate blood test 
42U7.00 RBC folate normal normal 
42U8.00 RBC folate low abnormal 
42U9.00 RBC folate borderline normal 
42UA.00 Whole blood folate normal normal 
42UB.00 Whole blood folate low abnormal 
42UC.00 Whole blood folate borderline normal 
42UD.00 RBC folate abnormal abnormal 
42UE.00 Plasma folate level blood test 
42UZ.00 Blood folate NOS blood test 
42V..00 Haemoglobin variants blood test 
42V1.00 Haemoglobin electrophoresis blood test 
42V1.11 Electrophoresis - Hb blood test 
42ZZ.00 Haematology NOS blood test 
42a..00 Plasma cell count blood test 
42a0.00 Percentage plasma cell count blood test 
42b..00 Percentage cell count blood test 
42b0.00 Percentage neutrophils blood test 
42b1.00 Percentage lymphocytes blood test 
42b2.00 Percentage monocytes blood test 
42b3.00 Percentage basophils blood test 
42b4.00 Percentage metamyelocytes blood test 
42b5.00 Percentage blast cells blood test 
42b6.00 Percentage smear cells blood test 
42b7.00 Percentage granulocytes blood test 
42b8.00 Percentage nucleated Red Blood Cells blood test 
42b9.00 Percentage eosinophils blood test 
42bA.00 Percentage myelocyte count blood test 
42bB.00 Percentage promyelocyte count blood test 
42bC.00 Percentage reticulocyte count blood test 
42bD.00 T cell total % blood test 
42bE.00 Percentage hypochromic cells blood test 
42f..00 Hess test blood test 
42g..00 Haematology test blood test 
42g0.00 Whole blood viscosity blood test 
43F..00 Rheumatoid factor blood test 
43F..11 Latex test blood test 
43F..12 Rose Waaler test blood test 
43F1.00 Rheumatoid factor positive abnormal 
43F2.00 Rheumatoid factor negative normal 
43F3.00 R.A. latex test blood test 
43F4.00 Rose Waaler test - sheep cells blood test 
43F4000 Heterophile agglutin test normal normal 
43F4100 Heterophile agglutin test abnormal abnormal 
43F5.00 Serum rheumatoid antigen level blood test 
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43F6.00 Fluid rheumatoid factor level blood test 
43F7.00 Rheumatoid factor screening test blood test 
43F8.00 Serum rheumatoid antibody level blood test 
43F9.00 Rheumatoid factor IgG level blood test 
43FA.00 Rheumatoid factor IgM level blood test 
43FB.00 IgA rheumatoid factor level blood test 
43FZ.00 Rheumatoid factor NOS blood test 
43G..00 Autoantibody titres blood test 
43G1.00 Anti-nuclear factor blood test 
43G1.11 Anti-nuclear antibody blood test 
43G1000 Anti-nuclear factor positive abnormal 
43G1011 Anti-nuclear antibody positive abnormal 
43G1100 Anti-nuclear factor negative normal 
43G1111 Anti-nuclear antibody negative normal 
43G1200 Anti-nuclear factor weakly positive abnormal 
43G1211 Anti-nuclear antibody weakly positive abnormal 
43G2.00 Antimitochondrial autoantibod. blood test 
43G3.00 Anti smooth muscle autoantibod blood test 
43G3000 Smooth muscle antibodies negative normal 
43G3100 Smooth muscle antibodies positive abnormal 
43G3200 Smooth muscle antibodies weakly positive abnormal 
43G4.00 Parietal cell autoantibodies blood test 
43G4000 Parietal cell antibodies negative normal 
43G4100 Parietal cell antibodies positive abnormal 
43G4200 Parietal cell antibodies weakly positive abnormal 
44...00 Blood chemistry blood test 
441..00 Blood chemistry - general blood test 
4411.00 Blood sent for chemistry blood test 
4412.00 Blood chemistry normal normal 
4412000 Urea and electrolytes normal normal 
4412100 Urea and electrolytes abnormal abnormal 
4413.00 Blood chemistry abnormal abnormal 
441Z.00 Blood chemistry - general NOS blood test 
44D..00 Liver function tests - general blood test 
44D..11 Liver function tests blood test 
44D1.00 Liver function tests normal normal 
44D2.00 Liver function tests abnormal abnormal 
44D6.00 Liver function test blood test 
44DZ.00 Liver function tests NOS blood test 
44E..00 Serum bilirubin level blood test 
44E1.00 Serum bilirubin normal normal 
44E2.00 Serum bilirubin raised abnormal 
44E3.00 Total bilirubin blood test 
44E4.00 Direct (conjugated) bilirubin blood test 
44E5.00 Indirect (unconj.) bilirubin blood test 
44E6.00 Serum bilirubin borderline normal 
44E7.00 Serum conjugated:total bilirubin ratio blood test 
44E8.00 Plasma conjugated bilirubin level blood test 
44E9.00 Plasma total bilirubin level blood test 
44EA.00 Plasma unconjugated bilirubin level blood test 
44EB.00 Serum conjugated bilirubin level blood test 
44EC.00 Serum total bilirubin level blood test 
44ED.00 Serum unconjugated bilirubin level blood test 
44EZ.00 Serum bilirubin NOS blood test 
44F..00 Serum alkaline phosphatase blood test 
44F1.00 Serum alk. phos. normal normal 
44F2.00 Serum alk. phos. raised abnormal 
44F3.00 Total alkaline phosphatase blood test 
44F4.00 Alk. phos. - liver isoenzyme blood test 
44F5.00 Alk. phos. - bone isoenzyme blood test 
44F5000 Alkaline phosphatase bone isoenzyme raised abnormal 
44F6.00 Alk. phos. - bile isoenzyme blood test 
44F7.00 Alkaline phosphatase isoenzyme studies blood test 
44F8.00 Plasma alkaline phosphatase bile isoenzyme level blood test 
44F9.00 Plasma alkaline phosphatase bone isoenzyme level blood test 
44FA.00 Plasma alkaline phosphatase liver isoenzyme level blood test 
44FB.00 Serum alkaline phosphatase bile isoenzyme level blood test 
44FC.00 Serum alkaline phosphatase bone isoenzyme level blood test 
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44FD.00 Serum alkaline phosphatase liver isoenzyme level blood test 
44FE.00 Serum alkaline phosphatase electrophoresis blood test 
44FG.00 Alkaline phosphatase - bile isoenzyme level blood test 
44FH.00 Alkaline phosphatase liver isoenzyme level blood test 
44FI.00 Alkaline phosphatase - bone isoenzyme level blood test 
44FJ.00 Heat stable alkaline phosphatase measurement blood test 
44FZ.00 Serum alkaline phosphatase NOS blood test 
44G..00 Liver enzymes blood test 
44G..11 ALT - blood level blood test 
44G..12 SGPT - blood level blood test 
44G1.00 Liver enzymes normal normal 
44G2.00 Liver enzymes abnormal abnormal 
44G3.00 ALT/SGPT serum level blood test 
44G3000 ALT/SGPT level normal normal 
44G3100 ALT/SGPT level abnormal abnormal 
44G4.00 Gamma - G.T. level blood test 
44G4000 Gamma glutamyl transferase level normal normal 
44G4100 Gamma glutamyl transferase level abnormal abnormal 
44G5.00 Serum 5 - nucleotidase blood test 
44G5000 Serum 5-nucleotidase level normal normal 
44G5100 Serum 5-nucleotidase level low abnormal 
44G5200 Serum 5-nucleotidase level raised abnormal 
44G6.00 Plasma hydroxybutyrate dehydrogenase level blood test 
44G7.00 Plasma gamma-glutamyl transferase level blood test 
44G8.00 Serum hydroxybutyrate dehydrogenase level blood test 
44G9.00 Serum gamma-glutamyl transferase level blood test 
44GA.00 Plasma alanine aminotransferase level blood test 
44GB.00 Serum alanine aminotransferase level blood test 
44GZ.00 Liver enzymes NOS blood test 
44H..00 Cardiac enzymes blood test 
44H1.00 Blood sent: cardiac enzymes blood test 
44H2.00 Cardiac enzymes normal normal 
44H3.00 Cardiac enzymes abnormal abnormal 
44H3000 Cardiac enzymes abnormal - first set abnormal 
44H4.00 CK - creatine kinase level blood test 
44H4.11 Creatine phosphokinase level blood test 
44H5.00 AST - aspartate transam.(SGOT) blood test 
44H5.11 AST serum level blood test 
44H5.12 SGOT serum level blood test 
44H5000 AST/SGOT level normal normal 
44H5100 AST/SGOT level abnormal abnormal 
44H5200 AST/SGOT level raised abnormal 
44H6.00 LDH (HBD) level blood test 
44H6.11 LDH blood level blood test 
44H6.12 Serum total lactate dehydrogenase level blood test 
44H7.00 Cardiac enzymes equivocal blood test 
44H8.00 Serum creatinine phosphokinase MB isoenzyme level blood test 
44H9.00 Total lactic dehydrogenase blood test 
44HA.00 Serum total lactate dehydrogenase level blood test 
44HB.00 AST serum level blood test 
44HB.11 SGOT serum level blood test 
44HC.00 Plasma aspartate transaminase level blood test 
44HD.00 Plasma lactate dehydrogenase level blood test 
44HE.00 Plasma creatine kinase level blood test 
44HF.00 Serum lactate dehydrogenase level blood test 
44HG.00 Serum creatine kinase level blood test 
44HH.00 LDH blood level blood test 
44I..00 Serum electrolytes blood test 
44I1.00 Blood sent for electrolytes blood test 
44I2.00 Electrolytes normal normal 
44I3.00 Electrolytes abnormal abnormal 
44I4.00 Serum potassium blood test 
44I4000 Normal serum potassium level normal 
44I4100 Raised serum potassium level abnormal 
44I4200 Low serum potassium level abnormal 
44I5.00 Serum sodium blood test 
44I5000 Serum sodium level normal normal 
44I5100 Serum sodium level abnormal abnormal 
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44I6.00 Serum chloride blood test 
44I6000 Serum chloride level normal normal 
44I6100 Serum chloride level abnormal abnormal 
44I7.00 Serum bicarbonate blood test 
44I7000 Serum bicarbonate level normal normal 
44I7100 Serum bicarbonate level abnormal abnormal 
44I8.00 Serum calcium blood test 
44I8000 Normal serum calcium level normal 
44I8100 Raised serum calcium level abnormal 
44I9.00 Serum inorganic phosphate blood test 
44I9000 Serum phosphate level normal normal 
44I9100 Serum phosphate level abnormal abnormal 
44IA.00 Plasma anion gap blood test 
44IB.00 Serum anion gap blood test 
44IC.00 Corrected serum calcium level blood test 
44ID.00 Serum ionised calcium level blood test 
44IE.00 Serum ionized calcium (pH 7.4) level blood test 
44IZ.00 Serum electrolytes NOS blood test 
44J..11 Urea - blood blood test 
44J..12 Urea and electrolytes blood test 
44J..13 Serum urea level blood test 
44J1.00 Blood urea normal normal 
44J2.00 Blood urea abnormal abnormal 
44J3.00 Serum creatinine blood test 
44J3000 Serum creatinine abnormal abnormal 
44J3100 Serum creatinine low abnormal 
44J3200 Serum creatinine normal normal 
44J3300 Serum creatinine raised abnormal 
44J3z00 Serum creatinine NOS blood test 
44J4.00 Serum osmolality blood test 
44J8.00 Blood urea blood test 
44J8.11 Urea - blood blood test 
44J9.00 Serum urea level blood test 
44JA.00 Plasma urea level blood test 
44JB.00 Urea and electrolytes blood test 
44JH.00 Plasma osmolality blood test 
44JZ.00 Blood urea/renal function NOS blood test 
44K..00 Blood urate blood test 
44K..11 Serum uric acid blood test 
44K1.00 Blood urate normal normal 
44K2.00 Blood urate raised abnormal 
44K2.11 Hyperuricaemia abnormal 
44K3.00 Blood urate level borderline normal 
44K4.00 Blood urate abnormal abnormal 
44M..00 Serum / plasma proteins blood test 
44M1.00 Serum proteins normal normal 
44M2.00 Serum proteins low abnormal 
44M3.00 Serum total protein blood test 
44M3000 Serum total protein normal normal 
44M3100 Serum total protein abnormal abnormal 
44Y..00 Blood gases blood test 
44Y1.00 Blood gases normal normal 
44Y2.00 Blood arterial pH blood test 
44Y2000 Blood pH normal normal 
44Y2100 Blood pH abnormal abnormal 
44Y3.00 Blood venous pH blood test 
44Y4.00 Arterial oxygen level blood test 
44Y4000 Blood oxygen level normal normal 
44Y4100 Blood oxygen level abnormal abnormal 
44Y5.00 Mixed venous oxygen level blood test 
44Y6.00 Arterial carbon dioxide blood test 
44Y6000 Arterial carbon dioxide normal normal 
44Y6100 Arterial carbon dioxide abnormal abnormal 
44Y7.00 Blood gases abnormal abnormal 
44Y8.00 Arterial blood gas analysis blood test 
44Y9.00 Blood oxygen saturation (calculated) blood test 
44YA.00 Blood oxygen saturation blood test 
44YB.00 Mixed venous carbon dioxide level blood test 
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44YC.00 Mixed venous oxygen saturation blood test 
44YD.00 Hydrogen ion concentration blood test 
44YZ.00 Blood gases NOS blood test 
44Z..00 Blood chemistry NOS blood test 
44Z2.00 Bone profile blood test 
44ZR.00 Calcium profile blood test 
44h..00 Blood electrolyte levels blood test 
44h0.00 Blood potassium level blood test 
44h1.00 Blood sodium level blood test 
44h2.00 Blood chloride level blood test 
44h3.00 Blood bicarbonate level blood test 
44h4.00 Blood calcium level blood test 
44h5.00 Blood inorganic phosphate level blood test 
44h6.00 Plasma sodium level blood test 
44h7.00 Plasma calcium level blood test 
44h8.00 Plasma potassium level blood test 
44h9.00 Plasma corrected calcium level blood test 
44hA.00 Blood total carbon dioxide (calculated) blood test 
44hB.00 Actual bicarbonate level blood test 
44hC.00 Standard bicarbonate level blood test 
44i..00 Plasma electrolyte levels blood test 
44i0.00 Plasma bicarbonate level blood test 
44i1.00 Plasma chloride level blood test 
44i2.00 Plasma inorganic phosphate level blood test 
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Appendix II: Most commonly recorded symptoms 
and conditions and their frequency in the medical 
records of patients with lung cancer 
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Most commonly recorded symptoms and diagnosis and their frequency 
in the medical records of patients with lung cancer 
Read code description frequency 
[D]Sleep disturbances 1002 
Knee pain 1005 
Cellulitis NOS 1018 
Shortness of breath symptom 1018 
Resp. system examined - NAD 1021 
Oedema 1026 
Osteoporosis 1029 
Hip joint pain 1030 
Dermatitis NOS 1051 
Blood sample -> Biochem Lab 1054 
Letter invite to screening 1063 
Acute myocardial infarction 1077 
Glaucoma 1092 
[D]Cough 1092 
Diabetic on diet only 1106 
Duodenal ulcer - (DU) 1106 
Foot pain 1110 
Nausea 1114 
Influenza vaccination declined 1120 
Intramuscular injection of vitamin B12 1121 
[D]Haemoptysis 1130 
Standard chest X-ray 1146 
Wheezing 1156 
Skin lesion 1162 
Arthritis 1196 
O/E - dry skin 1200 
Atrial fibrillation 1205 
C/O - low back pain 1207 
Seen in rheumatology clinic 1220 
Wound dressing NOS 1224 
Seen in dermatology clinic 1229 
Rheumatoid arthritis 1231 
Throat soreness 1235 
Dysuria 1255 
[D]Vertigo NOS 1257 
Chronic obstructive pulmonary disease monitoring 1258 
Diarrhoea symptoms 1262 
Immunisations 1266 
Psoriasis unspecified 1275 
Asthma annual review 1298 
Intermittent claudication 1313 
Vomiting 1314 
ECG 1332 
Type 2 diabetes mellitus 1334 
Geriatric screen - seen 1334 
Sinusitis 1339 
Pure hypercholesterolaemia 1342 
Acute conjunctivitis 1350 
Conjunctivitis 1357 
Dizziness symptom 1358 
Haemoptysis - symptom 1365 
Examination of patient 1427 
Seen in cardiac clinic 1430 
Gout 1437 
Physiotherapy 1440 
C/O: a pain 1463 
Warfarin monitoring 1464 
Health ed. - alcohol 1470 
Haematuria 1472 
Telephone triage encounter 1503 
Seen in ENT clinic 1506 
Pain relief 1515 
Seen in diabetic clinic 1516 
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Seen by practice nurse 1531 
Breathlessness 1553 
Follow-up diabetic assessment 1560 
Upper respiratory tract infection NOS 1560 
Hypertension screen 1564 
O/E - foot 1570 
Urinary tract infection, site not specified 1572 
Hip pain 1585 
Cataract 1593 
Acute exacerbation of chronic obstructive airways disease 1600 
Cystitis 1640 
Seen in oncology clinic 1648 
Repeat prescription monitoring 1684 
Emergency hospital admission 1691 
[D]Dizziness 1698 
C/O: a rash 1736 
Epigastric pain 1753 
Body Mass Index 1755 
Leg pain 1763 
Fall - accidental 1799 
Anxiety states 1859 
Laboratory test requested 1887 
Leg ulcer NOS 1926 
Diarrhoea 1934 
Seen by respiratory physician 1938 
Diabetic monitoring 1947 
Chesty cough 1973 
[D]Rash and other nonspecific skin eruption NOS 1981 
Seen in chest clinic 2000 
Backache, unspecified 2019 
Seen in urology clinic 2034 
Back pain without radiation NOS 2039 
Depression screening using questions 2042 
Intramuscular injection 2062 
Constipation 2114 
Otitis externa NOS 2122 
[D]Insomnia NOS 2150 
Knee joint pain 2233 
[D]Abdominal pain 2234 
Eczema NOS 2237 
Headache 2260 
Diabetic on oral treatment 2261 
Seen in orthopaedic clinic 2273 
[D]Shortness of breath 2279 
Constipation symptom 2279 
Refer for X-Ray 2318 
Sciatica 2412 
Wax in ear 2476 
Influenza vaccination invitation letter sent 2497 
X-ray report received 2520 
Bronchitis unspecified 2527 
Patient informed - test result 2531 
O/E - BP reading 2585 
Osteoarthritis 2603 
Chronic obstructive airways disease 2647 
Abdominal pain 2698 
Shortness of breath 2719 
Blood sample taken 2770 
Backache 2780 
Urinary tract infection, site not specified NOS 2809 
Acute bronchitis 2916 
Feet examination 2994 
Pain 3019 
Ischaemic heart disease 3162 
Diabetes mellitus 3237 
Cervicalgia - pain in neck 3329 
Hormone replacement therapy 3370 
Seen in hospital casualty 3388 
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Injection given 3429 
Respiratory tract infection 3491 
CHD monitoring 3776 
Upper respiratory infection NOS 3941 
Geriatric screening 3942 
Shoulder pain 3950 
Low back pain 3956 
Weight loss advised 4082 
Depressive disorder NEC 4176 
Dyspepsia 4285 
Syringe ear to remove wax 4538 
O/E - blood pressure reading 4594 
Asthma 4811 
Angina pectoris 4886 
Chronic obstructive pulmonary disease 5200 
Hypertensive disease 5322 
Chest infection NOS 5400 
Cardiac disease monitoring 5420 
C/O - cough 5576 
Influenza vaccination 5989 
Smoking cessation advice 6119 
Hypertension monitoring 6217 
Diabetes monitoring admin. 6251 
Asthma monitoring 6528 
Hypertension monitoring 6887 
Essential hypertension 7451 
Chest pain 8236 
Cough 9976 
Health ed. - smoking 10609 
Blood sample -> Lab NOS 11400 
Chest infection 12167 
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